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"It's not how hard you hit. It's how hard you get hit...and keep moving forward."  
— Randy Pausch (The Last Lecture) 
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Abstract	  
The clinical course of Parkinson’s disease (PD) is complicated by the development of 
motor and non-motor complications. This thesis, using clinical motor and non-motor 
assessments and positron emission tomography (PET) imaging with 11C-raclopride, 11C-
DASB and 18F-DOPA, aims to explore in PD the role of: (1) postsynaptic dopamine D2 
receptor dysfunction, (2) serotonergic dysfunction in the development of non-motor 
symptoms such as depression and body weight change, (3) striatal serotonergic neurons in 
levodopa- and graft -induced dyskinesias (LIDs and GIDs), and (4) the efficacy of 
treatment with continuous dopaminergic stimulation.  
The main findings are as follows: (1) D2 receptor dysfunction in the hypothalamus but not 
in the putamen was evident in PD, possibly accounting for the development of non-motor 
symptoms. (2) A staging of serotonergic dysfunction throughout the clinical course of PD 
has been demonstrated in this thesis and showed that serotonergic system is involved early 
on. (3) Higher serotonin transporter availability has been found in PD patients with 
elevated depressive symptoms and in PD patients with significant changes in their body 
weight. (4) Striatal serotonergic terminals are involved in peak-dose LIDs in PD, and 
administration of a high bolus dose of a 5-HT1A agonist was able to normalize extracellular 
dopamine levels and alleviate dyskinesias. (5) Excessive serotonergic innervation was 
found in two PD patients with GIDs who had experienced major recovery after striatal 
transplantation with fetal cells. GIDs were markedly attenuated by repeated administration 
of low doses of a 5-HT1A agonist, which dampens transmitter release from serotonergic 
neurons, indicating that serotonergic hyperinnervation was the likely cause of GIDs. (6) 
Continuous dopaminergic stimulation with levodopa intestinal gel induced good clinical 
response and stable and prolonged synaptic levels of striatal dopamine release.  
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My observations provide fundamental insight for the role and interaction of serotonergic 
and dopaminergic systems in the pathophysiology of PD and have key implications for the 
management of motor and non-motor complications with drugs or cell therapies. 
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Introduction	     1	  
 
 
1.1	  Parkinson’s	  Disease	  	  
	  
1.1.1 Parkinson’s	  Disease	  
Idiopathic (or “primary parkinsonism” or “sporadic”) Parkinson’s disease (PD) is the most 
common cause of chronic progressive parkinsonism and one of the most frequent 
neurodegenerative disorders. PD usually results in significant decline in quality of life for 
both patients and family and contributes to substantial economic and institutional costs on 
families and society. 
The disease is named after English physician James Parkinson, who made a 
detailed description of the disease in his essay: "An Essay on the Shaking Palsy" in 1817 
(Parkinson, 2002; Figure 1; Figure 2). The pathology of PD is characterized by neuronal 
loss accompanied by the formation of Lewy inclusion bodies in basal ganglia and other 
cortical and subcortical areas of the brain (Figure 3).  
According to the PD Foundation of United States of America (USA) and the PD 
Society of United Kingdom (UK), PD affects about 1 million people in the USA, 120,000 
people in the UK and more than 4 million people worldwide. The disorder occurs in all 
races, but PD is somewhat more prevalent among Caucasians. Men develop the disease 
slightly more often than women.  
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Figure 1 Frontispiece of James Parkinson's Essay on Shaking Palsy (the first description of 
Parkinson's disease in the public domain) 	  	  
 
Figure 2 Sir William Richard Gowers, neurologist, researcher and artist, drew this illustration in 1886 as 
part of his documentation of Parkinson's disease. The image appeared in his book, “A Manual of Diseases of 
the Nervous System”, still used today by medical professionals as a primary reference for this disease 
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The incidence of PD increases with age although symptoms of PD can appear at 
any age, but the average age of onset is about 60. Onset before age 30 is rare, but up to 
10% of cases of idiopathic PD begins by age 40. However, some people have developed 
the disease in their teens. PD has a prevalence of approximately 0.5 to 1 percent (%) 
among persons 65 to 69 years of age, rising to 1 to 3% among persons 80 years of age and 
older (Tanner and Goldman, 1996). The incidence and prevalence of PD are growing as 
the population ages and the number of cases is expected to double in the next 25 years 
(Dorsey et al., 2007). 
The cardinal symptoms of PD include tremor with a frequency of 4–6 Hz, which is 
maximal when the limb is at rest and is decreased with a voluntary movement. The tremor 
may appear as a pill-rolling motion of the hand and is typically unilateral at onset, though 
an estimated 30% of patients have little or no perceptible tremor, and these are classified 
as “akinetic-rigid”. Rigidity (stiffness, increased muscle tone), the second cardinal 
symptom, refers to an increase in resistance to passive movement about a joint. The 
resistance can be either smooth (lead pipe) or oscillating (cogwheeling). Bradyskinesia (or 
akinesia in advance disease) refers to slowness (or absence) of movement. Bradykinesia is 
also expressed as micrographia (small handwriting), hypomimia (decreased facial 
expression), decreased blink rate, and hypophonia (soft speech). Finally, postural 
instability, usually appearing in advanced PD, denotes failure of postural reflexes, which 
leads to impaired balance and falls (Jankovich, 2008). 
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Figure 3 Schematic illustration of basal ganglia including caudate nucleus, putamen and globus pallidus 
(image taken from CNSforum) 
 
 
1.1.2 The	  Role	  of	  PET	  in	  Understanding	  the	  Dopaminergic	  
Function	  	  
Dopamine is transmitted via four major pathways in the human brain (Figure 4). The first 
extends from the substantia nigra to the caudate nucleus-putamen (neostriatum) and is 
concerned with sensory stimuli and movement (nigostriatal pathway). The second and 
third pathways project from the ventral tegmental area (VTA) to the mesolimbic forebrain 
and are thought to be associated with cognitive, reward and emotional behaviour 
(mesocortical and mesolimbic pathways). The fourth pathway, known as the 
tuberoinfundibular (TI) system, transmits dopamine from the hypothalamus to the 
pituitary gland and is concerned with neuronal control of the hypothalamic-pituitary 
endocrine system. 
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Figure 4 The dopamine pathways in the brain (image taken from CNSforum) 
 
 
 Positron emission tomography (PET) neuroimaging techniques provide a useful tool 
for understanding the complex functional anatomy of the basal ganglia and their disorders. 
PET provides an in vivo tool for evaluating the dopaminergic and non-dopaminergic 
function in PD and has a potential role in the use as a biological marker in the differential 
diagnosis of typical and atypical parkinsonism, in monitoring disease’s progression, in 
understanding the mechanisms underlying motor fluctuations (MF) and non-motor 
symptoms. PET has also a role in assessing the efficacy of neuroprotective and restorative 
strategies. 
 PET uses short-lived radioisotopes bound to specific tracers which, after 
administration, can be monitored in the brain and obtain structural and kinetic 
information, such as the distribution of receptors in the brain (Table 1). PET in 
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comparison with other brain imaging techniques, provides high sensitivity and high spatial 
and temporal resolution. On the other hand, the availability of PET is still limited due to 
high costs and complicated function. In the future, if technical and cost limitations are 
adequately addressed, PET imaging may well provide a valuable adjunct to clinical 
assessment when evaluating the complications and management of PD. 
 
Table 1 Positron Emission Tomography techniques in Parkinson’s disease  
PET TRACER TARGET ASSESSMENT USE IN PD 
11C-CFT (WIN35,428) DAT Presynaptic Dopaminergic 
System 
- Monitoring Progression (Yagi et al., 2010) 
- Differential Diagnosis (Tatsch et al., 2010) 
18F-CFT DAT Presynaptic Dopaminergic 
System 
- Monitoring Progression (Nurmi et al., 2003) 
- Differential Diagnosis (Tatsch et al., 2010) 
11C-methylphenidate (MP) DAT  Presynaptic Dopaminergic 
System 
- Monitoring Progression (Lee et al., 2000) 
- Differential Diagnosis (Tatsch et al., 2010) 
- Motor Fluctuations and Dyskinesias (Sossi et al., 
2007) 
11C-nomifensine DAT Presynaptic Dopaminergic 
System 
- Monitoring Progression (Leenders et al., 1990) 
- Differential Diagnosis (Tatsch et al., 2010) 
- Motor Fluctuations and Dyskinesias (Tedroff et 
al., 1992)  
11C-RTI32 - DAT 
- NAT 
- Presynaptic 
Dopaminergic System 
- Noradrenergic System 
- Depression (Remy et al., 2005) 
- Differential Diagnosis? 
 
11C-DHTBZ VMAT2 Presynaptic Dopaminergic 
System 
 
- Monitoring Progression (Lee et al., 2000) 
- Motor Fluctuations and Dyskinesias (Troiano et 
al., 2009) 
- Differential Diagnosis?  
18F-DOPA AAAD 
 
 
Monaminergic Systems: 
- Presynaptic 
Dopaminergic System 
- Noradrenergic System 
- Serotonergic System  
- Monitoring Progression (Brooks et al., 1990) 
- Modifying Progression (Whone et al., 2003) 
- Differential Diagnosis (Burn and Brooks, 1993) 
- Detection of preclinical disease (Ribeiro et al., 
2002) 
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- Motor Fluctuations and Dyskinesias (de la Fuente 
et al., 2000) 
- Dementia (Ito et al., 2002) 
- Sleep (Hilker et al., 2003) 
- Drug Development (Whone et al., 2003) 
- Evaluation of Restorative Approaches (Lidvall 
and Bjorklund, 2004) 
11C-SCH23390  
 
D1 receptors Postsynaptic Dopaminergic 
System 
Monitoring Progression (Turjanski et al., 1997) 
11C-FLB457 D2/D3 receptors Postsynaptic Dopaminergic 
System 
Drug Development? 
 
11C-raclopride D2/D3 receptors - Dopamine release 
- Postsynaptic 
Dopaminergic System 
 
- Motor Fluctuations and Dyskinesias (de la Fuente 
et al., 2004) 
-Addictive and Compulsive Behaviour (Evans et 
al., 2006) 
- Drug Development (Piccini et al., 1999) 
- Evaluation of Restorative Approaches  
(Piccini et al., 1999)] 
- Monitoring Progression? 
11C-PHNO D3/D2 receptors - Postsynaptic 
Dopaminergic System 
- Dopamine release 
Addictive and Compulsive Behaviour?  
11C-WAY100635 5-HT1A receptors Serotonergic System 
 
- Tremor (Doder et al., 2003) 
- Depression (Doder et al., 2003) 
- Fatigue? 
11C-McN5652 
 
SERT Serotonergic System 
 
- Depression (Kerenyi et al., 2003) 
- Fatigue? 
11C-DASB SERT Serotonergic System 
 
- Depression, Anxiety (Politis et al., 2010) 
- Motor Fluctuations and Dyskinesias  (Politis et 
al., 2010) 
- Fatigue (Pavese et al., 2010) 
- Weight Changes? 
15-O2 rCMRO2 Brain Metabolism 
 
- Differential Diagnosis (Wolfson et al., 1985) 
- Dementia? 
15-H2O rCBF Brain Metabolism - Evaluation of Restorative Approaches (Piccini et 
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  al., 2005) 
- Dementia? 
18F-FDG Relative Regional 
CMRglc 
Brain Metabolism 
 
- Dementia (Peppard et al., 1992) 
- Psychosis (Nagano-Saito et al., 2004) 
- Fatigue (Tirelli et al., 1998) 
11C-PMP AChE Cholinergic System Dementia (Bohnen et al., 2006) 
11C-MP4A AChE Cholinergic System  Dementia (Hilker et al., 2005) 
11C-NMPB Postsynaptic Muscarinic 
receptors  
Cholinergic System  Dementia (Asahina et al., 1998) 
11C-PIB Fibrillar β-amyloid β-amyloid plaque load Dementia (Maetzler et al., 2008) 
11C-PK11195 Peripheral BDZ sites Microglial Activation 
 
- Detection of preclinical disease (Ouchi et al., 
2005) 
- Monitoring Progression (Gerhard et al., 2006) 
- Drug Development? 
- Evaluation of Restorative Approaches? 
11C-diprenorphine μ, κ and δ opioid sites Opioid System 
 
Motor Fluctuations and Dyskinesias (Piccini et al., 
1997) 
11C-deprenyl Monoamine Oxidase B MAO-B inhibition Drug Development (Bench et al., 1991) 
11C-KW6002 Adenosine A2A 
receptors 
Adenosinergic System Drug Development (Hirani et al., 2001) 
11C-SCH442416 Adenosine A2A 
receptors 
Adenosinergic System Motor Fluctuations and Dyskinesias? 
11C-MHED 
 
NET 
 
Myocardial Sympathetic 
Innervation 
Cardiac Sympathetic Denervation (Berding et al., 
2003) 
18F-L829165 NK1 receptors Substance P Motor Fluctuations and Dyskinesias (Whone et al., 
2002) 
11C-MePPEP Cannabinoid CB1 
receptors  
Cannabinoid System Motor Fluctuations and Dyskinesias? 
Depression and Psychosis? 
11C-CNS5161 NMDA receptors Glutamatergic System Motor Fluctuations and Dyskinesias? 
AAAD=Aromatic Amino Acid Decarboxylase; AchE=Acetylcholinesterase; BDZ=benzodiazepine; DAT=Dopamine Transporter; 
NAT=Noradrenaline Transporter; VMAT2=Vesicular Monoamine Transporter  
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1.1.2.1	  Imaging	  the	  Presynaptic	  Dopaminergic	  System	  
The function of presynaptic dopaminergic terminals can be assessed in vivo with PET by 
measuring aromatic amino acid decarboxylase (AAAD) activity, dopamine transporter 
(DAT) availability and vesicular monoamine transporter (VMAT2) density (Figure 5). 
The radiotracer 18F-DOPA was first described as a marker of presynaptic 
terminals in 1983 (Garnett et al., 1983). The uptake of 18F-DOPA in the striatum reflects 
four different processes: (i) the transport of the radioligand through the blood-brain 
barrier, (ii) the uptake of the radioligand into the presynaptic dopamineric neurons, (iii) 
the metabolism by AAAD and (iv) the vesicular storage of 18F-dopamine. AAAD activity 
and density of the dopaminergic presynaptic terminals are the principal determinants of 
18F-DOPA uptake as measured by the influx constant Ki. Therefore, the quantification of 
18F-DOPA uptake within the striatum of PD patients is likely to reflect the number of 
surviving dopaminergic neurons.  
In PD there is a characteristic gradient of loss of striatal dopamine terminal 
function with posterior putamen being the most affected (Figure 6). The rate of striatal 
18F-DOPA accumulation, as measured by PET, therefore directly reflects the activity of 
AAAD in dopamine terminals (Kuwabara et al., 1993). It has been shown that striatal 
uptake of 18F-DOPA in PD correlates with the degree of motor dysfunction. Several 
studies have described a significant inverse correlation between 18F-DOPA uptake and 
the degree of motor disability as measured by the Part III of Unified Parkinson’s Disease 
Rating scale (UPDRS) (Brooks et al., 1990 Brain; Vingerhoets et al., 1997; Broussolle et 
al., 1999). 
Other reports assessing striatal pathology in PD have shown that striatal 18F-
DOPA uptake correlated with nigro-striatal degeneration (Pate et al., 1993; Snow et al., 
1993). Furthermore, in PD patients putaminal 18F-DOPA uptake inversely correlates with 
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the degree of motor impairment (Remy et al., 1995; Morrish et al., 1996; Vingerhoets et 
al., 1997) whereas the correlation between motor symptoms and decreases in caudate 18F-
dopa uptake is weaker (Morrish et al., 1996). Striatal 18F-DOPA uptake in vivo also 
correlates with the number of substantia nigra dopamine neurons and the striatal dopamine 
levels as observed at post mortem (Snow et al., 1993). By using this PET technique, an 
average of 7-12% annual decline in baseline putamen dopaminergic function has been 
reported in early PD patients (Morrish et al., 1998).  
 
 
Figure 5 PET imaging of presynaptic dopaminergic function in healthy controls and early Parkinson’s 
disease patients 
 
Interestingly, as has been shown by one study, reductions in 18F-DOPA uptake 
correlate with increased rigidity and bradykinesia but not with increased tremor. The latter 
suggests that pathways other than the nigrostriatal might be implicated in the expression of 
this symptom (Otsuka et al., 1996).  
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The neurodegeneration in PD is not standardized across all areas. At symptom 
onset, the ventrolateral nigral dopaminergic projections to the dorsal putamen are more 
affected, whereas the dorsomedial projections to the head of the caudate nucleus seem to 
be preserved until more advanced disease (Fearnley and Lees, 1991). Likewise, in early 
cases, the reduction in 18F-DOPA uptake is bigger in the putamen than the caudate 
nucleus. 
Furthermore, in early hemiparkinsonian cases, reduction in 18F-DOPA uptake is 
more pronounced in the dorsal posterior putamen contralateral to the affected limbs 
(Morrish et al., 1995). As PD progresses and symptoms become bilateral, there is 
reduction of 18F-DOPA uptake in the ventral and anterior putamen and dorsal caudate. In 
more advanced stages, the uptake within the ventral head of caudate also falls.    
 The PET radiotracers 11C-nomifensine, 11C-RTI32, 11C-CFT and 18F-CFT were 
all developed to bind to DAT and measure its availability (Leenders et al., 1990; Salmon 
et al., 1990; Tedroff et al., 1990; Frost et al., 1993; Marié et al., 1995; Guttman et al., 
1997). These tracers, which also provide a measure of presynaptic dopamine terminal 
integrity, show similar findings in PD compared to those seen with 18F-DOPA PET, and 
provide a sensitive means of discriminating patients with early PD from healthy subjects.  
 11C-DHTBZ with PET is a reliable technique of measuring VMAT2 density.  It has 
been shown that 11C-DHTBZ uptake is reduced in the striatum of PD patients, thus 
providing another marker for evaluating the integrity of presynaptic dopaminergic 
terminals (Lee et al., 2000). 
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Figure 6 Transverse 18F-DOPA PET images of a healthy control (left) and a patient with idiopathic 
Parkinson’s disease (right). In Parkinson’s disease, there is asymmetric loss of uptake of the tracer, and a 
more pronounced loss in the caudal putamen than in the rostral putamen and the caudate nucleus 
 
 
1.1.2.2	  Imaging	  the	  Postsynaptic	  Dopaminergic	  System	  
At least five different subtypes of dopamine receptors have been described and are 
distributed throughout the brain (Figure 7). They broadly fall into D1-type receptors (D1 
and D5), which activate adenyl cyclase, and D2-type receptors (D2, D3 and D4; Figure 8), 
which either inhibit or have no effect on this enzyme. The striatum expresses mainly D1 
and D2 receptors and these play a primary role in modulating locomotor function by 
mediating the direct and indirect pathway of dopaminergic transmission to the basal 
ganglia output nuclei, respectively (Levy, 1997). 
 
 
 46	  
 
Figure 7 Distribution of dopamine D1–D5 receptors in normal brain. There are five sub-types of dopamine 
receptor and subtypes D1–D5 are widely distributed throughout both the cerebral cortex and the limbic 
system. Certain sub-types are also found in other specific areas of the brain, for example the D1 and D2 
receptors are expressed in the striatum (image taken from CNSforum) 
 
11C-raclopride (RAC) with PET is a selective marker for dopamine D2 and D3 
receptors and due to the fact that it can only bind to D2 receptors on the cell surface (low 
lipophilicity prevents internalization) makes RAC PET a valuable tool to investigate 
postsynaptic dopamine D2 receptor availability (Laruelle et al., 2000).  
RAC PET studies in de novo PD patients have shown 10-20% increases in D2 
receptor availability in the putamen contralateral to the more affected limbs while the 
binding in caudate nucleus remains intact (Leenders et al., 1992; Rinne et al., 1993; 
Turjanski et al., 1997). In addition, RAC BP inversely correlated with presynaptic 18F-
DOPA uptake in patients with early disease (Sawle et al., 1993), suggesting that the 
mildly upregulated putamen and the normal caudate nucleus D2 binding take place where 
dopamine terminal function is relatively preserved.  
 
 47	  
 
Figure 8 The dopamine D2-, D3-, D4 receptor coupled to inhibitory G-proteins. Dopamine D2-like 
receptors have an inhibitory effect on neurotransmission when bound by an agonist (image taken from 
CNSforum) 
 
Serial RAC PET studies have shown that as disease progresses and PD patients are 
exposed to dopaminergic therapy, D2 binding normalizes in the putamen, but caudate 
nucleus binding is reduced by around 20% (Brooks et al., 1990; 1992; Antonini et al., 
1994; Turjanski et al., 1997; Dentresangle et al., 1999). Whereas increased putaminal 
RAC BPND seen in de novo patients could correspond to compensatory mechanisms and 
receptor upregulation, reduction of binding in caudate nucleus in more advanced cases 
may reflect either disease progression or an effect of chronic exposure to dopaminergic 
therapy and specifically dopamine agonist (DA) treatment. In a comparative study 
between PD patients on frequent medication and patients that have completely 
discontinued their medication; there was a greater reduction in striatal D2 receptor 
availability as measured by RAC PET in the medicated patients (Thobois et al., 2004).  
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Although this could be due to direct competition between RAC and exogenous source of 
dopamine, another possible mechanism could concern internalisation of D2 receptors upon 
dopamine binding, hence reduction in available RAC binding sites. However, further 
studies are needed to address this mechanism and also to investigate associations with 
dopaminergic treatment duration and amounts in larger series of subjects. 
PET with 11C-FLB457, another marker of dopamine postsynaptic D2 and D3 
receptors, has also been employed to investigate the expression of extratriatal D2 and D3 
receptors in PD. Advanced PD patients showed reduced 11C-FLB457 binding in the 
thalamus, anterior cingulate cortex (ACC), dorsolateral prefrontal and temporal cortex 
(Kaasinen et al., 2000; 2003), suggesting a possible role of extrastriatal dopamine 
receptors in the presence of cognitive and emotional deficits seen in PD. 
 PET with 11C-SCH23390 has been also used to evaluate the expression of striatal 
D1 receptors in PD. In de novo hemiparkinsonian patients later shown to be levodopa (L-
DOPA) responsive, 11C-SCH23390 PET showed that putamen D1 receptor availability is 
generally preserved contralateral to the affected limbs (Rinne et al., 1990). PD patients 
who have been exposed to L-DOPA for several years showed a 20% reduction in striatal 
D1 receptor binding (Turjanski et al., 1997).  
 
1.1.2.3	  Studying	  Dopamine	  Release	  
One of the most fascinating applications of PET is the ability to evaluate synaptic 
neurotransmitter fluxes in the living human brain. These fluxes are reflected as changes in 
neuroreceptor availability to radiotracers and PET with RAC has been used for this 
purpose. 
RAC competes with endogenous dopamine for D2 receptor binding, allowing an 
indirect measure of synaptic dopamine levels based on changes in D2 receptor availability.  
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This concept was proven in studies that found RAC binding potential (BP) to be 
dependent on, and caused by changes in occupancy of D2 receptors by dopamine 
(Laruelle et al., 2000). A number of studies have demonstrated its ability to detect in vivo 
changes in synaptic cleft dopamine levels following pharmacological or task challenges. 
For example, an amphetamine challenge elicits an increase in synaptic dopamine that 
results in a rapid reduction in RAC BP (Doudet et al., 2003). It has been estimated that a 
10% reduction in availability of D2 receptors for RAC BP reflects a fivefold increase in 
synaptic dopamine levels (Breier et al., 1997). 
For the investigation of dopamine release, the use RAC PET in healthy individuals 
has contributed to improve the understanding of the complex nigrostriatal dopaminergic 
system in the basal ganglia. An early study performed by Koepp and colleagues (1998), 
demonstrated significant striatal release of dopamine when healthy individuals were asked 
to perform a goal-directed motor task, namely a video game.  This was reflected by a 
reduction in RAC BP in these subjects, suggesting a role of dopaminergic transmission in 
learning, attention and sensorimotor integration.  In another RAC PET study, decreases of 
RAC BP were reported in the striatum when individuals participated in card selection 
tasks for monetary rewards, highlighting the possible role of striatal dopamine in reward 
systems (Zald et al., 2004).   
The use of RAC PET to assess dopamine release allows comparisons to be made 
regarding dopaminergic system function between healthy controls and PD patients. In one 
particular study, changes in brain dopamine levels in patients and healthy volunteers were 
investigated during the execution of stereotyped, sequential finger movements (Goerendt 
et al., 2003). During the performance of the task, there was a significant reduction in RAC 
BP in the striatum of healthy controls corresponding to an increase in endogenous synaptic 
dopamine. However, although reductions in RAC BP were also observed in PD patients, 
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significant changes were only seen in brain regions known to be less affected by the 
disease process, such as the ipsilateral putamen.   
Dopamine levels can be increased at the synapse after administration of drugs that 
inhibit or reverse the function of DAT that is important in the reuptake of dopamine. 
Examples include methylphenidate (Schlaepfer et al., 1997), cocaine (Volkow et al., 1994) 
and amphetamines (Carson et al., 1997; Ginovart et al., 1999). Rapid reduction in RAC 
BP has also been shown following administration of L-DOPA (Tedroff et al., 1996) or a 
methamphetamine challenge (Piccini et al., 2003) in PD patients. In the latter study, RAC 
PET showed that the endogenous release of dopamine is significantly greater in normal 
subjects when compared to advanced PD patients. Moreover, in the group of PD patients, 
there was a correlation between percentage reduction in putamen RAC BP and the 
UPDRS motor scores. Interestingly, even in advanced PD cases the frontal dopamine 
release was within the normal range suggesting that reduced striatal rather than frontal 
release of endogenous dopamine is likely to be most relevant to executive dysfunctions 
associated with PD. 
 A more recent study using RAC PET assessed dopamine release in patients with 
early PD and normal controls after visuomotor tasks with and without financial rewards 
according to success (Sawamoto et al., 2008). Dopamine release in striatum was only 
detected in normal controls while both groups showed significant increases in the levels of 
synaptic dopamine in the prefrontal cortex (PFC) suggesting that although the capacity to 
release striatal dopamine during motor tasks is impaired in early PD patients, it is 
relatively preserved in the PFC. 
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1.2	  Parkinson’s	  Disease	  Complications	  
The clinical course of PD is usually complicated with oscillations in the response to 
treatment and additional symptoms of motor and non-motor nature. The motor 
complications commonly reflect loss of control of the motor symptoms by the given 
treatment, and they commonly occur as the disease progresses and patients receive long-
term dopaminergic replacement therapy (DRT). Non-motor symptoms refer to symptoms 
other that the ones related to movement and motor function and can appear in any stage of 
the disease. They commonly include problems with mood, appetite and weight changes, 
and sleep, bowel and urinary problems.  
 
1.2.1	  Motor	  Complications	  in	  Parkinson’s	  Disease	  
As PD progresses and patients receive long-term DRT, it becomes increasingly difficult to 
adequately control symptoms with medications. The most common problems that arise are 
motor complications, which include dyskinesias and other type of MF. These problems 
constitute one of the most difficult issues encountered in the management of PD (Figure 
9).  
MF refer to unanticipated loss of effect of a given dose of a dopamine analogue (L-
DOPA or DA) — instead of a smooth, predictable symptomatic benefit, the patient may 
lose benefit earlier than usual (termed "wearing-OFF") or may suddenly switch from ON 
(symptoms controlled) to OFF (symptoms return).  
Dyskinesias are involuntary movements that occur when dopamine levels are too 
high (“peak-dose” – most common form), when dopamine levels are rising or falling 
(“diphasic”), when dopamine levels are low and are of dystonic nature (“OFF-dystonia”), 
when dopamine levels are high and are of dystonic nature (“ON-dystonia”) and when 
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there is no predictable pattern in dopamine levels and the involuntary movements (“yo-
yo”). 
 
 
 
Figure 9 Classification of Parkinson’s disease Motor Complications 
 
 
While there is individual variability in the phenomenology of dyskinesias, certain 
types are more commonly seen during specific phases (Nutt, 1992). Thus, ON phase 
dyskinesias are typically characterized by choreiform and choreo-dystonic movements that 
appear spontaneously and can be provoked or exaggerated by anxiety, speaking and 
physical activity (Marsden et al., 1981; Nutt, 1992). This type of dyskinesias can affect 
 53	  
virtually any muscle group, but predominate in the upper body (Luquin et al., 1992). 
Biphasic dyskinesias typically manifest as stereotypic, repetitive or ballistic movements, 
can have dystonic nature and mainly affect the lower limbs (Marsden et al., 1981; Nutt, 
1992). In the OFF phase, dystonic posturing, typically of the legs and feet, is the 
predominant type, although rare cases of hyperkinesias during the OFF state are also seen 
(Marsden et al., 1981; Quinn, 1998). Such hyperkinetic OFF phase dyskinesias resemble 
biphasic dyskinesias, thus appearing as repetitive, stereotypic and dystonic movements 
(Cubo et al., 2001). The same patient may exhibit all three patterns of dyskinesias and 
some patients may also experience dyskinesias in one part of the body while remaining 
parkinsonian (i.e. OFF) in another (Marsden et al., 1981; Luquin et al., 1992; Nutt, 1992).  
 
1.2.1.1	  Levodopa-­‐Induced	  Dyskinesias	  
L-DOPA remains the most effective symptomatic drug for PD, however its use is 
hampered by the emergence over time of fluctuations of motor symptoms and troublesome 
involuntary movements. These complications severely affect the quality of life of PD 
patients. The mechanisms, which contribute to the occurrence of these MF and 
dyskinesias, are not yet fully understood.  
PD dyskinesias induced with L-DOPA treatment were first reported by Cotzias 
and colleagues (1969); the group credited with the first successful use of L-DOPA in 
treating PD. The reported incidence rates of dyskinesias show a wide range, from 9–80% 
(Parkinson’s Study Group, 1996) and this usually depends on the risk factors. These 
include the age of PD onset, with young onset patients (40-59) having a 50% incidence of 
dyskinesias compared to patients with onset after 70 years of age at 16% (Kumar et al., 
2005). Other risk factors include the severity of PD and nigral denervation (Markham, 
1971), the amount of L-DOPA dose (Nutt et al., 1992) and the duration of L-DOPA 
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therapy  (Parkinson’s Study Group, 1996) with most of the patients developing 
dyskinesias after a period of L-DOPA treatment, which varies from 5 to 7 years in 
duration. 
Today, the greatest challenge for clinicians treating PD is to find appropriate 
solutions for preventing and managing dyskinesias and other MF that eventually will 
appear in some stage of the disease, severely diminishing patients’ quality of life. 
 
1.2.1.2	  The	  Role	  of	  PET	  in	  Understanding	  Motor	  Fluctuations	  and	  
Dyskinesias	  
Lines of evidence suggest that the development of MF and dyskinesias in PD are a result 
of changes leading to dysfunction in both the presynaptic and postsynaptic dopaminergic 
systems while other systems may as well play a role. 18F-DOPA PET has shown that PD 
patients with MF had a 28% decrease of presynaptic terminals in putamen compared to 
PD patients with stable responses to L-DOPA (de la Fuente-Fernández et al., 2000). A 
more recent study using PET with the DAT marker 11C-methylphenidate, has suggested 
that decreases in DAT expression may ultimately result in an increase in dopamine 
turnover and higher oscillations in synaptic dopamine concentrations and thereby, act as a 
predisposing factor for the occurrence of motor complications as disease progresses (Sossi 
et al., 2007). 
 By using PET with 11C-SCH23390 and RAC, the role of striatal dopamine D1 and 
D2 receptors in the development of dyskinesias has been explored in small series of PD 
patients. Turjanski and colleagues (1997) found that D1 and D2 receptor availability in the 
putamen and D1 receptor availability in the caudate were similar between dyskinetics and 
non-dyskinetics and within the normal range when compared to a group of normal 
controls. Moreover, RAC PET showed that D2 binding in the caudate was reduced about 
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15% in both groups. These observations, though made in small series of PD subjects, 
suggest that changes in striatal postsynaptic receptor availability are not primarily 
associated with the onset of motor complications. 
By using RAC PET to indirectly assess changes in presynaptic dopamine release, 
it was found that patients with fluctuating responses to L-DOPA had a more dramatic fall 
(~11%) in striatal RAC BP following L-DOPA administration when compared to patients 
with early PD or those with a stable response to treatment (Hwang et al., 2002).  
Furthermore, another study has reported that fluctuating responders to L-DOPA had a 
23% fall in RAC BP in the putamen compared to the more modest 10% fall found in 
stable responders to L-DOPA. Also, individual reductions in putaminal RAC inversely 
correlated with UPDRS motor scores in the OFF medication state (Torstenson et al., 
1997).    
 Taken together, these data indicate that as the severity of PD advances and the loss 
of dopamine terminal increases, the striatal control of dopamine release after 
administration of exogenous L-DOPA is progressively impaired. This could be due to the 
fact that the remaining terminals, following administration of exogenous L-DOPA, 
increase dopamine synthesis and the remaining DATs cannot compensate by reuptaking 
the excess of dopamine and therefore, cannot regulate the release of dopamine back in a 
physiological range. 
 Similar results have been reported in another RAC PET study involving an oral 
challenge with L-DOPA (de la Fuente-Fernández et al., 2001). In this study, the authors 
reported that in a group of PD patients with fluctuating responses to L-DOPA, synaptic 
levels of dopamine were three times higher than in PD patients with stable responses to L-
DOPA, one hour after L-DOPA administration. By contrast, whereas stable responders 
maintained the increased dopamine levels four hours after L-DOPA administration, the 
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synaptic levels in the group of PD patients with fluctuating responses to L-DOPA dropped 
to baseline, OFF state levels. 
In a further study conducted by the same group, it was found that there was a 
positive correlation between L-DOPA-induced increases in synaptic dopamine levels in 
both caudate and putamen and PD duration.  Also, an identical dose of L-DOPA induced 
increasingly larger changes in dopamine levels as the disease progresses (de la Fuente-
Fernandez et al, 2004).  The authors proposed that increasingly higher levels of L-DOPA-
induced dopamine release, as the disease progresses, could result in more dramatic 
changes in receptor occupancy and subsequent development of dyskinesias.  
Furthermore, in another in vivo indirect evaluation of synaptic dopamine release 
after a single oral dose of L-DOPA, PD patients with dyskinesias had a more pronounced 
reduction in putaminal RAC BP after L-DOPA when compared to stable responders. In 
the dyskinetic group, severity of dyskinesias correlated with higher levels of dopamine 
release suggesting that that the presence of dyskinesias is governed by the levels of 
dopamine generated at striatal D2 receptors (Pavese et al., 2006).     
 PET with 11C-diprenorphine has been used in order to investigate the role of opioid 
system in the development of PD dyskinesias. Reductions in 11C-diprenorphine binding 
in caudate, putamen, thalamus and ACC, were reported in the group of PD dyskinetics 
compared to stable responders (Piccini et al., 1997). Additionally, PET with 18F-L829165 
has shown that thalamic NK1 availability was reduced in dyskinetic PD patients while it 
remained normal in PD patients with stable responses to L-DOPA (Whone et al., 2002). 
Taken together, these last two findings suggest that elevated levels of endogenous peptides 
may also contribute to the appearance of dyskinesias. 
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1.2.1.3	  The	  Serotonergic	  Hypothesis	  in	  Levodopa-­‐Induced	  Dyskinesias	  
In patients with PD, the efficacy of L-DOPA replacement therapy depends on its ability to 
restore dopamine neurotransmission in the denervated areas of the forebrain, above all in 
the striatum. Formation of dopamine from exogenous L-DOPA and its storage and release 
is known to take place in other cellular elements beside the surviving dopaminergic 
terminals within the striatal tissue, including the serotonergic terminals.  
The brainstem serotonin (5-HT) neurons have been reported to be affected by the 
disease process to a varying degree (Agid and Javoy-Agid, 1987; Hornykiewicz, 1998). 
However, the 5-HT innervation of the striatal complex has been found to be in the normal 
range (Patel et al., 2000; Kim et al., 2003) or only moderately reduced (14-26%) (Kerenyi 
at al., 2003; Guttman et al., 2007) in comparison to the profound dopaminergic 
denervation (70-80%) and may thus play a role in the handling of exogenous L-DOPA 
(Lavoie and Parent, 1990; Nicholson and Brotchie 2002). 
5-HT neurons have been shown to be able to convert exogenous L-DOPA to 
dopamine, and store and release dopamine in an activity-dependent manner (Ng et al., 
1970; 1971; Tanaka et al., 1999; Maeda et al., 2005). L-DOPA-derived dopamine acting 
as a ‘false transmitter’ in serotonergic neurons may be particularly important in advanced 
stages of the disease when a major part of the nigrostriatal dopaminergic system has 
degenerated and the remaining dopaminergic neurons are in a compromised functional 
state (Tanaka et al., 1999; Kannari et al., 2001). The integrity of the 5-HT system may 
thus be an important factor in determining the development and maintenance of drug-
induced dyskinesias.  
The ability of L-DOPA to induce dyskinesias increases over time, resulting in a 
gradual loss of the therapeutic window of L-DOPA medication in more advanced PD 
patients (Mouradian et al., 1989). As discussed previously, de la Fuente-Fernandez and 
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colleagues (2004) have shown in a RAC PET study that peak dose dyskinesias in 
advanced PD patients are associated with excessive swings in synaptic dopamine (and 
hence dopamine receptor occupancy) induced by oral L-DOPA administration. This 
suggests that in the absence of functional striatal dopaminergic terminals L-DOPA-
derived dopamine may be released in a non-physiological ‘dysregulated’ manner from the 
residual 5-HT terminals (Figure 10).  
 
 
Figure 10 In normals and early stages of Parkinson’s disease levodopa is converted into dopamine in striatal 
dopaminergic terminals (top box). Dopamine storage into vesicles and D2 autoreceptors in these terminals 
provide smooth, regulated dopamine release. As Parkinson’s disease progresses dopamine axons degenerate 
and levodopa is increasingly taken up by the serotonergic terminals (bottom box). Dopamine release from 
these terminals is poorly regulated resulting in uncontrolled, excessive swings in dopamine release which 
contribute to dyskinesias (Modified from Carta et al., 2007) 
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In this model presented in Figure 10 (modified from Carta et al., 2007), the full 
therapeutic benefits of L-DOPA treatment will be maintained as long as there is a 
sufficient residual dopaminergic innervation to provide sites for dopamine storage and 
physiologically regulated dopamine release (Figure 10, top box). As dopaminergic neuron 
degeneration progresses, the 5-HT afferents will emerge as the prime site for L-DOPA-
derived dopamine storage and release. However, due to the lack of normal auto-regulatory 
feedback dopamine released from 5-HT terminals will be poorly regulated, resulting in 
uncontrolled, excessive swings in dopamine release (Figure 10, bottom box). In addition 
the L-DOPA-derived dopamine will displace endogenous 5-HT from the neuronal storage 
sites which is likely to have additional negative consequences since 5-HT released from 
serotonergic terminals normally exerts a negative feedback, via 5-HT1A and 5-HT1B auto-
receptors, on neuronal impulse flow. Under this condition, the activity at the 5-HT 
synapses is likely to be increased, which would further exacerbate the excessive swings in 
dopamine release. 
Recent experimental studies have demonstrated that the presence of L-DOPA-
induced dyskinesias (LIDs) in rats with 6-hydroxydopamine lesions of the nigrostriatal 
system is critically dependent on the integrity of serotonergic projections. In one study, the 
removal of striatal 5-HT afferents or the dampening of 5-HT activity by 5-HT1A or 5-HT1B 
receptor agonist drugs resulted in attenuation of the dyskinetic effects of L-DOPA (Carta 
et al., 2007). Several studies have shown that in adult rats and mice with nigro-striatal 
dopaminergic denervation, striatal serotonergic hyperinnervation can be observed 
following treatment with L-DOPA and dopamine can be detected in the serotonergic 
fibers.  
It has also been observed that the severity of dyskinesias positively correlates with 
the functional integrity of 5-HT terminals measured autoradiographically with a tracer for 
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the SERT. Animals with the same degree of dopaminergic denervation, and receiving the 
same doses of L-DOPA show a large variability in developing dyskinesias the severity of 
which critically correlates with integrity of 5-HT terminals (Cenci and Lundblad, 2006). 
Moreover, lesions of these terminals, whilst greatly reducing dyskinesias, do not appear to 
affect the antiparkinsonian effect of L-DOPA indicating that this is still dependent on 
surviving dopaminergic terminals.  
A recent study has reported that that the 5-HT1A agonist, buspirone, reduces the 
expression and development of LIDs in 6-OHDA lesioned rats without increasing 
parkinsonism (Eskow et al., 2007). Taken together, data from these experimental studies 
suggests that drugs acting by dampening the activity of the 5-HT neurons, particularly 
agonists of the 5-HT1A and 5-HT1B autoreceptors, may improve dyskinesias.  
 
1.2.1.3.1	  Buspirone	  in	  Parkinson’s	  Disease	  Dyskinesias	  
Buspirone, a partial agonist of 5-HT1A receptors, has been used with some success in a 
clinical trial of patients with tardive dyskinesia (TD) indicating that relatively high doses 
of buspirone might be efficacious in the treatment of TD (Moss et al., 1993). Furthermore, 
in experimental studies, it was demonstrated that buspirone administration has an 
inhibitory effect on an animal model of TD, although the exact mechanisms that may 
underlie the attenuating effect of buspirone on TD remain to be investigated (Queiroz and 
Frussa-Filho, 1999). 
In PD, buspirone has been tried to assess effects on motor response. Patients 
receiving either very high doses of 50-70mg/day or anxiolytic doses (less than 40mg/day) 
for a 10-week period had no benefit or detriment in their parkinsonian symptoms 
(Hammerstad et al., 1986). In another study, it was shown that buspirone at the higher 
dose of 100mg/day significantly improved dyskinesias scores but also significantly 
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worsen PD disability (Ludwig et al., 1986). However, both in this and in the study by 
Hammerstad and colleagues (1986), only few subjects were included. Additionally and at 
variance to what was reported previously in these small clinical trials, a study in animal 
model of PD reported that buspirone at a dose of 3mg/kg also increased locomotor activity 
(Mignon and Wolf, 2002).  
Buspirone has been tested in PD patients with LIDs and ON-OFF fluctuations 
(Kleedorfer et al., 1991). In this study, the effect of buspirone was assessed as an acute 
challenge (doses of 10 and 20mg) and during three consecutive days (doses of 15, 30, 45 
and 60mg). The acute challenge did not show any effect on the severity of involuntary 
movements, did not alter the quality of DRT motor response and no unwanted side effects 
occurred. The three-day challenge alleviated (mean improvement = 20%) dyskinesias with 
doses between 15 to 30mg per day being the most effective without influencing 
parkinsonism (Kleedorfer et al., 1991). However in this study, only five subjects in total 
were included. 
In another study, it was found that after a three-week period of treatment with 
20mg/day buspirone, PD patients with LIDs had no worsening of PD symptoms while 
buspirone significantly lessened the severity of LIDs in 71% of the patients suggesting 
that daily dosages of 20mg of buspirone might prove effective in reducing LID without 
worsening of parkinsonism (Bonifati et al., 1994).  
In agreement with these observations animal studies have shown that a 2mg/kg 
dose produced a significant 45% reduction in mice abnormal involuntary movement scale 
(AIMS) scores (Lundblad et al., 2005), that buspirone administered 30 min before L-
DOPA (IP) in rats in doses of 1, 2 and 4mg/kg decreased dyskinesias dose-dependently 
without any of these doses causing a decrease in the L-DOPA-induced locomotor scores 
(Dekundy et al., 2007) and that 0.25, 1.0 and 2.5 mg/kg (IP) of buspirone administered in 
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L-DOPA-primed rats, dose-dependently reduced and delayed LID development and 
improved L-DOPA-related motor performance by improving L-DOPA’s anti-parkinsonian 
efficacy (Eskow et al., 2007). These results support potential long-term benefits of 5-HT1A 
agonists for reduction of L-DOPA-related side effects (Eskow et al., 2007). 
 
1.2.2 Non-­‐Motor	  Complications	  in	  Parkinson’s	  Disease	  
The clinical course of PD, alongside the motor symptoms, is usually complicated with 
non-motor symptoms such as depression and anxiety, psychosis, sleep problems, cognitive 
decline and changes in weight and appetite (Figure 11). Non-motor symptoms in PD have 
great significance in terms of quality-of-life measures and financial expenses (Chaudhuri 
et al., 2006; Chaudhuri and Schapira, 2009). 
Non-motor symptoms have been reported to correlate with advancing age and 
severity of PD, though some of these symptoms such as depression, olfactory problems, 
constipation and sleep disorder, can occur early in the course of the disease (Chaudhuri et 
al., 2005). The early occurrence of non-motor symptoms is closely associated with the 
progression of Lewy body pathology (Braak et al., 2003). Lewy body pathology begins in 
olfactory bulb and lower medulla and later extends to substantia nigra pars compacta at a 
time where the motor features of PD become apparent. VTA and the hypothalamus 
represent key areas where dopaminergic systems affected by Lewy body pathology could 
contribute towards the development of non-motor symptoms through their extensive 
projections forming the major dopaminergic brain pathways such as the mesolimbic and 
TI pathways. 
PD pathology affects non-dopaminergic systems and Lewy body pathology is 
found in nucleus basalis of Meynert (cholinergic system), locus coeruleus (noradrenergic 
system) and raphe nuclei (serotonergic system). The nature of the non-motor features in 
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PD could involve dysfunction of these systems, associated with the clinical presentation of 
mood and appetite disorders, and sleep and endocrine problems. PET provides a useful in 
vivo tool for exploring non-dopaminergic system dysfunctions and their associations with 
clinical expressions.  
 
 
Figure 11 Classification of Parkinson’s disease Non-Motor Complications 
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1.2.2.1	  The	  Role	  of	  Hypothalamus	  in	  the	  Development	  of	  Non-­‐Motor	  
Complications	  
The pathophysiology underlying the emergence of the non-motor symptoms in PD 
remains uncertain. The hypothalamus, located at the base of the brain, acts as an integrator 
to regulate and coordinate electrolyte balance, feeding and energy metabolism, wake-sleep 
cycles, thermoregulation, stress responses, and sexual behavior and reproduction. 
Hypothalamic dysfunction could lead to endocrine and autonomic dysfunction, mood 
problems, sleep disturbance, and problems with sexual and appetite function. Therefore, 
dysfunction in the hypothalamus may have a role in the development of non-motor 
symptoms in PD. 
Postmortem studies implicate hypothalamic involvement in PD. Javoy-Agid and 
colleagues (1984) reported that dopamine concentrations in the hypothalamus were 
reduced in PD, suggesting that deficient hypothalamic dopamine transmission may play a 
role in the autonomic and endocrine abnormalities of this disorder. Shannak and 
colleagues (1994) reported a mild to moderate reduction in noradrenaline (NA), 5-HT and 
dopamine levels in the hypothalamus of patients with idiopathic PD. In agreement with 
these postmortem observations, 18F-DOPA PET has shown that the hypothalamic 
monoamine storage capacity is significantly reduced in patients with idiopathic PD 
(Pavese et al., 2006; Moore et al., 2008). 
While the presynaptic function of monoaminergic terminals in the hypothalamus 
has been studied, postsynaptic receptor function has remained unexplored. Dopamine D2 
and D3 receptors are both expressed throughout the hypothalamus (Gurevich and Joyce, 
1999) and PET with RAC provides means for exploring their function in patients with PD.  
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1.2.2.2	  PET	  Imaging	  of	  Serotonergic	  Function	  	  	  
Lines of evidence from biochemical, postmortem and imaging studies suggest that the 
serotonergic system is affected in PD (Toghi et al., 1993; Kerenyi et al., 2003; Kish, 2003; 
2008; Guttman et al., 2007; Albin et al., 2008). Braak has suggested that Lewy body 
pathology occurs in a gradual ascending fashion in PD, starting from the dorsal motor 
nucleus in presymptomatic stages and spreading to the pons and midbrain (Braak et al., 
2003). The median raphe is involved on stage 2, however, the pattern of serotonergic 
terminal loss is still unclear.  
The serotonergic system is thought to modulate mood, emotion, sleep, and 
appetite, so changes in its function may contribute to the non-motor features commonly 
associated with PD (Chaudhuri et al., 2006; Langston, 2006). The readiotracer 11C-
WAY100635 binds specifically to 5-HT1A receptors. These receptors are expressed both 
presynaptically, as somatodendritic autoreceptors localized on 5-HT cell bodies in the 
midbrain raphe nuclei where they inhibit 5-HT release, and postsynaptically, on cortical 
pyramidal neurons and on glia. Midbrain raphe 5-HT1A binding provides a functional 
measure of serotonergic system integrity and can be measured in vivo with 11C-
WAY100635 PET. A study using PET with 11C-WAY100635 has shown that the 
midbrain 5-HT1A binding is reduced by 29% in PD patients when compared with a group 
of normal controls (Figure 12).  
 
 
 66	  
 
Figure 12 Sagittal 11C-WAY100635 PET images showing reduced median raphe serotonin 5-HT1A binding 
in a Parkinson’s disease patient (right) compared to a normal control (left)  
 
Additionally, UPDRS combined tremor scores, but not rigidity or bradykinesia, 
correlated with decreased 5-HT1A binding in the raphe suggesting an important role for 
serotonergic neurons in the pathogenesis of tremor (Doder et al., 2003). While the 
brainstem 5-HT neurons have been reported to be affected by the PD, non-selective tracers 
with single photon emission computed tomography (SPECT) have suggested that the 
striatal 5-HT innervation is within the normal range (Patel et al., 2000; Kim et al., 2003). 
With regards to studying the serotonergic system, the importance of the 5-HT 
transporter (SERT, 5-HTT) in regulating 5-HT function is well documented; SERT is a 
membrane protein that is frequently targeted by antidepressant medication and is a marker 
for serotonergic neurons (Frankle et al., 2004). SERT is essential for the termination of the 
effect of 5-HT in the synapse (Figure 13).   
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Figure 13 The serotonin transporter; Mechanism of action. The action of serotonin at the synapse is 
terminated by its reuptake across the presynaptic membrane. This is an energy dependent process. 
Sodium/potassium ATPases use energy from ATP hydrolysis to create a concentration gradient of ions 
across the pre-synaptic membrane that drives the opening of the transporter and co-transport of sodium and 
chloride ions and serotonin from the synaptic cleft. Potassium ions binding to the transporter enable it to 
return to the outward position. Release of the potassium ions into the synaptic cleft equilibrates the ionic 
gradient across the pre-synaptic membrane. The serotonin reuptake transporter is then available to bind 
another serotonin molecule for re-uptake (image taken from CNSforum) 
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 PET imaging studies of SERT in PD have reported striatal and variable extra-striatal 
reductions. 11C-DASB and 11C-McN5652 PET have shown that SERT binding sites in 
the striatum are only moderately reduced (Kerenyi et al., 2003; Guttman et al., 2007). 
Guttman and colleagues (2007) found significant lower levels of 11C-DASB BP in the 
orbitofrontal cortex (22%), caudate nucleus (30%), putamen (26%) and midbrain (29%) of 
advanced PD patients when compared to a group of normal controls. 
PET with 11C-DASB has also been used to investigate whether changes in the 
serotonergic system occurs in early PD. In a study by Albin and colleagues (2008), 
patients with early PD had diffuse reductions in 11C-DASB BP throughout several brain 
regions, which were similar to that seen in advanced PD (Guttman et al., 2007). The 
authors of this study reported greatest reductions in 11C-DASB BP within the forebrain 
regions such as the cingulate cortices and insula (40-50%) when compared to normal 
controls. Other brain regions including the amygdala, hippocampus, thalami and basal 
ganglia had intermediate reductions in 11C-DASB BP (30-35%). These findings could 
reflect loss of SERT-expressing terminals and/or loss of serotonergic neurons as a result of 
disease. However, since 11C-DASB could be competing with synaptic 5-HT for SERT 
sites (Laruelle et al., 2003), another possible explanation for these results could be a SERT 
down-regulation to compensate for the lower levels of available 5-HT in the synapse. 
Another significant finding from this study was that serotonergic neurons within the 
caudal brainstem regions and medulla were relatively spared as reflected by a lower 
reduction of 11C-DASB BP (~20%) (Albin et al., 2008). These observations contradict 
Braak and colleagues’ (2003) hypothesis that pathologic changes to the serotonergic 
system in PD begin in the medulla.   
Although there seems to be some evidence of changes in serotonergic innervation 
within the PD brain, whether dysfunction and degeneration of these neurons plays a major 
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role in disease pathogenesis remains inconclusive. This is due to the limited number of 
studies assessing small cohorts of PD patients and which were therefore underpowered for 
performing correlations between regional cerebral SERT binding and clinical parameters 
(Kerenyi et al., 2003; Guttman et al., 2007; Albin et al., 2008).   
 
1.2.2.3	  The	  Role	  of	  PET	  in	  Understanding	  the	  Non-­‐Motor	  symptoms	  	  
 
1.2.2.3.1	  Depression	  
Depression affects 40-50% of patients with PD, is the most important factor impairing 
patients’ quality of life and is frequently unrecognized and undertreated (Taylor et al., 
1986; Starkstein et al., 1990; Dooneef et al., 1992; Cummings and Masterman, 1999; 
Kuopio et al., 2000). Clinical symptoms of depression on a PD background overlap with 
those of the condition itself, and PD depression has a different symptom profile to 
endogenous depression (Taylor et al., 1986; McDonald, 2008). The American Academy of 
Neurology (AAN) has recommended the “patient-report” Beck depression inventory – II 
(BDI-II) and the “clinician-report” Hamilton Rating Scale for Depression (HRSD) when 
screening for depression in PD (Miyasaki et al., 2006).  
The etiology of depression in PD remains uncertain. It is also unclear whether the 
pathophysiology of depression in PD is relevant to other forms of depression. Given this, a 
rationale approach for evaluating the efficacy of anti-depressants in PD is currently 
lacking (Miyasaki et al., 2006; Weintraub et al., 2005). 
Dopaminergic, serotonergic, and noradrenergic dysfunction may all be implicated 
in PD depression as all maybe affected by Lewy body pathology (Remy et al., 2005). 
Changes in noradrenergic and limbic dopaminergic neurotransmission have been studied 
using PET with 11C-RTI32. PD patients with depression have been reported to have lower 
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11C-RTI32 binding in locus coeruleus, thalamus and areas of the limbic system including 
ventral striatum, amygdala and ACC when compared to a group of non-depressed PD 
patients (Figure 14). Hence, the severity of anxiety in PD showed an inverse correlation 
with 11C-RTI32 binding in most of these regions, whereas apathy was inversely 
correlated with the radiotracer binding in the ventral striatum (Remy et al., 2005). 
 
 
 
Figure 14 Statistical parametric maps showing loss of 11C-RTI32 binding in the locus coeruleus, thalamus, 
ventral striatum and amygdala of depressed compared to euthymic Parkinson’s disease cases 
 
 In areas with low dopaminergic innervation such as the locus coeruleus, reduced 
11C-RTI32 binding mainly implicates the function of noradrenergic neurons, whereas in 
other areas a combined involvement of both dopaminergic and noradrenergic pathways is 
more likely to play a role. These findings suggest an important role of dopaminergic and 
noradrenergic systems dysfunction in the pathogenesis of depression in patients with PD.   
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The serotonergic system is known to modulate mood and emotion, and the 
pathophysiology of depression in PD could, therefore, be related to abnormal serotonergic 
neurotransmission with accompanying receptor changes in limbic regions (Fox et al., 
2009). The implications that 5-HT is involved in depressive symptoms are mainly based 
on the fact that depression can be induced by depletion of the monoamine either by 
inhibition of synthesis (Shopsin et al., 1976), or tryptophan depleting diets (Bell et al., 
2005; Young et al., 1985) leading to altered neurotransmission in the serotonergic 
pathways in the brain (Figure 15 and 16). Moreover, such conditions also tend to respond 
favourably to selective 5-HT reuptake inhibitors (SSRIs) (Stark and Hardison, 1985).   
 
 
Figure 15 Serotonin pathways in the normal brain. The principal centres for serotonergic neurones are the 
rostral and caudal raphe nuclei. From the rostral raphe nuclei axons ascend to the cerebral cortex, limbic 
regions and specifically to the basal ganglia. Serotonergic nuclei in the brain stem give rise to descending 
axons, some of which terminate in the medulla, while others descend to the spinal cord (image taken from 
CNSforum) 
 72	  
 Changes in the 5-HT neurotransmission have been evaluated using 11C-
WAY100635 PET (Doder et al., 2000) and showed that even though there is a 27-30% 
decrease in 5-HT1A binding in raphe nucleus of PD patients when compared to normal 
controls, there was no significant difference between depressed and euthymic PD patients 
at 5-HT presynaptic level. However, 5-HT1A receptors are also distributed postsynaptically 
on various cortical regions. In the same study, the group of depressed PD patients showed 
significant reductions in 5-HT1A binding in the ACC and superior and medial frontal gyrus 
when compared with the group of the euthymic PD patients. Taken together, these data 
suggest that the vulnerability to depression seen in PD is possibly associated with 
postsynaptic 5-HT1A receptor decreases in ACC and frontal cortex areas rather than 
presynaptic serotonergic function. 
The SERT is responsible for 5-HT transport back into presynaptic terminals after 
release into the synaptic cleft so maintaining a 5-HT pool available for subsequent release 
(Lesch and Gutknecht, 2005). Attempts to utilize PET to investigate the roles of the 
serotonergic system in both PD and non-PD depression have yielded inconsistent findings 
with either a reported decrease (Ouchi et al., 2009; Selvaraj et al., 2009), or an increase 
(Cannon et al., 2007; Hammoud et al., 2010) in the 11C-DASB BP. Boileau and 
colleagues (2008) studying seven patients with PET reported increased SERT binding in 
orbitofrontal cortex (OFC) in depressed early-stage PD cases compared to normal 
controls. Other studies such as post-mortem investigations found no difference in SERT 
density between patients with depression and healthy controls (Klimek et al., 2003; Bligh-
Glover et al., 2000). The reasons for the inconsistencies in findings between different 
studies are unclear. Whether this is due to factors such as differences in patient 
characteristics and experimental approach or whether it is dependent on time course of 
disease, remains to be seen. It is possible that longitudinal assessments of SERT binding 
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in patients over time would be able to elucidate this. To date, no study in PD has been 
powered to explore the relationship between SERT changes and depressive symptoms, 
rated with specific scales such as the BDI-II and HRSD.  
 
 
Figure 16 Serotonin pathways in the depressed brain. Serotonin transmission from both the caudal raphe 
nuclei and rostal raphe nuclei is reduced in patients with depression compared with non-depressed controls. 
Increasing the levels of serotonin in these pathways, by reducing serotonin reuptake and hence increasing 
serotonin function, is one of the therapeutic approaches to treating depression (image taken from 
CNSforum) 
 
1.2.2.3.2	  Weight	  and	  Body	  Mass	  Index	  
PD patients have been shown to characteristically lose weight (Abbott et al, 1992; Chen et 
al, 2003) and demonstrate a decrease in body mass index (BMI) (Beyer et al, 1995) 
compared to age-matched normal controls in several clinical studies. It has been reported 
that the frequency of BMI loss among such patients is between 52% and 65% (Abbott et 
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al., 1992; Moroo et al., 1994). Female PD patients tend to lose BMI to a greater extent 
than male PD patients (8.5% vs. 4.3%) (Durrieu et al., 1992) and the degree of BMI loss is 
more pronounced in advanced PD patients (Markus et al., 1993; Moroo et al., 1994; Uc 
EY et al., 2006).  
Although disease progression, age of diagnosis, sex and level of disabilities in 
patients are regarded as important factors in the development of weight loss in PD 
(Durrieu et al., 1992; Uc et al., 2006), the exact neurobiological mechanisms involved 
have not been fully understood. Various factors, involving disease symptomatology and 
medication side effects may contribute to BMI loss including depression (McDonald et al., 
2003) and DRT (Beyer et al., 1995; Bachmann et al, 2009). Increased energy expenditure 
(Chen et al., 2003) has been shown to not be the primary cause of BMI loss in these 
patients. In contrast weight gain has been observed in PD patients on L-DOPA (Gasparini 
et al., 1975) implicating its pharmacological action in the hypothalamus, a region 
associated with appetite regulation (Morton et al., 2006). BMI gain has been consistently 
demonstrated in patients following pallidotomy (Gironelli et al, 2000; Ondo et al., 2000; 
Vitek et al., 2003) and stimulation of the subthalamic nucleus (Barichella et al., 2003; 
Macia et al., 2004) with no association with amelioration of dyskinesia indicating that the 
increased energy expenditure due to these involuntary movements may not be responsible 
for BMI change in PD. 
The role of the serotonergic system in appetite regulation has been clearly 
established and there has been some experimental evidence suggesting that aspects of the 
serotonergic system are dysfunctional in subjects that are susceptible to weight changes 
(Wurtman et al., 1996; Leibowitz and Alexander, 1998). For example, regulation of 
growth hormone secretion by the 5-HT1 receptors in response to receptor agonists was 
found to be compromised in de novo PD patients when compared to normal controls 
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(Volpi et al., 1997). Furthermore, the drug tesofensine, which inhibits reuptake of synaptic 
5-HT (although also inhibits dopamine and NA reuptake) was found to effectively induce 
weight loss in moderately obese men (Sjödin et al., 2010). These findings could imply an 
involvement of the serotonergic system in weight change in PD and also in obese 
individuals.       
Animal studies have shown that a decrease in cerebral 5-HT levels is able to 
induce a subsequent down-regulation in SERT density (Rothman et al., 2003). In obese 
individuals, it is possible that a reduction in SERT density is caused by a compensatory 
down-regulation mechanism, which aims to curb the individual’s eating to reduce weight.  
With regards to weight loss in PD, it is possible that damage to the serotonergic system by 
the disease process leads to a reduction in brain 5-HT levels. Consequently, the lowered 5-
HT concentration triggers a down-regulation in SERT in the PD brain. Hence, this results 
in increased 5-HT concentrations in the brain due to reduced capacity for SERT to 
reuptake 5-HT. Abnormally high 5-HT levels in PD would then greatly diminish appetite 
and contribute to weight loss seen in the patients.   
In vivo investigations in healthy and overweight populations provide promising 
results suggestive of a serotonergic involvement to human BMI regulation. Two 18F-
altanserin PET studies found a positive correlation between 5-HT2A receptors and BMI in 
various regions including the superior temporal cortex, inferior temporal cortex, 
dorsolateral prefrontal cortex, sensory motor cortex (Adams et al., 2004), ACC, insula and 
hippocampus (Erritzoe et al., 2009) in humans. A recent 11C-DASB study found a 
negative correlation between SERT binding in the midbrain and a pre-defined caudate-
putamen-thalamus region and BMI in healthy and obese patents (Erritzoe et al., 2010). 
These findings supported an earlier preliminary report in healthy subjects, which found a 
negative correlation between SERT binding and BMI in the raphe nuclei, thalamus, insula 
 76	  
and posterior cingulate cortex (PCC) (Matsumoto et al., 2008). These findings may be 
suggestive of a direct role of SERT on BMI regulation or may reflect a compensatory 
mechanism due to low extracellular 5-HT levels. In contrast a 123I-nor-β-CIT SPECT 
twin study reported a positive correlation between SERT and BMI with higher SERT 
binding found in the heavier twin (Koskela et al., 2008).   
The pathophysiology underlying BMI change in PD patients remains unknown and 
to date no in vivo studies have been undertaken. There is evidence suggesting that 
serotonergic neurotransmission in PD is altered (Fox et al., 2009). Early postmortem 
studies found a depletion of 5-HT in caudate nucleus, hypothalamus and frontal cortex of 
PD patients (Fahn et al., 1971; Scatton et al., 1983; Shannak et al., 1983) with a greater 
degree of loss in the caudate nucleus compared to the putamen in a more recent 
pathological study (Kish et al., 2008). This effect may impede functions related to the 
serotonergic system, such as appetite and cognitive and emotional processes related to 
eating behaviour and ultimately BMI regulation leading to BMI change.  
 
1.3	  Therapy	  A:	  Fetal	  Cell	  Transplantation	  in	  
Parkinson’s	  Disease	  	  
Transplantation of human fetal dopamine neurons grafted in the striatum of PD patients 
has been investigated for over two decades. The pattern of recovery has varied between 
cases with some patients exhibiting significant symptomatic relief with reduced OFF 
phase severity and decreased requirement for DRT while others have not benefited as 
much or have developed adverse effects such as OFF-medication dyskinesias, These 
dyskinesias have became a major road-block for the further development of dopamine cell 
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replacement strategies for PD including stem cells (Lindvall and Hagell, 2000; Lindvall 
and Björklund, 2004). 
 Clinical trials assessing the efficacy and safety of intrastriatal transplantation of 
fetal ventral mesencephalic (VM) tissue in patients with PD rely on the rationale that the 
grafted tissue will restore the striatal dopamine transmission and improve striatal-cortical 
circuitries thereby producing long-lasting clinical improvement. However, despite the 
current scientific developments, the mechanisms responsible for the success or failure of 
grafting human fetal VM tissue are only partly understood. 
 PET with the use of specific radioligands has been proven to be an useful in vivo 
tool for the development of a clinically competitive cell replacement therapy in PD. PET 
with 18F-DOPA has been used to monitor survival and storage of dopamine in grafted 
neurons and can be used for screening patients who are not suitable for transplantation. 
PET with RAC and pharmacological challenge with L-DOPA or amphetamine can assess 
the ability of the grafted dopaminergic cells to increase the synaptic levels of dopamine. 
Activation studies with PET and H215O allow measures of regional changes in brain 
metabolism and blood flow (Brooks, 2004). Functional magnetic resonance imaging 
(fMRI) and diffusion tensor imaging (DTI) techniques can also assess the effect of the 
transplanted dopamine cells on the of basal-ganglia–cortical networks and the relevance of 
the restoration of these circuitries on the clinical outcome. PET with 11C-DASB can 
provide insight on the role of serotonergic terminals into the mechanisms underlying 
postoperative OFF-medication dyskinesias by providing a means to quantify the amount 
of serotonergic innervation present in the dopaminergic-rich transplanted graft. 
 
 78	  
1.3.1	  Monitoring	  the	  Presynaptic	  Dopaminergic	  System	  and	  Graft	  
Survival	  
11C-RTI-121 PET studies in rats have demonstrated a correlation between the survival of 
striatal grafts and striatal binding of the tracer (Sullivan et al., 1998). To date, there are no 
11C-dihydrotetrabenazine PET data on the expression and survival of VMAT2 in VM 
tissue grafts. Also, imaging techniques have been unable to detect significant changes in 
DAT binding after transplantation of VM tissue in humans- though putaminal 18F-DOPA 
uptake improved (Cochen et al., 2003). Two post-mortem studies have reported opposite 
results concerning DAT expression in grafted neurons (Kordower et al., 1996; 2008). 
18F-DOPA PET can provide an in vivo means of objectively monitoring the 
progression of neurodegenerative disorders and the functional effects of restorative 
treatments. Functional imaging with 18F-DOPA PET has indeed been used early on in the 
European open trials to objectively monitor survival and growth of human fetal dopamine 
neurons grafted in the striatum of PD patients (Lindvall and Hagell, 2000; Lindvall and 
Björklund, 2004; Brooks, 2004). Several of these open trials have shown significant 
increases in 18F-DOPA uptake after striatal grafts supporting the concept that human fetal 
VM dopamine neurons can survive and grow in the brain of PD patients (Lindvall 1990; 
1994; 1999; Freed et al., 1992; Sawle et al., 1992; Widner et al., 1992; Peschanski et al., 
1994; Freeman et al., 1995; Remy et al., 1995; Wenning et al., 1997; Hagell et al., 1999; 
Hauser et al., 1999; Piccini et al., 1999; 2000; 2005; Brundin et al., 2000; Mendez et al., 
2000; 2002; Cochen et al., 2003). Histopathological analyses have confirmed survival of 
the dopaminergic grafts and demonstrated their ability to reinnervate the striatum 
(Kordower et al., 1995; 1996; 1998).  
Available clinical data show that the outcome following transplantation is 
dependent on restoration of the number of viable dopaminergic neurons innervating the 
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striatum as assessed by 18F-DOPA PET. According to data from open trials it appears that 
an increase in 18F-DOPA uptake of 50–60% of the normal mean is necessary to achieve 
clinically valuable antiparkinsonian effects (Hagell et al., 1999; Brundin et al., 2000). 
The Lund group has reported up to six-year follow-up data on four PD patients 
who had received unilateral putaminal implants and on two PD patients who had received 
unilateral putaminal and caudate implants of human fetal VM tissue (Wenning et al., 
1997). All these patients received immunosuppression therapy. After one year following 
transplantation, there was a mean 68% increase in putaminal 18F-DOPA uptake on the 
implanted side but only 6% mean increase in the implanted caudate whereas the non-
implanted putamen showed a corresponding 25% mean decrease in 18F-DOPA uptake. 
The changes in 18F-DOPA PET following implantation were mirrored by improvements 
in the OFF state UPDRS motor scores which were reduced by 18% in the first 
postoperative year while the mean time in OFF fell by 34%. One of these PD cases was 
withdrawn from any dopaminergic medication and his putaminal 18F-DOPA uptake 
reached normal levels.  
Five of these six PD patients subsequently received transplantation of human fetal 
VM tissue on the side that had not been grafted originally (Hagell et al., 1999). Twelve to 
18 months following the second graft, there was an 85% mean increase in 18F-DOPA 
uptake in the more recently transplanted putamen but no further 18F-DOPA change in the 
previously transplanted putamen. Clinical scores in the majority of the PD patients who 
received the second graft were further improved with reduced bradykinesia scores, 
reduced time spent in OFF and lower dopaminergic medication requirements.  
A few years later the Lund group performed bilateral putamen and caudate 
transplantation of human fetal VM tissue in four more PD patients (Brundin et al., 2000). 
By six months postoperatively the mean 18F-DOPA uptake had increased in these patients 
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by 53% in putamen and by 24% in caudate compared to the baseline. At the 20-month 
follow-up 18F-DOPA uptake was increased of only 3% in the putamen and 4% in the 
caudate compared to the previous assessment (Figure 17). However, clinical parameters 
such as the UPDRS motor scores, continuously improved over this period with scores 
falling by an average of 50%. These data suggest that graft function and integration 
continues despite the stabilization of dopamine storage capacity. Furthermore, 
dopaminergic medication requirements were reduced by a mean of 50% and one subject 
was withdrawn from any dopaminergic medication.  
 
 
 
Figure 17 Serial 18F-DOPA PET scans in a Parkinson’s disease patient before transplantation (left), and 
eight (middle) and 21 (right) months after transplantation with human fetal ventral mesencephalic tissue in 
caudate and putamen bilaterally 
 
Remy and colleagues (1995) reported up to two-year 18F-DOPA PET follow-up 
data on three PD patients who had received unilateral putaminal transplantation of human 
fetal VM tissue and on two PD patients who additionally received unilateral caudate 
implants. In these patients a 61% mean increase in 18F-DOPA uptake in the grafted 
putamen was shown after one year postoperatively, whereas in the grafted caudate no 
significant changes were reported. Putaminal 18F-DOPA uptake values correlated with % 
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times in ON and timed finger dexterity when OFF. The results of this study indicated that 
transplantation of human fetal VM tissue, by restoring putaminal 18F-DOPA uptake to 
normal levels, is able to restore normal limb function in patients with PD. 
  An open label study performed in Tampa assessed four PD patients who had 
received bilateral putaminal transplantation of human fetal VM tissue (Freeman et al., 
1995). They found that six months after transplantation there were 53% and 33% mean 
increases in right and left putaminal 18F-DOPA uptake, respectively. The clinical scores 
were also improved with a 37% mean decrease in UPDRS total scores, a 41% mean 
increase in Schwab and England disability score, a 65% mean decrease in time spent OFF 
and 92% mean decrease in ON dyskinesias. Two of these transplanted PD cases died from 
unrelated causes and post mortem examination showed viable tyrosine hydroxylase 
staining graft tissue forming connections with host neurons (Kordower et al., 1995).   
 Given the encouraging results of these open trials, two major double-blind sham-
surgery controlled trials assessing the efficacy of transplantation of human fetal VM tissue 
in PD were sponsored by the National Institute of Health (NIH) in the USA. The first 
double-blind trial involved 40 advanced PD patients with mean disease duration of 14 
years and age ranging from 34 to 75 years of age (Freed et al., 2001). The subjects were 
randomized to receive either bilateral intraputaminal transplantation of human fetal VM 
tissue or sham-surgery and no immunotherapy was used. The primary end point of the 
study was not fulfilled, as the patients who had received transplantation did not show a 
significant improvement in the global clinical impression scale as reported by the patients 
themselves one year after surgery. However, there was a significant 18% mean 
improvement in the UPDRS motor scores in the OFF state when compared with the sham-
surgery group. PET imaging showed a 40% mean increase in putaminal 18F-DOPA 
uptake. When the transplanted patients were subdivided into two groups according to age 
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older or younger than 60 it was observed that patients younger than 60 had significant 
clinical improvement (UPDRS motor score fell by 38%) in comparison to baseline. 
Unfortunately, 15% of patients in this trial developed OFF-dystonia and OFF-medication 
dyskinesia. 
 In a recent report the long-term clinical and PET outcome of 33 of the participants 
in the original trial of Freed and colleagues were retrospectively assessed. These subjects 
were followed for two years after transplantation while 15 were followed for two more 
additional years (Ma et al., 2010). This study showed that UPDRS motor scores declined 
over time postoperatively and that the difference in clinical improvement between younger 
and older patients seen at one year after transplantation was not evident at longer-term 
follow-up. Furthermore, putaminal 18F-DOPA uptake correlated with changes in clinical 
parameters suggesting that the clinical benefit and graft viability were sustained up to four 
years after transplantation and that clinical difference related to the age of the subjects 
may not persist over the long term. 
 In the second NIH-funded double-blind trial, 34 PD patients were randomized to 
receive either bilateral intraputaminal transplantation of human fetal VM tissue procured 
from four fetuses per side or tissue from one fetus per side or to undergo sham-surgery 
(Olanow et al., 2003). All patients received immunosuppressant treatment for a period of 
6-months after operation. The primary endpoint of the trial was set as the change in 
UPDRS motor score in the OFF state. Two patients died during the trial while another 
three died after the trial, all from unrelated causes. In total, 31 patients completed this trial. 
Post mortem findings showed significantly greater tyrosine hydroxylase staining in the 
putamen of the patients who received transplantation than the sham surgery patients, with 
evident graft innervation of intrinsic cells. 18F-DOPA scans showed significant increases 
of 20 and 30% in mean putaminal uptake in patients who had received tissue from one and 
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four fetuses, respectively while there were no changes in putaminal uptake in the control 
sham-surgery group.  
Similarly to the previous double-blind trial, this study did not showed significant 
difference in the primary endpoint. The mean OFF UPDRS motor scores in the patients 
transplanted with four fetus group improved by 0.7 points over 2 years while it 
deteriorated by 3.5 and 9.4 points in the patients transplanted with one fetus and in the 
sham-surgery control group, respectively. These clinical changes were not significantly 
different overall. However, at six months and before discontinuation of 
immunosuppression the transplanted groups were both significantly improved. Also, 
transplanted PD patients with less severe disease who had received tissue from four 
fetuses per side improved by an adjusted mean score of 1.5. However, there were no 
significant differences in ON time without dyskinesias, the total OFF time, activities of 
daily living scores and dopaminergic requirements needed between the groups. 
Furthemore, this study yet again highlighted the problem of OFF-medication dyskinesias, 
which were evident in more than half of the transplanted PD patients.        
 
1.3.2	  Indirect	  Assessment	  of	  Dopamine	  Release	  and	  Graft	  
Function	  
RAC and 123I-IBZM are both benzamide ligands with affinity for the D2 receptor in the 
low nanomolecular range and therefore are subject to competitive displacement by 
endogenous dopamine (Volkow et al., 1994; Chugani et al., 1988). Acute administration 
of substances such as amphetamine, methylphenidate, or L-DOPA which are known to 
increase the levels of extracellular dopamine result in a reduction of striatal RAC and 
123I-IBZM binding (Laruelle et al., 1995; de la Fuente-Fernadez et al., 2001; Goerendt et 
al., 2003). In normal subjects, 0.3 mg/Kg infusion of methamphetamine results in a 25% 
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decrease of striatal RAC binding, which has been estimated to represent a 10-fold increase 
in extracellular dopamine levels (Morris et al., 1995). In patients with PD, a similar 
amount of methamphetamine induces only 40% of the dopamine release seen in normal 
subjects (Piccini et al., 2003).  
 Studies with RAC PET and pharmacological challenges have shown that human 
fetal VM tissue can restore dopamine release in the striatum of patients with PD. In one 
patient who had received unilateral intraputaminal transplantation of human fetal VM 
tissue 10 years previously and had subsequently showed major clinical improvement, 18F-
DOPA uptake was observed to be restored to normal levels in the grafted putamen, 
whereas 18F-DOPA uptake was only about 10% of normal level in the non-grafted 
putamen. Dopamine release from the grafted cells was also shown to be within normal 
levels in the grafted putamen, suggesting that grafted neurons can continue for a decade to 
store, release dopamine and give rise to substantial symptomatic relief (Piccini et al., 
1999).    
 
1.3.3	  Graft-­‐Induced	  Dyskinesias	  
Troublesome involuntary movements in the absence of dopaminergic medication, so-
called OFF-medication dyskinesias, are a serious adverse effect of fetal neural grafts that 
hinders the development of cell-based therapies for PD. The mechanisms underlying these 
dyskinesias are not well understood and it is not known whether they are the same as in 
the dyskinesias induced by L-DOPA treatment. OFF-medication, Graft-induced 
dyskinesias (GIDs) have been reported in subsets of PD patients in all clinical trials (Freed 
et al., 2001; Hagell et al., 2002; Olanow et al., 2003). Occurrence of GIDs was one of the 
major concerns raised in the two NIH sponsored double-blind sham-surgery controlled 
trials (Freed et al., 2001; Olanow et al., 2003). Indeed in both trials a significant number of 
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patients  (15% and 56.4%, respectively) developed GIDs. The Lund group also reported 
occurrence of GIDs in 14 transplanted patients (8 mild, 5 moderate), although only in one 
patient GID constituted a major clinical problem (Hagell et al., 2002).     
 Notwithstanding the several mechanisms having been proposed, the pathogenesis 
of GID remains unclear. In their initial report, Freed and colleagues (2001) suggested that 
GIDs could be related to fiber outgrowth from the graft causing increased dopamine 
release. This hypothesis was supported by two further observations. Ma and colleagues 
(2002) observed that PD patients with GIDs showed an imbalance between dopaminergic 
innervation in the ventral and dorsal putamen with asymmetric increases in 18F-DOPA 
uptake in the nongrafted ventral striatum. Another study (Huang et al., 2003) reported that 
GIDs in one patient were associated with an increased caudate 18F-DOPA uptake and in 
two other patients with greater than expected striatal RAC displacement after a L-DOPA 
challenge. In these cases, RAC binding in the OFF state was reduced below normal, 
suggesting that striatal D2 receptors were occupied by excessive release of dopamine both 
under baseline conditions and after L-DOPA challenge. 
 There are, however, several lines of evidence against this view. Olanow and 
colleagues (2003) reported no differences in either regional or global levels of striatal 18F-
DOPA uptake between patients with and without GIDs. In another study, the severity of 
GIDs was inversely correlated with baseline 18F-DOPA uptake before surgery rather than 
post transplantation increases. The authors argued against GIDs arising as a consequence 
of excessive dopaminergic function (Hagell et al., 2002). In support to this view, in one of 
the double-blind sham-surgery trials (Freed et al., 2001), there was no obvious 
relationship between the severity of GIDs and increases in 18F-DOPA uptake. 
Furthermore, a subsequent study using a RAC paradigm with administration of placebo or 
methamphetamine reported no evidence that GIDs were caused by abnormal dopamine 
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release from the grafts. Also these authors did not observe any correlation between 
baseline or after methamphetamine putaminal RAC binding and dyskinesia severity scores 
in the contralateral side of the body (Piccini et al., 2005). 
Observations from animal models of dyskinesias have indicated a possibility that 
failure of the grafts to restore a precise distribution of dopaminergic synaptic contacts on 
host neurons could result in abnormal gating of corticostriatal inputs, causing abnormal 
striatal signaling and synaptic plasticity which may result in an increase in dyskinesia 
(Cenci and Hagell, 2005). 
The occurrence of GIDs may be also induced by inflammatory and immune 
responses around the graft. In this context, it is interesting to note that in the study of 
Olanow and colleagues (2003), dyskinesias developed after discontinuation of 
immunosuppressive therapy, with signs of an inflammatory reaction around the grafts in 
autopsied cases. In agreement with this observation, withdrawal of immunosuppression at 
29 months after transplantation in the Lund subjects associated with increased dyskinesias, 
which might have been caused either by growth of the graft or worsening of a low-grade 
inflammation around the graft (Piccini et al., 2005).  
 An important factor for the development of GIDs could include the composition of 
the cell suspension. The composition of the graft derived from human fetal VM tissue 
contains a varied proportion of non-dopaminergic neurons or non-neuronal cells with 
different properties such as firing pattern, transmitter release, and axonal growth capacity 
(Isacson et al., 2003). Among these non-dopaminergic neurons, serotonergic neurons have 
been found at post mortem in the grafted tissue of PD patients (Mendez et al., 2008). 
Animal models of PD indicate that serotonergic neurons may contribute to the dyskinesias 
induced by L-DOPA treatment by converting L-DOPA to dopamine, which is stored and 
then released from the serotonergic terminals in a dysregulated manner (Carta et al., 
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2007). Graft-derived serotonergic neurons may mishandle the release of dopamine in the 
extracellular space and therefore result in an increase GID. Also, it has been stated that the 
ratio between 5-HT and dopamine neurons could be the driving factors for the 
development of the dyskinesias (Carlsson et al., 2007; 2009; Cartal et al., 2007; Munoz et 
al., 2008). 
  
1.4	  Therapy	  B:	  Continuous	  Dopaminergic	  Stimulation	  
in	  Parkinson’s	  Disease	  
A growing number of preclinical and clinical studies suggest that pulsatile stimulation of 
striatal dopamine receptors from the use of short acting oral L-DOPA preparations may 
influence the development and increase the frequency of dyskinesias and MF. In contrast, 
a more continuous and less pulsatile form of dopaminergic stimulation delivered by long-
acting DAs or infusions of L-DOPA may result in a stable clinical response and also have 
a protective effect against the onset of motor complications (Olanow et al., 2006).  
Based on these observations new L-DOPA formulations and routes of 
administration have been introduced in the treatment of PD during the last decade, 
including slow release preparations, addition of a catechol-O-methyltransferase (COMT) 
inhibitor (entacapone or tolcapone), and IV and enteral (duodenal) infusions of L-DOPA 
(Box 1). These strategies aim to achieve more stable L-DOPA plasma levels and 
optimisation of L-DOPA pharmacokinetics (de la Fuente-Fernandez et al., 2001).   
However whether they actually provide continuous dopaminergic stimulation by 
inducing stable and more prolonged levels of striatal dopamine remains to be ascertained. 
Also, the long-term effects of these pharmacological approaches on the ability of the 
striatum to generate dopamine also remain to be clarified.  
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RAC PET following pharmacological challenge has been applied in several studies 
to estimate synaptic levels of dopamine in PD (Piccini et al., 1999; 2003; 2005; e la 
Fuente -Fernandez et al., 2001; 2004; Evans et al., 2006; Pavese et al., 2006). Results from 
these studies have shown that striatal reductions in RAC binding after challenge with L-
DOPA are more rapid, larger, and shorter lived with greater motor disability (Pavese et al., 
2006) and disease progression (de la Fuente -Fernandez et al., 2004). Taken together, 
these results strongly indicated that aberrant presynaptic processing of L-DOPA in the 
striatum is associated with motor complications. It needs to be investigated whether 
enteral infusions of L-DOPA/carbidopa are able to produce steady striatal levels of 
dopamine release associated with a good locomotor response. 
 
Box 1 Enteral Levodopa/Carbidopa gel infusion (Duodopa®)  
Enteral levodopa/carbidopa gel infusion (Duodopa®) is an orphan drug licensed for 
treatment of advanced Parkinson’s disease patients with severe motor fluctuations and 
dyskinesias. Patients receive a percutaneous endoscopic gastrostomy using a special 
catheter through which levodopa/carbidopa intestinal gel is infused via a portable pump to 
provide continuous intra-intestinal infusion of levodopa/carbidopa. 
 
1.5	  Aims	  and	  Groups	  of	  Investigations	  
 
Dopamine D2 Receptor Dysfunction in Parkinson’s Disease 
(a) To investigate the effect of medication, motor disability and depressive symptoms on 
striatal postsynaptic dopamine D2 receptors in PD patients. 
(b) To investigate the functional integrity of hypothalamic postsynaptic dopamine D2 
receptors. It is hypothesised that dysfunction of these receptors would be evident in 
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idiopathic PD patients possibly accounting in part for the non-motor symptomatology 
commonly seen in the clinical course of the disease.   
 
Serotonergic Dysfunction in Parkinson’s Disease 
(a) To provide an index of presynaptic serotonergic terminal dysfunction in different 
clinical stages of PD and to correlate SERT binding with general disease disability scales. 
A secondary aim is to investigate the relationship between SERT binding and chronic 
exposure to dopaminergic therapy. 
(b) To investigate the relationship between depressive symptoms and SERT availability. It 
is hypothesised that anti-depressant naive PD patients with the highest BDI–II and HRSD 
scores would show relatively increased SERT availability, possibly reflecting lower 
extracellular 5-HT levels. 
(c) To investigate the relationship between BMI changes and SERT availability. It is 
hypothesised that PD patients with the highest BMI changes over the last year would show 
altered SERT availability, possibly reflecting changes in extracellular 5-HT levels. 
 
Levodopa-Induced Dyskinesias in Parkinson’s Disease 
(a) To investigate the integrity of striatal postsynaptic dopamine D2 receptors in LID in 
patients with PD.  
(b) To investigate the role of striatal serotonergic terminals in LID in patients with PD. It 
is hypothesised that PD patients with LIDs will not show differences in levels of integrity 
of striatal serotonergic terminals in comparison to PD patients with stable response to L-
DOPA. Furthermore, a bolus dose (a single dose given all at once) of the 5-HT1A receptor 
agonist, buspirone, will attenuate the high synaptic dopamine levels generated after 
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administration of L-DOPA in PD patients with LIDs and will consequently, reduce the 
dyskinesia severity without increasing PD symptoms. 
 
Graft-Induced Dyskinesias in Parkinson’s Disease Patients with Neural 
Transplants 
To investigate the role of serotonergic neurons within intrastriatal grafts in the 
development of GIDs in two PD patients who had shown recovery of motor function after 
intrastriatal fetal VM tissue transplantation. It is hypothesized that a dense serotonergic 
network will be responsible for generating dysregulated synaptic levels of dopamine and 
that low repeated doses of the 5-HT1A receptor agonist, buspirone, will normalize synaptic 
dopamine levels and consequently, reduce dyskinesia severity without increasing PD 
symptoms. 
 
Dopaminergic Stimulation in Parkinson’s Disease 
To investigate the ability of enteral L-DOPA/carbidopa gel infusions (Duodopa®) 
to produce steady striatal levels of dopamine and to correlate these levels with changes in 
motor and non-motor symptoms. It is hypothesised that enteral levodopa/carbidopa gel 
infusion (Duodopa®) by providing stable and prolonged L-DOPA delivery will also result 
in more stable and prolonged synaptic levels of dopamine within the brain and possibly 
generate a significant clinical improvement.  
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Methodology    2	  
 
 
2.1	  Subjects	  and	  Permissions	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	        
 
Clinical and PET imaging data from 85 PD subjects (69M, 16F) and 45 normal controls 
(35M, 10F) were collected and analyzed in the studies included in this PhD thesis. The PD 
subjects fulfilled the UK Brain Bank clinical criteria for idiopathic PD (Hughes et al., 
1992). All normal controls were in good health, with no history of neurological or 
psychiatric illness and they were under no medication during the time of the assessments. 
Normal controls undertook a screening visit to confirm suitability and only 21 (19M, 2F) 
were new recruits. Data for the remaining 24 (16M, 8F) normal control subjects were 
taken from a previously developed electronic database.  
Subject recruitment was performed in Charing Cross and Hammersmith Hospitals 
Movement Disorder clinics, Hammersmith Hospital General Neurology clinics, Queen 
Square Movement Disorder clinics, King’s College and Lewisham Hospitals Movement 
Disorder clinics, through advertisement in London newspapers, PD Society UK, Local PD 
newsletters and magazines, and publicity posters. 
All subjects have given informed written consent in accordance with the 
Declaration of Helsinki (International Committee of Medical Journal Editors, 1991). All 
studies received ethical approval from the Hammersmith and Queen Charlotte’s and 
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Chelsea Hospitals Research Ethics Committee. Permission to administer radioactive 
substances (RAC, 11C-DASB, 18F-DOPA) was obtained from the Administration of 
Radioactive Substances Advisory Committee (ARSAC) of the Department of Health, UK. 
The Radioactive tracers were fully supplied by Hammersmith Imanet plc, London, UK. 
 
2.2	  Medication	  
	  
2.2.1	  Levodopa	  	  
L-DOPA 250/carbidopa 25 (Sinemet 275®) is a combination of carbidopa and L-DOPA 
for the treatment of PD. Carbidopa, an inhibitor of AAAD, is a white, crystalline 
compound, slightly soluble in water, with a molecular weight of 244.3. It is designated 
chemically as (—)-L-α hydrazino- α-methyl-β-(3,4-dihydroxybenzene) propanoic acid 
monohydrate. Its empirical formula is C10H14N2O4•H2O, and its structural formula is seen 
in Figure 18. The tablet content is expressed in terms of anhydrous carbidopa and has a 
molecular weight of 226.3. 
 
 
Figure 18 Structural Formula of Carbidopa 
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L-DOPA, an aromatic amino acid, is a white, crystalline compound, slightly 
soluble in water, with a molecular weight of 197.2. It is designated chemically as (—)-L-
α-amino-β-(3,4-dihydroxybenzene) propanoic acid. Its empirical formula is C9H11NO4, 
and its structural formula is seen in Figure 19. 
 
 
 
Figure 19 Structural Formula of Levodopa 
 
L-DOPA 250/carbidopa 25 preparation also contains the inactive ingredients 
cellulose, magnesium stearate, starch and FD&C Blue 2. 
 
2.2.1.1	  Mechanism	  of	  Action	  
Current evidence indicates that symptoms of PD are related to depletion of dopamine in 
the corpus striatum. Administration of dopamine is ineffective in the treatment of PD 
because it does not cross the blood-brain barrier. However, L-DOPA, the metabolic 
precursor of dopamine, does cross the blood-brain barrier, and presumably is converted to 
dopamine in the brain (Figure 20). This is thought to be the mechanism whereby L-DOPA 
relieves symptoms of PD.  
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Figure 20 Metabolism of Levodopa 
	  
2.2.1.2	  Pharmacodynamics	  
When L-DOPA is administered orally, it is rapidly decarboxylated to dopamine in 
extracerebral tissues so that only a small portion of a given dose is transported unchanged 
to the central nervous system (CNS). For this reason, large doses of L-DOPA are required 
for adequate therapeutic effect, and these may often be accompanied by nausea and other 
adverse reactions, some of which are attributable to dopamine formed in extracerebral 
tissues. Since L-DOPA competes with certain amino acids for transport across the gut 
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wall, the absorption of L-DOPA may be impaired in some patients on a high protein diet. 
Carbidopa inhibits decarboxylation of peripheral L-DOPA. It does not cross the blood-
brain barrier and does not affect the metabolism of L-DOPA within the CNS. The 
incidence of L-DOPA-induced nausea and vomiting is less with L-DOPA/carbidopa than 
with L-DOPA alone. In many patients, this reduction in nausea and vomiting will permit 
more rapid dosage titration. Since its decarboxylase inhibiting activity is limited to 
extracerebral tissues, administration of carbidopa with L-DOPA makes more L-DOPA 
available for transport to the brain.  
 
2.2.1.3	  Pharmacokinetics	  
Carbidopa reduces the amount of L-DOPA required to produce a given response by about 
75% and, when administered with L-DOPA, increases both plasma levels and the plasma 
half-life (t1/2) of L-DOPA, and decreases plasma and urinary dopamine and homovanillic 
acid. The plasma t1/2 of L-DOPA is about 50 mins, without carbidopa. When carbidopa 
and L-DOPA are administered together, the t1/2 of L-DOPA is increased to more than 1.5 
hours (Tables 2 and 3). L-DOPA/carbidopa clearance and volume of distribution but not 
the t1/2, peak plasma concentration (Cmax) and time to peak plasma drug concentration 
(Tmax) are affected by age (Okereke, 2002).	  	  	  
 
Table 2 Levodopa / Carbidopa Pharmacokinetics 
GENERAL LEVODOPA / CARBIDOPA PHARMACOKINETICS 
tmaxa 0.5-2hrs 
t1/2b 1-3hrs 
% Bioavailability  ~80-89% 
 atmax = time to peak plasma drug concentration; bt1/2 = half-life 
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Table 3 Parmakocinetic Parameters of Absorption of Levodopa 250 / Carbidopa 25 in normal 
controls and Parkinson’s disease patients (modified from Rainero et al., 1988) 
LEVODOPA 250 / CARBIDOPA 25 PHARMACOKINETICS 
 Cmax (μg/ml)a Tmax (min)b 
Normal Controls 1.07±0.4d 166±52.6 
PD patients ALL 1.35±0.4 135±60.9 
PD early – no MFc 1.43±0.6 160±40.9 
PD advanced – no MF 1.35±0.4 126±93.4 
PD advanced with MF 1.27±0.3 114±39.1 
aCmax = peak plasma concentration; btmax = time to peak plasma drug concentration; cMF = Motor 
Fluctuations; dValues expressed as mean ± SD 
 
2.2.2	  Buspirone	  
Buspirone is a drug with anxiolytic properties that belongs to the azaspirondecandione 
class of compounds. Buspirone is not chemically or pharmacologically related to 
benzodiazepines, barbiturates, or other sedative or anxiolytic drugs. Buspirone 
hydrochloride is a white crystalline, water-soluble compound with a molecular weight of 
385.503 g/mol and is designated chemically as 8-[4-(4-pyrimidin-2-ylpiperazin-1-
yl)butyl]-8- azaspiro[4.5]decane-7,9-dione. Its empirical formula is C21H31N502, and its 
structural formula is seen in Figure 21. 
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Figure 21 Structural Formula of Buspirone 
 
 
2.2.2.1	  The	  5-­‐HT1A	  Receptor	  
There are 7 different types of 5-HT receptors (5-HT1 to 5-HT7) distributed throughout the 
brain (Figure 22). The 5-HT1, 5-HT2 and 5-HT5 receptors are further classified into 
subtypes. The 5-HT1 receptors are classified into A, B and D subtypes, which are found in 
the CNS and blood in vessels. Coupled to inhibitory G-proteins, the 5-HT1A receptors 
(Figure 23) have an inhibitory effect on neurotransmission when bound by an agonist.  
In the mouse brain, the 5-HT1A receptors are widely distributed throughout the 
basal ganglia. They are located on dorsal raphe neurons with efferents to the striatum, and 
are also localized on cortical neurons sending glutamatergic projections to the basal 
ganglia (Knobelman et al., 2000). 
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Figure 22 Distribution of 5-HT1A receptors in the normal brain. There are seven sub-types of 5-HT receptor 
and the 1A subtype is widely expressed throughout the brain. The highest levels of this subtype are found in 
the hippocampus and medial temporal cortex, with slightly lower levels in the pre-frontal cortex. Low levels 
of 5-HT1A are found in the basal ganglia (image taken from CNSforum) 
 
 
Figure 23 The 5-HT1A receptor (image taken from CNSforum) 
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2.2.2.2	  Mechanism	  of	  Action	  
Buspirone's mechanism of action is very complex and, to date, it is not completely 
elucidated. Several different neuropharmacologic processes can be involved. Buspirone 
has high affinity for 5-HT1A receptors (partial agonist), moderate affinity for presynaptic 
dopamine D2 autoreceptors (antagonist), and weak affinity for 5-HT2 receptors but no 
affinity for the benzodiazepine receptor complex in vitro. Buspirone has been found to 
increase the firing rate of midbrain dopaminergic neurons and in the locus coeruleus 
increases the spontaneous firing of noradrenergic neurons.  
Although, mechanisms of action are very complex, investigations suggest that 
buspirone's main neuropharmacologic effects are mediated via 5-HT1A receptors. Binding 
of the 5-HT1A partial agonist buspirone to the 5-HT1A receptor causes the dissociation of 
inhibitory G-proteins. The G-protein alpha subunit binds to and inhibits adenylate cyclase. 
This prevents the conversion of ATP to cAMP and the initiation of other secondary 
messenger signaling mechanisms; hence cell depolarisation is inhibited (Figure 24) (Rang 
et al., 2001). 
Buspirone inhibits the firing of 5-HT neurons as well as the synthesis and use of 5-
HT (Tunnieliff, 1991; Pecknold, 1994). It is also been proposed that buspirone influences 
postsynaptic 5-HT1A receptors resulting in increased 5-HT1A functioning (Peroutka, 1988) 
and also the 5-HT2 (Tunnieliff, 1991; Pecknold, 1994). 
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Figure 24 Mechanism of Action of the 5-HT1A partial agonist Buspirone (image taken from CNSforum) 
 
 
In industry, buspirone has been registered as a partial agonist of 5-HT1A receptors 
(De Vivo and Maayani, 1986). However, it could also act as an antagonist of dopamine 
D2 receptors, but its affinity for these receptors is 16-fold weaker than its affinity for 5-
HT1A receptors (Peroutka, 1985). In an experiment in rats, Gobert and colleagues (1999) 
found that doses between 0.01 – 2.5 mg/kg (SC) dose-dependently decreased dialysate 
levels of 5-HT (50%), and increased those of dopamine (100%) and NA (140%) 
suggesting that there are several receptorial mechanisms via which buspirone may 
potentially modify frontocortical monoaminergic transmission (Table 4). 
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Table 4 Binding Affinities at recombinant Human and Rat receptor subtypes (suggested and modified from 
Gobert et al., 1999). Comparison between Buspirone and Raclopride 
AGENT ACTIVITY AFFINITY (Ki in nM) 
  5-HT 
uptake 
r5-HT1A h5-HT1A rα2A hα2A hD2 hD3 
BUSPIRONE MIXED >1000 15.8 8.9 >1000 >1000 34.0 12.0 
RACLOPRIDE ANTAGONIST 
D2/D3 
>1000 >1000 >1000 >1000 >1000 1.3 1.4 
ah = human; br = rat 
 
2.2.2.2.1	  Effect	  on	  Dopamine	  Receptors	  and	  Dopamine	  Neurotransmission	  
In a study in rats, buspirone was tested for effects on dopamine neurotransmission. In this 
study it was found that at the maximum effective dose of 3.0 mg/kg, (SC), buspirone 
markedly increased dopamine synthesis and metabolism by 400%. Hence, minimal action 
at the classical postsynaptic dopamine receptors was reported suggesting that (a) 
buspirone enhances dopamine neuronal activity, in part, by weakly inhibiting (antagonistic 
activity) presynaptic dopamine receptors, and (b) buspirone has minimal effects on 
postsynaptic dopamine receptors (McMillen et al., 1983). 
In agreement with this findings, a more recent study in rats, has reported that 
buspirone at 1.25, 2.5, 5 mg/kg (IP) by selectively blocking presynaptic nigrostriatal 
dopamine D2 autoreceptors, increases synthesis of dopamine and makes more dopamine 
available for release. Only at very high doses of 10, 20, 40 mg/kg (IP) does it block 
postsynaptic striatal dopamine D2 and D1 receptors (Dhavalshankh et al., 2007). 
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2.2.2.3	  Pharmacodynamics	  and	  Pharmacokinetics	  
Buspirone is rapidly and almost completely absorbed after oral administration [tmax = 0.89 
hours ± 0.15; mean ± standard deviation (SD)]. Cmax of the drug averaged 1.13 ± 0.15 
ng/mL (mean ± SD) following a single oral dose of 10mg in a study in healthy adults. The 
mean bioavailability of the oral compared to the intravenous (IV) dose is 3.9% ± 4.3 
(mean ± SD), due to the extensive first pass metabolism of buspirone (Table 5). 
 
Table 5 Buspirone Pharmacokinetics 
GENERAL BUSPIRONE PHARMACOKINETICS 
tmax (h)a  0.89 ± 0.15hc 
Cmax (ng ml-1)b 1.13 ± 0.15ng/mL  
% Bioavailability  ~3.9% ± 4.3 
atmax = time to peak plasma drug concentration;  bCmax = peak plasma concentration; cValues 
expressed as mean  ± SD 
 
The effect of food on buspirone pharmacokinetics has been evaluated and results 
have shown that food increased the Cmax of buspirone almost 2-fold, whereas there was 
negligible change in tmax and t1/2 between fed and fasting states (Mahmood and Sahajwalla, 
1999). 
 
2.2.2.3.1	  30mg	  Bolus	  Dose	  
Buspirone has been studied as a bolus 30mg dose administered orally in 10 healthy 
subjects (Lamberg et al., 1998). The pharmacokinetic variables Cmax, tmax and t1/2 are 
presented in Table 6 and Figure 25. 
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Table 6 Buspirone Pharmacokinetics after a Single 30mg Oral dose in 10 healthy subjects (modified from 
Lamberg et al., 1998)   
30mg BUSPIRONE PHARMACOKINETICS 
tmax (h)a (median; range) 1.5 (0.5-4) 
Cmax (ng ml-1)b (mean ± SD) 6.6 ± 3.7  
t1/2(h)c (mean ± SD) 2.8 ±0.7  
atmax = time to peak plasma drug concentration; bCmax = peak plasma concentration; ct1/2 = half-life 
 
 
 
 
Figure 25 Plasma concentrations of Buspirone in 10 healthy subjects (mean ± SE) after a 30mg oral dose 
(figure modified from Lamberg et al., 1998) 
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2.3	  Clinical	  Evaluations	  
	  
2.3.1	  Evaluation	  of	  Motor	  Symptoms	  
Clinical evaluation of the motor symptom severity was performed using the UPDRS Part 
III (Fahn et al., 1987) and a modified version of the H&Y (Hoehn and Yahr, 1967). In all 
studies, subjects were assessed with UPDRS Part III and H&Y staging in OFF medication 
condition (on two or three different days) and in ON medication condition after 
administration of L-DOPA 250/carbidopa 25. For the buspirone trial, UPDRS Part III was 
performed every 15 min over a period of 150 min after administration of L-DOPA 
250/carbidopa 25 and on another day, every 15 min after administration of buspirone 
preceding administration of L-DOPA 250/carbidopa 25. In the transplanted PD patients 
UPDRS Part III scores evaluations were carried out on eight occasions over three different 
days while scores from previous assessments were retrospectively analyzed.  
The UPDRS Part III motor examination provides a nearly comprehensive coverage 
of the cardinal motor symptoms in patients with PD (e.g., tremor, rigidity, bradykinesia, 
etc.) and contains 27 questions (for 14 subitems) for the different body regions, scored 
from 0 (normal) to 4 (maximal severity) with a maximum (worst) total score of 108. Axial 
symptoms, bradykinesia, tremor and rigidity were separately assessed combining the 
appropriate UPDRS motor score subitems. 
The axial-symptoms score comprised the sum of subitems “Speech”, “Posture”, 
“Gait” and “Postural Stability” (maximum worst score = 16). The bradykinesia scores was 
obtained summing the subitems “Facial Expression”, “Finger taps”, “Hand Movements”, 
“Rapid Alternating Movements”, “Leg Agility”, “Arising From Chair” and “Body 
Bradykinesia/Hypokinesia” (maximum worst score = 44). The tremor score was the sum 
of subitems “Tremor at Rest” and “Action or Postural Tremor of hands” (maximum worst 
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score = 28). Finally, the rigidity scores was derived from the “Rigidity” subitems 
(maximum worst score = 20). 
The modified H&Y staging assesses the relative level of disability with “stage 0” = 
“no signs of disease”, “Stage 1” = “unilateral disease”, “Stage 1.5” = “unilateral plus axial 
involvement”, “Stage 2” = “bilateral disease, without impairment of balance”, “Stage 2.5” 
= “mild bilateral disease, with recovery on pull test”, “Stage 3” = “mild to moderate 
bilateral disease; some postural instability; physically independent”, “Stage 4” = “severe 
disability; still able to walk or stand unassisted” and “Stage 5” = “wheelchair bound or 
bedridden unless aided”.  
 
2.3.2	  Evaluation	  of	  Involuntary	  Movements	  
For the clinical evaluation of dyskinesia, the AIMS (Guy, 1976) and UPDRS Part IV were 
used. In non-transplanted PD subjects, dyskinesia severity was rated every 15 min over a 
period of 150 min after administration of L-DOPA 250/carbidopa 25 and L-DOPA 
250/carbidopa 25 following the administration of buspirone.  
Transplanted PD subjects underwent a double-blind acute oral challenge with the 
5-HT1A agonist buspirone and with the administration of placebo on two different days, 
close apart. Patients stopped any other medication (Patient 7, amantadine; Patient 13, deep 
brain stimulation (DBS); Patient 15, amantadine and trihexyphenidyl) 72 hours before 
each challenge. Neither the patients nor the investigator knew whether buspirone or 
placebo was administered, and the day for giving one or the other was selected randomly. 
A total of 15mg of buspirone or similar dose of placebo was administered divided in three 
5mg doses at 30, 60 and 90 mins after the beginning of the AIMS assessments. 
Comparable assessments on another day without buspirone, DBS, placebo or amantadine 
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were also performed. AIMS and UPDRS motor score assessments were carried out 
throughout the trial. The total duration of assessments lasted for 4 hours. 
Each AIMS assessment had duration of 5 min and was preceding and succeeding 
for 2.5 min each 15-min interval. The highest amplitude or frequency (not the average) in 
a movement on 0-4 scale was reported. Zero points represent no abnormal involuntary 
movement (normal); One = minimal (may be extreme normal); Two = mild; Three = 
moderate and Four = severe. AIMS assesses facial and oral movements (forehead, 
eyebrows, periorbital area, cheeks, lips and perioral area, jaw and tongue; maximum worst 
score = 16), extremity movements (arms, wrists, hands, fingers, legs, knees, ankles and 
toes; maximum worst score = 8), trunk movements (neck, shoulders and hips; maximum 
worst score = 4) and global judgments (severity, incapacitation and patient’s awareness; 
maximum worst score = 12) with a total worst score of 40. 
 
2.3.3	  Evaluation	  of	  Daily	  and	  Lifetime	  Dopaminergic	  Medication	  
Intake	  
Calculation of a daily (D) and lifetime (L) total L-DOPA Equivalent Dose (LEDTOTAL), L-
DOPA LED (LEDL-DOPA) and DA LED (LEDDA) for each patient was based on theoretical 
equivalence to L-DOPA (similar to previous reports: Parkin et al., 2002; Evans et al., 
2004) based on Equations 1, 2 and 3.  The lifetime dopaminergic medication intake was 
calculated from medical notes and general practitioner letters and these data were cross-
checked with the subjects. 
In order to convert to Duodopa, the full dose of DA is taken equivalent to L-DOPA 
100/carbidopa 25 four to six times a day and then divided by 50%. The result of the break 
down of the agonist must be added to the L-DOPA dose that the patient is on in order to 
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get the correct dose to convert to Duodopa. The equivalents for Duodopa dose conversions 
are shown in Table 7. 
 
Equation 1 Equation for the calculation of daily and lifetime Dopaminergic Medication equivalent 
dose based on theoretical equivalence to Levodopa 
D or L – LEDTOTAL (mg or g) = (1 X Levodopa) + (0.77 X Levodopa CR) + (1.43 X Levodopa 
+ Entacapone) + (1.11 X Levodopa CR + Entacapone) + (20 X Ropinirole) + (20 X Ropinirole 
ER) + (100 X Pramipexole) + (30 X Rotigotine) + (10 X Bromocriptine) + (8 X Apomorphine) + 
(100 X Pergolide) + (67 X Cabergoline) 
aLevodopa with Carbidopa or Benserazide hydrochloride; bIn Levodopa/Carbidopa or Benserazide 
hydrochloride: Only Levodopa is calculated  
 
Equation 2 Equation for the calculation of daily and lifetime Levodopa equivalent dose based on 
theoretical equivalence to Levodopa 
D or L - LEDL-DOPA (mg or g) = (1 X Levodopa) + (0.77 X Levodopa CR) + (1.43 X Levodopa 
+ Entacapone) + (1.11 X Levodopa CR + Entacapone)  
aLevodopa with Carbidopa or Benserazide hydrochloride; b In Levodopa/Carbidopa or Benserazide 
hydrochloride: Only Levodopa is calculated  
 
Equation 3 Equation for the calculation of daily and lifetime Dopamine Agonists equivalent dose 
based on theoretical equivalence to Levodopa 
D or L - LEDDA (mg or g) = (20 X Ropinirole) + (20 X Ropinirole ER) + (100 X Pramipexole) 
+ (30 X Rotigotine) + (10 X Bromocriptine) + (8 X Apomorphine) + (100 X Pergolide) + (67 X 
Cabergoline) 
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Table 7 Equivalents for Duodopa dose conversions  
DOPAMINERGIC MEDICATION LEVODOPA UNITS 
Apomorphine 3-5mg 100  
Cabergoline 1.0-1.5mg 100  
Pramipexole 1mg 100  
Pergolide 1mg 100  
Ropinirole 5mg 100  
Rotigitine Patch 3-5mg 100  
200mg Levodopa / 50mg Carbidopa / 200mg Entacapone (Stalevo 200mg®) 260  
150mg Levodopa / 37.5mg Carbidopa / 200mg Entacapone (Stalevo 150mg®) 195  
100mg Levodopa / 25mg Carbidopa / 200mg Entacapone (Stalevo 100mg®) 130  
50mg Levodopa / 12.5mg Carbidopa / 200mg Entacapone (Stalevo 50mg®) 65  
250mg Levodopa / 50mg Carbidopa Sustained-Release (Sinemet CR®)  130  
100mg Levodopa / 25mg Carbidopa Sustained-Release (Half Sinemet CR®) 65  
100mg Levodopa / 25mg Carbidopa (Sinemet Plus®) 100  
100mg Levodopa / 10mg Carbidopa (Sinemet 110®) 100  
 
2.3.4	  Evaluation	  of	  Non-­‐Motor	  Symptoms	  
General clinical assessments included the PD questionnaire (PDQ), non-motor symptom 
(NMS) assessment scale for PD, the mini-mental state examination (MMSE) and UPDRS 
parts I and II.  
 
2.3.4.1	  Depression	  
For the assessment of depression levels, the HRSD and BDI-II were used. The HRSD is 
the most widely utilized rating scale to assess symptoms of depression. The HRSD is an 
observer-rated scale consisting of 17 to 21 items (including two 2-part items, weight and 
diurnal variation). Ratings are made on the basis of the clinical interview, plus any 
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additional available information, such as nursing or family member report. The items are 
rated on either a zero to four spectrum (0 = none/absent and 4 = most severe) or a zero to 
two spectrum (0 = absent/none and 2 = severe). The HRSD heavily emphasizes somatic 
symptoms of depression and works best for the assessment of individuals with relatively 
severe illness. The HRSD also relies on the clinical interviewing skills and experience of 
the rater in evaluating individuals with depressive illness. As most patients score zero on 
rare items in depression (depersonalization, obsessive and paranoid symptoms), the total 
score on the HRSD generally consists of only the sum of the first 17 items. A typical 
baseline score for a depressed patient in a treatment trial is 15-20. The strengths of the 
HRSD include its excellent validation/research base, and ease of administration. Although 
the author intended the scale to be utilized only in patients with primary depression, in 
real-life settings the scale is sometimes used to evaluate depressive symptoms in patients 
with other disorders, such as schizophrenia or bipolar disorder (Hamilton et al., 1960; 
1967; Faries et al., 2000). 
BDI created by Dr. Aaron T. Beck, is a 21-question multiple-choice self-report 
inventory, and one of the most widely used instruments for measuring the severity of 
depression. It is a self-report inventory that was revised in 1996 (BDI-II, Beck et al., 
1996) to be more consistent with Diagnostic and Statistical Manual-IV (DSM-IV) criteria 
for depression. Each statement is ranging from zero to three and the total score is 63 and 
subjects pick one statement in each group that best describes the way they have been 
feeling during the past two weeks (including the day of the test) from questionnaire 
administration. A score of 0–13 refers to minimal depression; 14–19: mild depression; 20–
28: moderate depression; and 29–63: severe depression. Higher total scores indicate more 
severe depressive symptoms. The BDI-II is positively correlated with the HRSD with a 
Pearson r of 0.71, showing good agreement. The test was also shown to have a high one-
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week test–retest reliability (Pearson r =0.93), suggesting that it was not overly sensitive to 
daily variations in mood.  
 In this thesis, depressive symptoms were screened with the BDI-II and HRSD 
scales while subjects also underwent a structured clinical interview for DSM-IV Axis I 
Disorders (SCID-I). The optimal cutoff for discriminating between depressed and non-
depressed PD patients has been set at 16-17 for BDI-II (Leentjens et al., 2000; Silberman 
et al., 2006) scale and at 13-14 for HRSD (Dissanayaka et al., 2007) scale.  
 
2.3.4.2	  Weight	  and	  Body	  Mass	  Index	  
All subjects were measured for height (m) and weight (kg) in two different occasions 12 
months apart. BMI was calculated in SI units (Equation 4). The second BMI measurement 
was close to the 11C-DASB PET scan.  
Changes in appetite have been also assessed by asking an open question and by 
using BDI-II, subitem 18 “Changes in Appetite” where “0 = I have not experienced any 
change in my appetite”, “1 = my appetite is somewhat less or greater than usual”, “2 = my 
appetite is much less or greater than usual” and “3 = I have no appetite at all or I carve 
food all the time”.     	  	  
Equation 4 Calculation of Body Mass Index in SI units 
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2.4	  Positron	  Emission	  Tomography	  (PET)	  
PET is a noninvasive nuclear medicine imaging technique that produces three-dimensional 
(3D) images mapping the functional activity of a given tissue. It is actually a combination 
of nuclear medicine and biochemical analysis, where it differs from the former in the fact 
that PET detects metabolism within living tissues, whereas most of the other types of 
nuclear medicine techniques detect the amount of a radioactive substance collected in 
body tissue at a certain location to examine the tissue’s function. 
PET is being used in both research and clinical practice for the diagnosis, the 
planning of treatment and the prediction outcome in various diseases. It can be applied in 
different regions of the body and it has been mainly used, in oncology, cardiology and 
neurology. In the brain, it has been utilized to investigate metabolism, brain receptor 
binding and alterations in regional blood flow, among others. Subsequently, one of its 
major applications has been in favor of elucidating complex neurological disorders like 
PD.  
Positrons were first identified in 1932 when the scattering of high-energy gamma 
rays by "a positively charged particle having a mass comparable with that of an electron" 
was demonstrated. Positrons are particles of equal mass but opposite charge to electrons 
and are their anti-matter equivalent. When emitted from an unstable nucleus a positron 
travels one to three mm before colliding with an electron in the outer shell of an atom. 
This results in annihilation and the energy is emitted as two 511keV gamma rays, released 
at 180 degrees to each other.  
PET relies on physical principles, using extremely short-lived radioisotopes such 
as carbon-11 (t1/2 ~20 min), nitrogen-13 (t1/2 ~10 min), oxygen-15 (t1/2 ~2 min), and 
fluorine-18 (t1/2 ~110 min) linked to particular tracers (t1/2 for radioisotopes is the amount 
of time it takes for half of the label to decay; the faster the decay, the less time between 
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injection and scanning). These, after administration, they can be monitored in the brain in 
real time to obtain structural and kinetic information, such as the distribution of receptors 
in the brain, or areas of increased blood flow stimulation. PET has high sensitivity and 
provides good spatial and temporal resolution. On the other hand, there are some 
limitations to consider. The widespread use of the PET could be limited by the high costs 
of cyclotrons that are needed to produce the short-lived radioisotopes for PET scanning 
and the need for specialized on-site chemical synthesis apparatus to produce radioisotopes. 
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2.4.1	  PET	  procedures	  
 
 
Figure 26 Schematic overview of the procedures for an 11C-raclopride PET scan 
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2.4.1.1	  The	  Cyclotron	  
The process begins with the production of negatively charged hydrogen ions in a device 
called a cyclotron (Figure 27 and 28). A cyclotron is a particle accelerator which generates 
a static magnetic and electric field between specifically designed electrodes within a 
vacuum chamber (Birattari et al., 1987).  
Following emission from an ion source a charged particle, generally a proton or 
deuteron, is accelerated by the electric field along a path which is made circular by the 
presence of the magnetic field.  These negatively charged hydrogen ions are converted 
into positively charged protons. The interaction of protons with the stable forms of 
elements such as the oxygen, the nitrogen and carbon will convert them to a radioactive 
condition. This radioactive condition is largely unstable because it possesses too many 
protons and is called radioisotope. 
As the particle gains energy it follows a spiral path from the centre of the cyclotron 
to a maximum radius from where it is then focused by an electrostatic deflecting beam to 
bombard a target. Using computer software, radioisotopes are then attached to the 
synthetic molecule of interest such as RAC, DASB or DOPA, in a biosynthesizer unit 
called hot cell (Figure 29). The substances that can be labeled for PET scanning are 
limited only by the physical t1/2 of the positron-emitting label.  
 
 
 115	  
 
 
Figure 27 Cyclotron in Vonberg Suite at Clinical Sciences Centre, Medical Research Council (Cyclotron 
Building, Hammersmith Hospital) 
 
 
 
Figure 28 Cyclotron and Ventilation System in Vonberg Suite at Clinical Sciences Centre, Medical 
Research Council (Cyclotron Building, Hammersmith Hospital) 
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Figure 29 Hot Cell for Synthesis and Production of Radioligand in Vonberg Suite at Clinical Sciences 
Centre, Medical Research Council (Cyclotron Building, Hammersmith Hospital; Image taken during the 
production of 11C-raclopride) 
 
 
2.4.1.2	  Positron	  and	  Coincidence	  Detection	  
The PET detector of the 511keV gamma ray emissions created by positron annihilation 
consists of a scintillation bismuth germanate crystal that is connected to a photomultiplier 
tube. The scintillation crystal emits low energy photons (visible light) after interaction 
with high-energy photons (gamma rays). The photomultiplier tube then converts the 
scintillation events into electrical pulses. 
The size of the crystal detection system is a major factor in the resolution of the 
PET camera and the maximal physical image resolution is approximately 1.1 to 1.2 times 
greater than the width of the individual detector crystals. In current PET scanners multiple 
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rings of detectors are stacked to assess volumetric data from a wide field of view (FOV). 
In two-dimensional (2D) scanning the coincidences within the same ring define an intra-
ring image and coincidences between adjacent rings form independent inter-ring images 
(cross-plane).  
PET can also be operated in a more sensitive 3D mode where coincident detections 
between all rings are counted (Cherry et al., 1993). This results in a six-fold increase in 
signal but also increases count due to scatter. When scattered events are subtracted the 
efficiency of coincidence detection at the centre of the FOV increases by a factor of 4.8 
(Spinks et al., 1992). There are several ways of estimating the scatter component of PET 
data acquisition. For this thesis, an approach in which data is acquired using a dual energy 
window technique was used. A lower energy data set, representing scatter, is subtracted 
from the main upper energy 511keV window data set (Grootoonk et al., 1992). The 
importance of 3D acquisition is that scans of comparable quality to 2D mode can be 
obtained after administration of approximately four times less radiation. This allows more 
scan repetitions to be performed. Use of 3D mode acquisition also enhances the ability to 
perform voxel rather than only region-based analyses. 
PET radiotracers emit positrons. The PET tracers produce positively charged 
positrons that travel a short distance in the brain before colliding with a negatively 
charged electron (Figure 30). The positron and the electron annihilate each other and in 
the process emit two photons at 180 degrees to each other. The photons are detected as 
“pairs in coincidence” by a series of specialized detectors arranged in a ring around the 
subject (Figure 31). “Random” as opposed to “true” coincidences can occur when two 
photons from separate annihilation events are detected simultaneously at opposing 
detectors. These are identified by introducing a delay into one side of the coincidence 
detection circuit by 48 nsecs; coincidences resulting from a single annihilation event are 
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not detected under these circumstances. The “true” coincidence rate is then calculated by 
subtracting the number of random events from the total number of detections (Dyson 
1960). 
Annihilation events in which one of the photons is deflected (scattered) but in 
which the two photons are nevertheless detected simultaneously at opposing detectors can 
still constitute a proportion of the true rate. However, scattered photons tend to have lower 
energy and so the scatter fraction may be minimised by energy windowing. True 
coincidence events at detector pairs are then histogrammed by a real-time sorter into 
sinograms, which are subsequently attenuation corrected and reconstructed into images by 
back projection. 
Unlike other scanning techniques, a PET scan is not designed to show structural 
detail of organs. Instead, it shows images containing more or less intense color to provide 
information about chemical activity within certain organs and tissues. This chemical 
activity may indicate areas of disease not detected by other scanning methods. 
PET scanning is non-invasive, but it does involve exposure to ionizing radiation. 
The total dose of radiation is small, however, usually around 7mSv. This can be compared 
to 2.2mSv average annual background radiation in the UK, 0.02mSv for a chest x-ray, up 
to 8mSv for a CT scan of the chest and 2-6 mSv per annum for aircrew. 
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Figure 30 The positron and the electron annihilate each other and in the process emit two photons at 180 
degrees to each other (Image adopted from NeuroCognition Laboratory Department of Psychology Tufts 
University) 
 
 
 
Figure 31 Multiple radiation detectors arranged around the subject’s head are connected by coincidence 
circuits (Image adopted from NeuroCognition Laboratory Department of Psychology Tufts University) 
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2.4.1.3	  Image	  Reconstruction	  and	  Attenuation	  Correction	  
The radiation emission profiles acquired by the PET detector system are recorded in 
digital form by a computer system. From this data, the computer system generates 3D 
images through the application of a “filtered back projection” reconstruction algorithm 
similar to that used in computed tomography (CT) (Phelps 1977). The algorithm consists 
of the projection of a series of radiation profiles (sinograms) recorded at different angles 
to produce a cross-sectional image of the original distribution of radioactivity. 
The sinograms used in image reconstruction in PET represent the distribution of 
activity in the scanned tissues, reduced by tissue attenuation. It is, therefore, necessary to 
correct for this attenuation in order to allow true quantitative reconstruction (Phelps 1977). 
The tissue attenuation is measured by performing transmission and blank emission scans. 
A 5 to 10-min transmission scan is performed prior to injection of tracer to correct for 
tissue attenuation of gamma radiation. The radioisotopes (known as PET tracers) are 
injected (IV bolus) in the bloodstream (Figure 32) where they migrate to the regions of 
interest (ROI). The injection is followed by a phase called ‘time lag’ where the scanner 
records the concentration and distribution of the tracer.  
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Figure 32 Radioactive tracer is injected into the arm of a subject lying in the PET scanner (Image adopted 
from NeuroCognition Laboratory Department of Psychology Tufts University) 
 
 
In a transmission scan the tissue attenuation of 511keV photons along all 
coincidence lines is calculated by exposing the subject to be imaged to an external ring or 
rotating point positron source emitting 511keV gamma radiation, usually 68Ge-68Ga. The 
blank emission scan is performed with no tissue between the detector rings to detect levels 
of background radiation. The ratio of the blank and transmission scan data provides 
attenuation coefficients for 511keV gamma rays on a voxel basis for the object to be 
studied. 
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2.4.1.4	  PET	  Scanners	  
The 966-Siemens/CTI ECAT EXACT HR++ (Knoxville, TN, USA) has 23.4cm total axial 
FOV (Figure 33). The camera has a reconstructed (image) transaxial spatial resolution of 
5.1 ± 0.6 mm and an axial resolution of 5.9 ± 0.6 mm over a 10cm radius FOV from the 
centre (Spinks et al., 2000). 
 
 
 
 
Figure 33 ECAT EXACT HR++ PET scanner at Clinical Sciences Centre, Medical Research Council 
(Cyclotron Building, Hammersmith Hospital) 
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The 962-Siemens/CTI ECAT EXACT HR+ (Knoxville, TN, USA) has an axial FOV of 
15.5cm (Figure 34). The mean image transaxial resolution (3D mode) over a 10cm radius 
FOV (from the centre) is 6.0 ± 0.5 mm (mean ± SD) and the axial resolution is 5.0 ± 0.8 
mm (mean ± SD) (Brix et al., 1997). 
 
 
 
 
 
Figure 34 ECAT EXACT HR+ PET scanner at Clinical Sciences Centre, Medical Research Council 
(Cyclotron Building, Hammersmith Hospital) 
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The GE Discovery RX PET/CT scanner has an axial FOV of 15.7cm (Figure 35). The 
mean image transaxial resolution over a 10cm radius FOV (from the centre) is 5.4 + 0.5 
mm (mean ± SD) (2D and 3D modes) and the axial resolution is 5.6 ± 0.8 mm (2D) and 
6.2 ± 0.4 mm (3D) (mean ± SD) (Kemp et al., 2006).	  
 
 
 
 
 
Figure 35 GE Discovery RX PET/CT scanner at Clinical Sciences Centre, Medical Research Council 
(Cyclotron Building, Hammersmith Hospital) 
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2.4.1.4.1	  The	  MRI	  Scanner	  
T1 Volumetric (TR = 1900, TE = 3.53, TI = 1100, Flip angle 15, 1mm isotropic voxels) 
and T2-weighted (Axial T2-spin echo: TR = 4540, TE = 97, 5mm slice thickness; Axial 
FLAIR: TR = 9000, TE = 114, T I= 2500, 5mm slice thickness) MRI sequences were also 
undertaken for purposes of PET co-registration, to facilitate with localising the ROIs and 
for excluding secondary structural brain pathology. MRIs were performed using a clinical 
1.5-Tesla (T) MRI system (Siemens MAGNETOM Avanto, Ehrlangen, De) (Figure 36). 
 
 
Figure 36 Siemens MAGNETOM Avanto 1.5-Tesla MRI scanner at Robert Steiner Unit, Medical Research 
Council (Hammersmith Hospital) 
 
2.4.1.5	  Scanning	  Procedures	  
Subjects on medication were asked to arrive at the hospital in an OFF medication state 
after overnight withdrawal of their antiparkinsonian or other medication. Patients 
receiving cabergoline or other ergot DAs withdrew this kind of medication 72 hours 
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before the scanning. Smoking, consumption of alcohol, coffee and other caffeinated 
beverages was not allowed at least 12 hours before scanning. Eating and drinking was not 
allowed for 8 hours before the scan. 
The subjects were positioned supine with their transaxial planes parallel to the line 
intersecting the anterior commissure (AC) – posterior commissure (PC) line. They were 
made comfortable and their head position maintained with the help of individualised foam 
holders. Head position, relative to the camera’s laser light, was monitored throughout the 
scans and was repositioned if movement was detected. Subjects were in a resting state 
with low light and no noise in the room.  
 
2.4.1.5.1	  11C-­‐raclopride	  
Subjects scanned with the 966-Siemens/CTI ECAT EXACT HR++ PET scanner received a 
mean RAC dose of 183MBq (ranging from 180 to 186 MBq) (bolus IV). Subjects scanned 
with the 962-Siemens/CTI ECAT EXACT HR+ PET scanner received a mean RAC dose 
of 250MBq (bolus IV). The radiochemical purity of the radioligand was more than 96% 
and the injection was smooth bolus by hand over 10 sec, followed by 0.9% normal saline 
flush for 10 sec. A 10-min 2D acquisition transmission scan followed a 2D acquisition 
two-min short transmission scan and repositioning took place where necessary. The 3D 
acquisition dynamic emission scan began 30 sec before tracer infusion, generating 20 
frames of tissue data over 60 mins and 30 sec.  
 The two RAC scan PET paradigms consisted of a RAC PET scan in OFF 
medication condition and a RAC PET scan one hour after administration of a 
suprathreshold dose of L-DOPA 250/carbidopa 25 (Sinemet 275®). In the three RAC PET 
scan paradigm another scan with a bolus dose of buspirone 15 mins before the 
administration of L-DOPA 250/carbidopa 25 (Sinemet 275®) was also performed. Normal 
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volunteers had a RAC PET scan in OFF medication state (baseline) and 12 of them had 
another RAC PET scan following either 0.2mg/kg dose of buspirone (six subjects) or 
0.35mg/kg dose of buspirone (six subjects) 75 mins before the beginning of the RAC PET 
scan. 
 The three RAC scan PET paradigm in the enteral L-DOPA/carbidopa gel infusion 
(Duodopa®) study consisted of one RAC PET scan with the infusion switched OFF and 
the patient in an OFF medication state, one RAC PET scan one hour after the infusion has 
been running (monitoring first to second hour after the infusion has been turned on) and 
one RAC PET scan four hours after the infusion has been running (monitoring fourth to 
fifth hour after the infusion has been turned on) with the patient in an ON medication state 
(Figure 37). In two cases, seven to eight and in one case nine to 10 hours after infusion 
switched on has been monitored. 
 
 
 
Figure 37 Design and timings of the three 11C-raclopride PET scans in the enteral Levodopa/Carbidopa gel 
infusion (Duodopa®) study 
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2.4.1.5.2	  11C-­‐DASB	  
Subjects scanned with the 962-Siemens/CTI ECAT EXACT HR+ PET scanner received a 
mean 11C-DASB dose of 450MBq (Range: 439 – 461 MBq). The radiochemical purity of 
the radioligand was more than 95% and the injection was smooth bolus by hand over 10s, 
followed by 0.9% normal saline flush for 10 sec. A 10-min 2D acquisition transmission 
scan followed a 2D acquisition two-min short transmission scan and repositioning took 
place where necessary. The 3D acquisition dynamic emission scan began 30 sec before 
tracer infusion (bolus IV), generating 28 time frames of tissue data over 90 min.  
Meteorological data (London Office, UK) for the periods of 11C-DASB PET 
scanning were also retrieved in order to account for confounding factors of weather and 
seasonal change on 11C-DASB binding (Praschak-Rieder et al., 2008). Twenty-five 
subjects were scanned during spring/summer (14 spring, 11 summer) and 19 during the 
fall/winter period (nine fall, 10 winter). The average humidity of the days of the scans was 
66.7% (SD = 15.3) and all but four scans were performed on a day that was either cloudy 
or rainy with no sun.   
 
2.4.1.5.3	  18F-­‐DOPA	  
Subjects were given 150mg of carbidopa orally before the 18F-DOPA PET (100mg one 
hour and a further 50mg 10 mins before the scan start) scan start. They were scanned with 
the 966-Siemens/CTI ECAT EXACT HR++ PET scanner and received a mean 18F-DOPA 
dose of 160 MBq (ranging from 140 to 180 MBq) and this was administered IV over 30 
sec, generating 25 frames of tissue data over 94 mins. Subjects scanned with the 962-
Siemens/CTI ECAT EXACT HR+ PET scanner received a mean 18F-DOPA dose of 
210MBq and this was administered IV over 30 sec, generating 28 frames of tissue data 
over 95mins. The radiochemical purity of the radioligand was more than 95% and the 
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injection was smooth bolus by hand over 10 sec, followed by 0.9% normal saline flush for 
10 sec. A 10-min 2D acquisition transmission scan followed a 2D acquisition two-min 
short transmission scan that reposition took place where necessary. The 3D acquisition 
dynamic emission scan began 30 sec before tracer infusion, generating 28 time frames 
over 90 min and 30 sec.  
 
2.4.1.6	  Tracer	  Kinetic	  Modelling	  
For RAC and 11C-DASB data analysis a quantitative tracer kinetic modelling was 
performed allowing estimation of BP. Mintun et al (1984) defined BP, based on in vitro 
radioligand binding, as the ratio of Bmax (receptor density) to KD (radioligand equilibrium 
dissociation constant). Because affinity of ligand binding is the inverse of KD, BP can be 
equivalently viewed as the product of Bmax and affinity (Equation 5). 
 
Equation 5 Binding potential in vitro (Mintun et al., 1984) 
 
Bmax = Density of receptors in vitro 
KD = dissociation constant 
 
In vivo BP measures target receptors in terms of specific radioligand binding. 
Specific binding is defined as that associated with the target and distinct from radioligand 
which is free in solution or nonspecifically associated with other macromolecular 
components. BP quantifies the equilibrium concentration of specific binding as a ratio to 
some other reference concentration (Innis et al., 2007). 
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BPND refers to the ratio at equilibrium of specifically bound radioligand to that of 
non-displaceable radioligand in tissue. BPND is the typical method for reference tissue 
methods that are used in the studies related to this thesis, such as the simplified reference 
tissue compartmental model (SRTM) (Lammertsma and Hume 1996; Gunn et al., 1997) 
that uses cerebellum as the reference tissue. The BPND measurement compares the 
concentration of radioligand in receptor-rich to receptor-free regions. BPND reflects but not 
typically equals Bmax/KD (Equation 5) as introduced by Mintun and colleagues (1984) that 
is true for in vitro measurements. For in vivo measurements as BPND, these terms are 
proportional to Bavail, the concentration of unoccupied or available receptor (Innis et al., 
2007) (Equation 6). 
 
Equation 6 Non-Displaceable Binding potential and its in vitro analog (Innis et al., 2007) 
 
fND = free fraction in nondisplaceable compartment 
Bavail = density of receptors available to bind radioligand in vivo 
KD = dissociation constant 
 
BPND does not require blood sampling and is relatively easy to implement. 
However, use of BPND as an outcome measure depends most heavily on the assumption 
that non-displaceable uptake is independent of subject groups or treatment effects. 
In the studies included in this thesis, in vivo RAC PET experiments are used in 
order to measure percentage change in BPND owing to reduced receptor availability after 
medication (displacement). Equation 7 describes the formula that is used. 
 
 131	  
Equation 7 Percentage change in 11C-raclopride non-displaceable binding potential after medication 
challenge 
 
 
 
2.4.1.6.1	  Movement	  Correction	  
Head movement was corrected using a frame-by-frame realignment procedure as 
previously described (Montgomery et al., 2006). Non–attenuated corrected (non-AC) 
images were used for realignment, to provide additional information by reducing the 
influence of redistribution of radiotracer producing erroneous realignments (Dagher et al, 
1998). The non-AC image was denoised using a level 2, order 64 Battle Lemarie wavelet 
filter (Turkheimer et al, 1999). The denoised frames were then realigned using a mutual 
information algorithm (Studholme et al., 1997), excluding the first three frames for RAC, 
the first seven for 11C-DASB and the first five for 18F-DOPA containing little 
information. Frame 10 for RAC, frame 13 for 11C-DASB and frame 12 for 18F-DOPA, 
were chosen as the reference frames because they offer good signal-to-noise ratio. Frames 
4-20 for RAC, 8-28 for 11C-DASB and 6-26 for 18F-DOPA of the original time series 
were then resliced and reassembled into a movement-corrected dynamic scan. Decay-
corrected time–activity curves (TACs) were derived and compared to those without 
movement correction (examples of RAC scans before and after movement correction are 
shown in Figures 38 to 40). Amount and timing of any movement were assessed 
graphically and compared with intrascan records. 
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Figure 38 11C-raclopride Time Activity Curves in the Striatum after no movement correction 
 
 
Figure 39 11C-raclopride Time Activity Curves in the Striatum after Movement Correction Reslicing and 
Reassembling Frames 4 to18 
 
 
Figure 40 11C-raclopride Time Activity Curves in the Striatum after Movement Correction Reslicing and 
Reassembling Frames 4 to20 
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2.4.2	  PET	  Radioligands	  
	  
2.4.2.1	  11C-­‐raclopride	  
RAC (3,5-dichloro -N- {[(2S)-1-ethylpyrrolidin-2-yl]methyl} -2-hydroxy-6-
methoxybenzamide) (C15H20Cl2N2O3) (Figure 41) has a molecular mass of 347.236 g/mol. 
It is a synthetic compound of the salicylamide series that has been used in the last two 
decades in PET and is a marker for dopamine D2 and D3 receptor binding by acting as a 
reversible antagonist. This has allowed scientists to directly assess the availability of D2 
receptors and indirectly, the levels of pre-synaptic dopamine release in PD (Antonini et 
al., 1997; Breier et al., 1997). 
There are a number of pharmacological aspects that make RAC a suitable PET 
ligand. This ligand has a low nanomolar affinity for D2 and D3 receptors and low 
lipophilicity such that the tracer reaches equilibrium between brain and plasma after IV 
administration within the time course of a PET scan (Farde 1986). Unlike spiperone-based 
tracers, its brain uptake is also influenced by endogenous dopamine, which competes for 
D2 receptor binding. Early studies reported a rapid uptake of ligand by the brain, striatal 
radioactivity reaching a peak at 25 mins post IV injection and then slowly declining as 
dissociation from binding sites occurred. Cerebellar activity peaked rapidly and then 
declined throughout the time course of the scan.  
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Figure 41 Chemical structure of raclopride ((3,5-dichloro-N-{[(2S)-1-ethylpyrrolidin-2-yl]methyl}-2-
hydroxy-6-methoxybenzamide) (C15H20Cl2N2O3) 
 
 
2.4.2.1.1	  Preparation	  and	  Synthesis	  
The synthesis of RAC commonly entails the methylation of the RAC precursor analogue; 
O-Desmethyl-raclopride-hydrobromide using 11C-methyltriflate (Ehrin et al., 1987; 
Slifstein et al., 2006). 11C-methyltriflate is produced by passing 11C-methyliodide (11C-
CH3I) through a silver triflate furnace (195’C) (Jewett et al., 1992), which involves 
bubbling 11C-O2 into a tetrahydrofuran solution of lithium aluminium hydride and 
distilling 11C-CH3I through a stream of argon. The newly formed 11C-methyltriflate is 
then subsequently trapped in a solution of O-Desmethyl-raclopride-hydrobromide and 
sodium hydroxide (NaOH) in dimethyl sulfoxide. Following the 5 min reaction, the crude 
product is purified using high pressure liquid chromatography (HPLC) and then diluted 
with water before being passed through a classic C18 Sep-Pak column. The final product is 
recovered from the column using 1mL ethanol and the solution is subsequently mixed 
with saline and filtered (Slifstein et al., 2006). Using this method of radiosynthesis, 2.96-
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5.55GBq of RAC is typically obtained with specific radioactivities ranging from 18.5-55.5 
GBq/μmol (Ribeiro et al., 2004).         
 Alternatively, the radiosynthesis of RAC using dimethylraclopride triflate which is 
a different precursor to O-Desmethyl-raclopride-hydrobromide has been described by 
Iwata and colleagues (2001) in which an automated loop method was used in the 
preparation of RAC (Iwata et al., 2001). Due to the absence of the by-production of 11C-
methylbromide, which is a problem when using O-Desmethyl-raclopride-hydrobromide 
(Langer et al., 1999), the use of dimethylraclopride triflate is expected to generate 
significantly higher yields of the meaningful product.   
 In the experiments of this thesis, 1mg of the RAC precursor (dimethylraclopride 
triflate) is dissolved in a solvent and NaOH is then added to the solution. This precursor 
solution is subsequently injected into a looped PTFE tube and is flushed using helium gas.  
11C-methyltriflate is then passed through the loop and following a short reaction, the 
solution is purified using HPLC and the resultant product is collected (Iwata et al., 2001).   
 
2.4.2.1.2	  Safety	  and	  Tolerability	  
Ribeiro and colleagues investigated the whole body biodistribution and radiation of RAC 
in a group of three healthy human male volunteers following IV injection of 320 ± 65 
MBq (mean ± SD) of the tracer. This has allowed the suitable radiation dose in healthy 
humans and which organs received the highest absorbed dose to be determined (Ribeiro et 
al., 2005). In these subjects, no adverse or subjective pharmacological effects were 
observed.  Furthermore, vital signs including the electrocardiograph (ECG) and blood 
pressure remained stable and normal after RAC injection and no apparent changes were 
seen in the blood and normal samples of the subjects before and after administration of the 
ligand. This suggests that the radiotracer lacks toxicity and the level of risk is minor.     
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  During the early stages of the scan in the same study, high radioactivity was seen 
in the intestines, liver and kidneys, while lower activity was present in the lungs, heart and 
brain. Also, towards the end of the scan (78 – 112 min post injection), high activity was 
observed especially in the kidneys and urinary bladder (followed by the intestines), which 
signifies the rapid excretion of the tracer through the renal system, followed by the 
intestinal route.  However, the level of activity remained high throughout the scan in the 
gall bladder, indicating that the tracer is accumulated in this region.   
 The mean effective dose for normal adults of RAC was estimated to be 6.7 ± 0.4 
μSv/MBq (mean ± SD). Regarding radiation protection, dosimetric estimates for RAC 
were within the acceptable range of doses in clinical medicine studies. The authors of the 
study has concluded that by using 222MBq for each injection, subjects may be able to 
undergo two to three PET scans per year for adequate cerebral D2 receptor imaging and 
for the evaluation of neuroprotective drugs (Ribeiro et al., 2005). The findings of this 
study were supported by another similar study where the authors have concluded that the 
doses of RAC commonly used in PET research (370-555 MBq) was much lower than the 
acceptable maximum single radiation dose under the USA federal regulations for studies 
performed under Radiation Drug Research Committee (Stilfstein et al., 2006).             
 
2.4.2.1.3	  Metabolism	  
Following administration of RAC, the metabolism of the tracer follows an expected trend 
with a gradual decrease in the percentage of un-metabolised RAC over time, as observed 
in rhesus monkeys (Carson et al., 1996). This was reflected by the un-metabolised fraction 
at 10 and 40 min being 0.67 ± 0.08 and 0.21 ± 0.09 (mean ± SD) respectively, following a 
bolus injection of RAC. Although similar observations were seen in humans (Farde et al., 
1989), the appearance of plasma metabolites was much higher in the monkeys than in the 
 137	  
humans. In the same study, it was reported that amphetamine administration, led to a more 
rapid level of metabolism as shown by a 16% reduction in the percentage of un-
metabolised RAC from 10 to 40 min after injection in the same monkeys (Carson et al., 
1996). Due to higher levels of synaptic dopamine, which is induced by amphetamine, the 
increased dopamine is likely to out compete the RAC for D2 receptor binding sites, hence 
making the tracer more vulnerable to rapid metabolism and clearance by enzymes. 
 
2.4.2.1.4	  Displacement	  Studies	  
Neurotransmitter fluxes can be indirectly measured with PET imaging in the living human 
brain. The two-scan RAC PET paradigm provides such an example (Figure 42). When 
endogenous dopamine binds to D2 receptors it competes with the reversible antagonist 
RAC. This phenomenon allows synaptic dopamine levels to be estimated indirectly from 
changes in tracer’s D2 receptor binding (Ross et al., 1989). 
Typically, D2 binding of RAC is computed from regional brain TACs using 
SRTM, which assumes that the cerebellum is devoid of dopamine receptors and so its 
TAC reflects non-specific binding levels in other brain regions. Following challenges that 
increase synaptic dopamine concentrations, reductions in radiotracer BPND are assumed to 
directly reflect changes in availability of D2 receptors due to occupancy by endogenous 
dopamine (Laruelle, 2000).  
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Figure 42 The two-scan 11C-raclopride PET paradigm 
 
In reality this theory is probably more complex as binding of dopamine leads to 
internalisation of D2 receptors (Chugani et al., 1988; Itokawa et al., 1996). However, 
internalisation of D2 receptors following dopamine release does not invalidate the model 
as RAC can only bind to D2 receptors on the cell surface due to its low lipophicility 
preventing diffusion through plasma membranes into the cell cytoplasm (Laruelle, 2000). 
Elevation of dopamine synaptic concentrations can be achieved in vivo by administering 
inhibitors of the DAT such as methylphenidate (Volkow et al., 1994) and cocaine 
(Schlaepfer et al., 1997) or with dopamine releasers such as amphetamines (Laruelle et al., 
1995; Breier et al., 1997; Carson et al., 1998; Ginovart et al., 1999). Consequent 
reductions in striatal RAC and 123I-IBZM binding have been demonstrated in PET and 
SPECT studies but none of these reports interrogated cortical areas. 
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2.4.2.1.5	  11C-­‐raclopride	  Data	  Analysis	  	  
 
Region of Interest (ROI) Analysis 
ROI analysis was performed using ANALYZE medical imaging software (Mayo 
Foundation, Rochester, MN, USA; Version 8.0b) on a Sun Sparc Ultra 10 workstation 
(Sun Microsystems Inc., Santa Clara, CA, USA). Parametric images of RAC BPND were 
generated from the dynamic RAC scans using a BASIS function implementation of the 
SRTM, with the cerebellum as the reference tissue (Gunn et al., 1997). Then, the 
parametric images of RAC BPND, for each subject, were anatomically coregistered and 
resliced to the corresponding volumetric T1-weighted MRI. This was performed using the 
Mutual Information Registration algorithm in the statistical parametric mapping (SPM; 
Version 2) software package (Wellcome Department of Cognitive Neuroscience, Institute 
of Neurology, London, UK) implemented in Matlab (The Mathworks Inc., Natick, MA, 
USA; Version 6.5). 
The resolution and the sensitivity of the EXACT HR++ and EXACT HR+ camera 
are sufficient to allow ROIs to be defined. ROIs were traced guided by the Talairach and 
Tournoux (1988) stereotaxic atlas in combination with the Duvernoy (1999) 3D sectional 
atlas on the individual coregistered MRIs and these were then used to sample the 
parametric PET images. For each patient, we calculated the averaged right and left ROIs. 
 For the hypothalamic ROI, The anterior border was defined by the AC and lamina 
terminalis; the superior border by the interventricular foramen and interthalamic adhesion; 
the posterior border by the posterior tuber and mamillary body and the inferior border by 
the optic chiasm, the optic nerve and the median eminence and infundibular recess. 
In case of two different PET scanners used on a given study, RAC BPND uptake 
was expressed as a % of the normal mean in healthy controls scanned with respective 
scanners. 
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In RAC PET analysis without the use of MRI, RAC PET kinetic modeling is 
performed using SRTM (Lammertsma and Hume, 1996) and cerebellar activity was the 
reference input function. ROI templates for striatal and cerebellar areas were defined on a 
MRI scan positioned in standard Montreal Neurological Institute (MNI) space (Hammers 
et al, 2003) and then normalised into individual native space for each scan using a RAC 
template. Three striatal subregions were defined bilaterally, based on previously described 
criteria (Martinez et al., 2003): the limbic striatum (LS) corresponds to the ventral 
striatum, and the caudate and putamen were subdivided along their rostrocaudal axis using 
the AC to derive the associative striatum (AST; precommissural dorsal caudate, 
postcommissural caudate and precommissural dorsal putamen) and the sensorimotor 
striatum (SMST; postcommissural putamen). The BPND was calculated as the ratio at 
equilibrium of specifically bound (striatal area) radioligand to that of nonspecifically 
bound (cerebellum) (Innis et al., 2007). Both cerebellar and striatal regions were sampled 
from Frames 4-20 of the dynamic scan after scans were corrected for head movement.  
 
Statistical Parametric Mapping (SPM) Analysis 
For SPM analysis, parametric images of RAC BPND were interrogated to localize 
significant differences in D2 receptor availability at a voxel level using SPM2 software. 
The PET parametric images of each subject were spatially transformed to a normal RAC 
template previously created in MNI space with the SPM software (Meyer et al., 1999). 
Subsequently, images were spatially smoothed using a 6 × 6 × 6 mm (full-width at half 
maximum) isotropic Gaussian kernel. Between-group comparisons of RAC BPND were 
performed. The contrasts were used to derive Z scores on a voxel basis, using the general 
linear model (Friston et al., 1995). 
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For the hypothalamus, an explicit mask was applied that was previously created in 
ANALYZE software, for including in the analysis only the sections where hypothalamus 
is visible in order to minimize voxels of no interest when making multi-comparison 
statistical corrections (total of 421 voxels were interrogated). 
 
2.4.2.2	  11C-­‐DASB	  
The PET tracer 11C-(3-amino-4- [2-[(di(methyl)amino)methyl]phenyl] 
sulfanylbenzonitrile) (C16H17N3S) (DASB) (Figure 43) has a molecular mass of 
282.392014 g/mol and it binds with high selectivity to the SERT which is important for 
the regulation of 5-HT function and allows accurate in vivo assessments of the 
serotonergic system to be made. This SERT ligand, which is part of the 2-(phenylthio)-
araalkylamines series ((5-trifluoromethyl-2- (2-dimethylaminomethyl-phenylsulfanyl) 
phenylamine) has been shown to readily cross the blood brain barrier (BBB). Furthermore, 
compared to other PET tracers that bind to SERT, 11C-DASB has a higher affinity and 
selectivity, while displaying moderately high specific to nonspecific ratios in vivo (Wilson 
et al., 2000).    
 
 
Figure 43 Chemical structure of 11C-DASB ((3-amino-4-[2-
[(di(methyl)amino)methyl]phenyl]sulfanylbenzonitrile) (C16H17N3S) 
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2.4.2.2.1	  Preparation	  and	  Synthesis	  	  
Based on the protocol described by Wilson (2000), 11C-DASB is synthesised by 
alkylation of their N-normethyl precursors using cyclotron-produced 11C-iodomethane 
(11C-CH3I) in 30-55% radiochemical yield following HPLC purification and formulation.  
For example in a study by Ginovart and colleagues (2003), 11C-CH3I was trapped in a 
HPLC sample loop coated with a solution of the N-normethyl precursor (1mg) in DMF 
(80μL) at ambient temperature. After 5 mins, the contents of the sample loop was injected 
onto a reverse-phase HPLC column and the fraction containing the collected product was 
evaporated to dryness, formulated in saline and then filtered through a 0.2μ filter. Specific 
activities of 25-55 GBq/μmol at the end of synthesis was obtained with an expected >98% 
radiochemical purity (Ginovart et al., 2003).   
 A new automated procedure of synthesis of 11C-DASB was also recently 
described by Haeusler (2009), which optimises Wilson’s initial protocol. This newly 
developed procedure has been applied more than 60 times, where there was a low failure 
rate (3.2%) and yields of up to 8.9GBq (average = 5.37 ± 1.6 GBq; mean ± SD) were 
obtained. Radiochemical yields based on 11C-CH3I (corrected for decay) were reported to 
be 66.3 ± 6.9% (mean ± SD) with a specific activity of 86.8 ± 24.3 GBq/μmol (mean ± 
SD). It is possible that this automated procedure could be implemented and established for 
the synthesis of 11C-DASB (Haeusler et al., 2009).     
 
2.4.2.2.2	  Safety	  and	  Tolerability	  
The first radiation dosimetry estimates for 11C-DASB based on whole-body distribution 
of activity were first reported in rats (Wilson et al., 2002) and monkeys (Tipre et al., 
2004). From these studies, the radiation burden of 11C-DASB was found to be relatively 
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low meaning that multiple PET scans on the same research subjects could be performed 
per year with no expected safety issues.  
 In the study by Wilson and colleagues (2002), the expected human dosimetry was 
calculated using the whole-body distribution from the rat data. After injection of an 
effective dose (effective dose 5.5 E-03 mSv/MBq in rats), the percentage of the injected 
11C-DASB for selected organs (i.e. the kidneys, lungs and brain) were scaled to reflect 
human values based on the differences in proportions of organ to total body mass in 
humans and rats. The calculated expected dose in humans was similar to that of most other 
neuroreceptor ligands labelled with carbon-11. The organs that received the highest 
radiation dose were the gastrointestinal tract and urinary bladder that is likely to be due to 
the high level of excretion of the tracer through the urinary and hepatobiliary routes. 
Furthermore, the lungs also contains a higher radiation dose which could be due to the 
high concentration of SERT binding sites, hence trapping a higher proportion of 11C-
DASB (although radiation dose in the lungs could be reduced by prior administration of 
SERT inhibitor). Nonetheless, despite the higher radiation doses within these regions, it is 
unlikely to be sufficient in inducing harmful effects (Wilson et al., 2002).      
          A more recent investigation that has directly assessed the dosimetry in human has 
re-enforced the safety of 11C-DASB uses in humans (Lu et al., 2004). In this study on 
seven healthy human subjects following a 669 ± 97 MBq (mean ± SD) 11C-DASB, no 
apparent changes in the ECG, blood pressure, heart rate and respiration rate were 
observed. Moreover, the blood and urine of the subjects following injection of 11C-DASB 
was also found to be normal. This was despite the higher radiation doses reported in the 
kidneys, gall bladder wall, lungs liver and urinary bladder wall. This provides further 
evidence that injection of 11C-DASB in humans is safe and not expected to induce 
adverse effects (Lu et al., 2004).         
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2.4.2.2.3	  Metabolism	  
For nearly all PET tracers, the plasma metabolite fraction increases continuously as 
expected following a single injected dose due to metabolism by enzymes. However, an 
intriguing feature of 11C-DASB pharmacokinetics is the atypical plasma metabolite 
profile. For 11C-DASB, an initial increase in metabolism following administration of the 
tracer as a bolus dose in healthy human volunteers was followed by a decrease in the 
metabolite fraction, before an increase again. This trend, as described in an investigation 
by Parsey and colleagues (2006) was reflected by an unusual lower percentage of un-
metabolised 11C-DASB at the two-min time point than in the 12-min time point. This 
phenomenon was not observed in other radioligands such as 11C-McN 5652 (Parsey et al., 
2000a) and 11C-WAY-100635 (Parsey et al., 2000b) where a gradual increase in level of 
metabolite was seen from the start through to the end.    
 There has been evidence in other studies that has led to suggestions that the 
decrease in 11C-DASB metabolism at the 12-min interval was due to binding of 11C-
DASB to lung SERT. For example, in humans, the concentration of SERT in the lungs 
(7.50 pmol/mg of protein) was an order of magnitude higher than in the dorsal raphe 
nucleus (329 fmol/mg) (Arango et al., 2001), which could explain why SSRIs such as 
venlafaxine has been found to accumulate in the lungs in humans (Malizia et al., 1997). 
Indeed, radioactivity due to accumulation of 11C-DASB was found to be especially high 
in the lungs (Wilson et al., 2002). Hence, taken in all together, it is possible that due to IV 
injection of 11C-DASB, the tracer must first pass through the pulmonary vasculature 
where it binds with high affinity to the lung SERT meaning that it is trapped there for a 
brief amount of time. This allows 11C-DASB to be temporarily protected from 
metabolism until it is released from the lung SERT that could explain the temporary 
decrease in level of metabolite. An increase in the metabolite fraction is then observed as 
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the tracer is distributed to other regions of the body such as the brain after it has left the 
lungs (Parsey et al., 2006).    
 
2.4.2.2.4	  11C-­‐DASB	  Data	  Analysis	  
The input function was derived from the non-specific tracer-binding signal in the posterior 
cerebellar grey matter cortex avoiding inclusion of the vermis (Kish et al., 2005). 
Following reconstruction of the dynamic 11C-DASB image volume, a summed image 
volume was created from the entire dynamic data set using an in-house software package. 
A standardized template of high-contrast ROIs was defined directly on the summed image 
and these ROIs were then applied to the dynamic dataset. By obtaining the regional 
concentrations of radioactivity (kBq/ml) from the full dynamic scan, the decay-corrected 
TACs were computed and movement during the scan assessed. Any movement detected 
was corrected using a frame-by-frame realignment procedure as previously described 
(Montgomery et al., 2006). Subject MRIs, after transformation to a voxel size of one mm3 
centered on AC and aligned to AC-PC line, were co-registered to the summed PET 
volume using the Mutual Information Registration algorithm in the SPM2 software 
package implemented in Matlab 6.5.  
Following co-registration, the definition of ROIs was performed on the co-
registered MRI with the help of the Duvernoy 3D sectional atlas (1999) using ANALYZE 
software. Anatomical borders were defined manually for:  
(i) Cerebellum: On the axial section. The anterior border is defined by the inferior 
semilunar lobule, the posterior border and the lateral border is defined by the transverse 
sinus and the medial border is defined by the cerebellar falx.  
(ii) Amygdala: On the axial section. The anterior border is defined by the basal 
part of lateral fissure and parahippocampal gyrus, the posterior border is defined by the 
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head of the hippocampus, the lateral border is defined by the temporal horn of the lateral 
ventricle and the medial border is defined by the parahippocampal gyrus.  
(iii) Insula: On the axial section. The anterior border is defined by the posterior 
orbital gyrus/circular sulcus of insula, the posterior border is defined by the most medial 
point of the superior temporal sulcus, the lateral border is defined by the lateral fissure and 
the medial border is defined by the external capsule.  
(iv) Thalamus: On the axial section. The anterior border is defined by the fornix, 
the posterior border is defined by the pulvinar, the lateral border is defined by the 
posterior limb of the internal capsule and the medial border is defined by the third 
ventricle.  
(v) Hypothalamus: On the sagittal section. The anterior border is defined by the 
AC and lamina terminalis, the superior border is defined by the interventricular foramen 
and interthalamic adhesion, the posterior border is defined by the posterior tuber and 
mamillary body and the inferior border is defined by the optic chiasm, the optic nerve and 
the median eminence and infundibular recess. 
(vi) Rostral Raphe: On the sagittal section. The superior border is defined by the 
superior colliculi, the inferior border is defined by the decussation of the superior 
cerebellar peduncle, the anterior border is defined by the red nucleus and the posterior 
border is defined by the cerebral aqueduct.  
(vii) Caudal Raphe: On the saggital section. The superior border is defined by the 
rostral raphe, the posterior border is defined by the fourth ventricle and the anterior border 
by the pons.  
(viii) ACC: On the sagittal section. The superior border is defined by the cingulate 
sulcus, the anterior border is defined by the genu of corpus callosum, the inferior border is 
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defined by the callosal sulcus and the posterior border is defined by the origin of the 
medial aspect of the post central sulcus.  
(ix) Posterior Cingulate: On the sagittal section. The anterior border is defined by 
the origin of the medial aspect of the precuneate gyrus, the superior border is defined by 
the cingulate sulcus, the posterior border is defined by the splenium of corpus callosum 
and inferior border is defined by the callosal sulcus. 
(x) Midpons: On the axial section. The anterior border is defined by the posterior 
cerebral artery, the posterior border is defined by the medial lemniscus and red nucleus, 
the lateral border is defined by the latero-mesencephalic cistern and the medial border is 
defined by the interpeduncular fossa. 
(xi) PFC: On the axial slice. The anterior border is defined by the superior frontal 
gyrus to the middle frontal gyrus, the posterior border is defined by the inferior frontal 
gyrus, the lateral border is defined by the middle frontal gyrus to the inferior frontal gyrus 
and the medial border is defined by the interhemispheric fissure the length of the medial 
frontal gyrus. 
(xii) Putamen: On the axial section. The anterior border is defined by the anterior 
limb of the internal capsule, the posterior border is defined by the posterior limb of the 
internal capsule, the lateral border is defined by the external capsule/claustrum and the 
medial border is defined by the lamina medullaris lateralis.   
(xiii) Caudate Nucleus: On the axial section. The anterior border is defined by the 
lateral ventricle, the posterior border is defined by the internal capsule, the medial border 
is defined by the lateral ventricle and fornix and the lateral border is defined by the 
external capsule.  
(xiv) Ventral Putamen: On the axial section. The anterior border is defined by the 
nucleus accumbens, the posterior border is defined by the posterior limb of internal 
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capsule, the lateral border is defined by the insula and the medial border is defined by the 
AC.  
(xv) Nucleus Accumbens: On the axial section. The anterior border is defined by 
the orbital gyrus, the posterior border is defined by the ventral putamen, the lateral border 
is defined by the insula and the medial border is defined by the subcallosal gyrus. 
ROIs were standardized for volume throughout subjects and were manually 
defined on both hemispheres for amygdala (1500mm3), cerebellum (8100mm3), 
hypothalamus (650mm3), insula (9500mm3), thalamus (8500mm3), rostral raphe nuclei 
(1050mm3), caudal raphe nuclei (900mm3), ACC (8000mm3), PCC (5000mm3), PFC 
(11000mm3), caudate nucleus (1400mm3), putamen (2100mm3) and ventral striatum 
(2250mm3).  
The transformation parameters generated from the co-registration were applied to 
the dynamic PET data set and the ROIs projected onto the image volume. ROIs were then 
sampled to give new TACs that were checked against intrascan notes and for movement 
correction improvement. Volume of Distribution Ratios (VDR) were computed for ROI 
TACs with the graphical analysis method of Logan (Logan et al., 1996) and the BPND was 
calculated as VDR-1 (Ginovart et al., 2001; Innis et al., 2007). Global BPND values 
accounting together for all the ROIs defined were also calculated. 
 
2.4.2.3	  18F-­‐DOPA	  
Garnett and colleagues (1983) first reported the use of 18F-DOPA to visualise the 
nigrostriatal dopaminergic system in vivo. 18F-DOPA (L-6-[18F] fluoro-3, 4-
dihydroxyphenylalanine) (C9H10FNO4) (Figure 44) has a molecular mass of 214.180938 
g/mol. 18F-DOPA resembles natural L-DOPA biochemically with similar kinetics (Firnau 
et al., 1986).  It is a large neutral amino acid that is able to cross freely through the BBB 
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where it can be converted to 18F-fluorodopamine by the enzyme dopa-decarboxylase and 
subsequently taken into catecholamine storage vesicles.  Therefore, when injected into the 
blood stream, 18F-DOPA is able to reach dopaminergic terminals and be used in the brain 
as a precursor for dopamine.  By utilising PET and 18F gamma radiation emitting 
properties, this provides a means of assessing the functional integrity of the presynaptic 
nigrostriatal dopaminergic projections with 18F-DOPA being a marker of presynaptic 
dopamine storage capacity (Firnau et al., 1986). However, the labeled 18F-DOPA has to 
be synthesised in the L-isoform since the transport system at the BBB only accepts L-
amino acids.       
 
 
 
Figure 44 Chemical structure of 18F-DOPA (18F-6-fluorodopa ((L-6-[18F] fluoro-3, 4-
dihydroxyphenylalanine) (C9H10FNO4) 
 
2.4.2.3.1	  Preparation	  and	  Synthesis	  
There are many ways in which 18F-DOPA can be synthesised based on the literature 
(Firnau et al., 1984; Diksic et al., 1985). An efficient and convenient method involves the 
reaction between L-methyl-N-acetyl-[/3-(3-methOxy-4-acetOxyphenyl)alaninate with 
acetyl hypofluorite in a three step protocol as described by Adam and colleagues (1986). 
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 The first stage involves the preparation of L-methyl-N-acetyl-[/3-(3-methOxy-4-
acetOxyphenyl)alaninate. Briefly, L-3-O-methyl DOPA is suspended in dry methanol 
mixed with hydrogen chloride (HCL) and stirred for a period of 24 hours, before being 
evaporated, dissolved in methanol and evaporated again.  The mixture is then further dried 
using a vacuum to create the solid amino-ester and immediately suspended in dry pyridine 
acetic anhydride and stirred. The mixture is poured into sulphuric acid (H2SO4) and 
extracted with ethyl acetate to release the resultant L-methyl-N-acetyl-[/3-(3-methOxy-4-
acetOxyphenyl)alaninate. 
 In the second stage of 18F-DOPA synthesis, the generated L-methyl-N-acetyl-[/3-
(3-methOxy-4-acetOxyphenyl)alaninate is dissolved in glacial acetic acid. Meanwhile, 
through an irradiation procedure as described by Ruth (1985), 18F-F2/Ne is converted to a 
gaseous acetyl hydrofluorite once passed through a KOAc/HOAc column. Fluorination of 
L-methyl-N-acetyl-[/3-(3-methOxy-4-acetOxyphenyl)alaninate was achieved by bubbling 
the solution (dissolved in acetic acid) with acetyl hydroflourate. After various stages of 
evaporation and drying, a close to 1:1 mixture of 18F-2-fluorodopa and 18F-6-fluorodopa 
isomers is generated and is dissolved in concentrated buffer at ph of 7. 
 The final stage of synthesis in Adam and colleagues’ protocol (1986) involves the 
extraction of the useful 18F-6-dopa isoform from the mixture and purification using 
HPLC. Separation of the isomers is achieved by passing the mixture through a semi-
preparative reverse phase column where 18F-6-dopa can be directly collected as a result 
(Adam et al., 1986).                           
 
2.4.2.3.2	  Safety	  and	  Tolerability	  
Although there are no known aversive or side effects associated with the use of 18F-
DOPA (Firnau et al., 1986), there could be possible issues based on early dosemetric data.  
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A dosimetric study in mongrel dogs has reported very high accumulation of radioactivity 
in the bladder wall that was orders of magnitude higher than in other organs. Based on 
these findings, estimations of the radiation dose in humans through scaling has led to a 
limit of 111MBq in the injected dose of 18F-DOPA in humans (Harvey et al., 1985).  
However, this dose limit has since been challenged by subsequent dosimetry studies on 
humans (Dhawan et al., 1996; Brown et al., 1998) where it was found that the adsorbed 
radiation dose in the bladder wall was significantly lower than that in the original report.  
In the study by Dhawan and colleagues (1996), it was concluded that an injected dose of 
no more than 333MBq 18F-DOPA is safe in humans (Dhawan et al., 1996).          
 
2.4.2.3.3	  Metabolism	  
18F-DOPA has similar kinetics to natural L-DOPA and therefore has a mostly similar fate 
in the brain.  Upon injection of the tracer into the bloodstream, it is rapidly metabolised by 
the peripheral AAAD enzyme at the -6- position on the aromatic ring of 18F-DOPA, 
forming 18F-dopamine (Cumming et al., 1988). However, 18F-dopamine in the periphery 
is unable to cross the BBB. Hence, an inhibitor of peripheral AAAD such as carbidopa is 
usually routinely administered during PET scanning to block the premature formation of 
18F-dopamine. 18F-DOPA in its injected form is able to cross the BBB via the non-
energy dependent neutral amino acid transport system, which allows it to be transferred 
into the brain. Centrally located AAAD that are present in high concentrations within the 
nigrostriatal nerve terminals act to convert the 18F-DOPA into 18F-dopamine.           
 A study by Boyes and colleagues (1986) has investigated the metabolism of 18F-
DOPA given to carbidopa treated human subjects through analysis of the plasma over a 
two-hour period. By using HPLC and alumina extraction to identify the 18F-labelled 
compounds in the plasma, it was reported that during the two-hour period, the 
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concentrations of both 18F and 18F-DOPA decreased as a bi-explonential function of time 
(biphasic kinetics). These observed pharmacokinetics for 18F-DOPA are similar to those 
for L-DOPA providing evidence that 18F-DOPA is a suitable analogue for L-DOPA.   
 From this study, it was also found that the metabolite 3-O-methyl 18F-DOPA was 
due to the action of COMT. The appearance of this methoxylated metabolite in the plasma 
is rapid, and can represent up to 50% of the plasma 18F after 30 mins from tracer 
administration (Boyes et al., 1986). This high level of metabolite can be a potential 
problem for 18F-DOPA PET studies, since 3-O-methyl 18F-DOPA competes with regular 
18F-DOPA for transportation into the brain via the non-energy requiring amino acid 
transport system. Hence, the presence of a high concentration of the metabolite could limit 
the level of tracer that reaches the brain. However, in a study by Doudet and colleagues 
(1991) it has been suggested that since 18F-DOPA levels are highest in the plasma in the 
first 20 mins (which means that transfer of the tracer is highest at this time) (Boyes et al., 
1986; Doudet et al., 1991), L-phenylalanine could be administered after this time to block 
subsequent transfer of the troublesome 18F-DOPA metabolite (Doudet et al., 1992).   
 
2.4.2.3.4	  18F-­‐DOPA	  Data	  Analysis	  
Parametric images of specific 18F-DOPA uptake (Ki maps) were created at a voxel level 
for the whole brain using the Patlak graphical approach (Patlak and Blasber, 1985) with a 
cerebellar cortex reference input function (for example see Figure 45). Influx constants (Ki 
values) were computed for each of the target regions. The Ki values or each region were 
tabulated and means and SDs calculated.  
In all subjects the positions of striatal, extra-striatal and occipital structures were 
defined by summing time frames to create an integrated image, representing activity 
collected 30-95 mins after 18F-DOPA administration. Qualitative summated images 
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“ADD images” created from the dynamic 18F-DOPA time series by integrating all frames 
of the dynamic image were also produced and then transformed into standard stereotaxic 
MNI space using an 18F-DOPA template created in-house from a normal subject 
database. ADD images contain both tracer delivery and specific uptake information and 
provide adequate anatomical detail to allow stereotaxic manipulations. Subsequently, the 
Ki maps were also individually normalized to MNI stereotaxic space by applying the 
transformation parameters defined during the normalization of their respective ADD 
image. This spatial transformation of parametric images made it possible to perform a ROI 
analysis using a template object map and to perform statistical parametric mapping. 
 
 
 
 
 
 
 
 
 
  
 
Figure 45 Integral images of 18F-DOPA in a normal volunteer superimposed onto the subject MRI. The 
yellow arrows point to the putamen and caudate nuclei 
 
In order to quantify the data, TACs were calculated by placing ROIs in a standard 
template arrangement. The data were analysed further by using an adaptation of the 
multiple time graphical analysis (MTGA), described by Patlak and co-workers (Patlak and 
low high 
caudate 
putamen 
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Blasber, 1985), using a nonspecific occipital reference tissue, rather than a plasma input 
function (Brooks et al, 1990). In brief, the MTGA assumes that there is an irreversible or 
bound region, into which a test substance enters during the study, but cannot leave. This 
corresponds to the striatum and the 18F-DOPA, respectively: The 18F-DOPA is 
effectively trapped by its conversion to 18F-dopamine. In addition, equilibrium of the 
18F-DOPA is assumed between the plasma and a so-called exchangeable, or not specific, 
region, represented by the occipital lobe.  
Irreversible tracer uptake into the striatum is measured by a comparison of the rate 
of change of activity in the striatum against a transformed and expanded time scale. An 
MTGA plot of striatum: occipital 18F uptake versus the transformed and expanded time 
scale of the integrated occipital/occipital 18F activity is linear between 30 and 90 mins of 
'real' time. The gradient of this plot may be regarded as the Ki value, which reflects 
specific striatal 18F accumulation. The Ki value is therefore, a composite rate constant 
reflecting striatal 18F-DOPA uptake, AAAD activity and the rate of 18F-DOPA 
metabolism. Because ROIs were placed over both caudate and putamen, independent Ki 
values could be derived for each of these structures. 
 
2.5	  Statistics	  
 
For the studies included in this thesis, the GraphPad InStat (Version 3.1a for Macintosh, 
GraphPad Software Inc., CA, USA) and the SPSS (SPSS versions 12 and 16 statistical 
software for Macintosh, SPSS Inc., IL, USA) software packages were used.  
For between groups comparisons regarding the clinical data one-way ANOVA 
assumptions were tested with the Bartlett and Kolmogorov and Smirnov methods. Where 
a successful normality test was obtained and SDs were not different among groups tested, 
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one-way ANOVA was employed and multiple comparisons were checked with Tuckey-
Kramer test. Where normality tests failed and SDs were different among groups tested, the 
nonparametric Kruskal-Wallis test was employed and multiple comparisons were checked 
with Dunn’s test. For comparisons between PET data and clinical characteristics, repeated 
measures of ANCOVA were employed and the clinical parameters served as covariates. 
The significance (alpha level) was set at p<0.05 corrected and all significance levels 
reported in two-group comparisons in this thesis are two-tailed.  
Between two-group comparisons were interrogated with parametric (t test) and 
non-parametric two-tailed p value test (Mann–Whitney U). The investigation for 
associations between individual putaminal and caudate RAC BPND and duration of disease 
and treatment, and amount of daily LEDTOTAL, were interrogated with the Spearman rank 
correlation test.  
 In the 11C-DASB studies on depressive symptoms and BMI changes, 
homogeneity and Gaussianity where tested with Bartlett, and Kolmogorov-Smirnov tests. 
First, using the Spearman correlation we investigated whether BDI-II scores correlated 
with HRSD scores in PD patients. Second, repeated measures ANCOVA was used to 
interrogate the association between depressive symptoms (BDI-II and HRSD) or BMI 
changes, clinical characteristics (disease duration, H&Y staging and UPDRS) and 
meterological data (temperate seasons, sunshine, humidity and temperature) with SERT 
binding where 11C-DASB BPND in ROIs was the repeated measure. If a significant 
interaction was found between a clinical variable and the repeated measure variable ROI, 
univariate tests were then carried out on the individual ROIs and resulting p values were 
corrected for multiple comparisons. Using the same statistical methodology we also 
investigated whether daily and lifetime dopaminergic medication intake (Daily and 
Lifetime LEDTOTAL, LEDDA and LEDL-DOPA) influenced BDI-II and HRSD scores, and 
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changes in the BMI. Group comparisons for differences in 11C-DASB BPND between PD 
patients with low, high BDI-II and HRSD scores, and healthy controls were tested with 
one-way ANOVA corrected for multiple comparisons (Tukey-Kramer). Similarly, group 
comparisons between PD patients with low, high BMI changes, and healthy controls were 
carried out. 
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3.1	  Implication	  of	  Clinical	  Characteristics	  on	  Striatal	  
D2	  Receptors	  
	  
3.1.1	  Subjects	  	  
Sixty-eight PD subjects in various stages of the disease were studied. Their clinical 
characteristics are shown in Table 8. All subjects undertook a RAC PET scan and 1.5T 
volumetric MRI scan in OFF medication condition. RAC BPND in caudate and putamen 
were checked for associations with (a) disease duration, (b) UPDRS motor scores in ON 
and OFF medication state, (c) BDI-II scores, (d) DA and L-DOPA treatment duration and 
(e) amount of daily and lifetime DA and L-DOPA intake. The aims of this study are 
presented in Box 2. 
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Box 2 Aims: Implication of Clinical Characteristics on Striatal D2 Receptors 
To investigate the effect of medication, motor disability and depressive symptoms on 
striatal postsynaptic dopamine D2 receptors in Parkinson’s disease patients. 
 
 
Table 8 Whole Sample Characteristics 
PARKINSON’S DISEASE PATIENTS 
Number of Subjects 68 
Sex 52M / 16F 
Age (years ± SD) 62.77 ± 9.13 
PD Duration (Years ± SD) 10.71 ± 6.36  
H&Y OFF (mean ± SD) 2.80 ± 0.93 
UPDRS III OFF (mean ± SD) 42.04 ± 13.00 
UPDRS III ON (mean ± SD) 20.81 ± 8.85 
MMSE (mean ± SD) 29.21 ± 1.38 
BDI-II (mean ± SD) 13.70 ± 8.65 
Duration of Dopaminergic therapy (years ± SD)* 6.45 ± 4.12 
DA duration (years ± SD)* 4.33 ± 3.70 
L-DOPA duration (years ± SD)* 5.46 ± 4.15 
Daily LEDTOTAL (mg ± SD) 911.02 ± 721.59 
Daily LEDDA (mg ± SD) 173.80 ± 180.44 
Daily LEDL-DOPA (mg ± SD) 738.99 ± 731.87 
Lifetime LEDTOTAL (g ± SD)* 1290.95 ± 1250.82 
Lifetime LEDDA (g ± SD)* 299.42 ± 391.42 
Lifetime LEDL-DOPA (g ± SD)* 991.52 ± 1057.64 
* Data from 40 subjects: Quality if data = 59% 
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3.1.2	  Results	  
There was a significant inverse correlation between individual caudate RAC BPND values 
and disease duration (Pearson r = -0.3865, p=0.0012) (Figure 46). 
 
 
Figure 46 Inverse correlation between individual caudate RAC BPND values and disease duration in 
Parkinson’s disease patients (n=68) 
 
PD patients currently receiving treatment with DAs showed significantly decreased 
caudate (Table 9 and Figure 47) and putamen (Table 10 and Figure 48) RAC BPND 
compared to PD patients who do not receive treatment with DAs. 
The amount of lifetime DA therapy inversely correlated with individual RAC BPND 
values in the caudate (Spearman r = -0.3309, p = 0.0487) and putamen (Spearman r = -
0.3296, p = 0.0494) of PD patients (n=40).   
 All other correlations between clinical characteristics and RAC BPND values in 
caudate and putamen (disease duration vs. putamen RAC BPND, UPDRS motor scores ON 
and OFF vs. caudate and putamen RAC BPND, BDI-II scores vs. caudate and putamen 
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RAC BPND and L-DOPA treatment duration and daily and lifetime amount vs. caudate and 
putamen RAC BPND) were not significant (p>0.05). 
 
Table 9 Caudate 11C-raclopride BPND in Parkinson’s disease patients Treated and Not Treated 
with Dopamine Agonists  
 NO DA YES DA 
Number of Subjects 22 46 
Average 2.0343333 1.818073* 
SD 0.33878 0.34897 
SE 0.073929 0.053217 
*Unpaired t test: p = 0.0220 
 
 
Figure 47 Significant decrease in caudate D2 receptor availability in Parkinson’s disease patients in 
treatment with dopamine agonists compared to those not treated with dopamine agonists (*p<0.05) 
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Table 10 Putamen 11C-raclopride BPND in Parkinson’s disease patients Treated and Not Treated 
with Dopamine Agonists  
 NO DA YES DA 
Number of Subjects 22 46 
Average 2.8873809 2.5602372* 
SD 0.39067 0.49629 
SE 0.085251 0.075683 
*Unpaired t test: p = 0.0104 
 
 
 
Figure 48 Significant decrease in putamen D2 receptor availability in Parkinson’s disease patients in 
treatment with dopamine agonists compared to those not treated with dopamine agonists (*p<0.05) 
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3.1.3	  Discussion	  
The data showed that longer PD duration correlates with decreased D2 receptor 
availability in caudate but not in putamen. PD patients on DAs express lower D2 binding 
in both caudate and putamen compared to PD patients not on DAs. Lifetime amount of 
DA intake also inversely correlates with D2 receptor availability in both caudate and 
putamen of PD patients. Other clinical characteristics such as levels of disability (as 
measure with UPDRS motor scores), depression levels (as measured with BDI-II scores) 
and treatment with L-DOPA do not influence the availability of D2 receptors according to 
this study’s results. 
RAC PET studies in de novo PD patients have shown 10-20% increases in D2 
receptor availability in the putamen contralateral to the more affected limbs while the 
binding in caudate nucleus seems intact (Leenders et al., 1992; Rinne et al., 1993; 
Turjanski et al., 1997). Further RAC PET studies have shown that as disease progresses, 
D2 binding normalizes in the putamen, but caudate nucleus binding is reduced by around 
20% (Brooks et al., 1990; 1992; Antonini et al., 1994; Turjanski et al., 1997; Dentresangle 
et al., 1999). The results from this study are compatible with previous investigations and 
show that as the disease progresses there is a linear decrease in D2 receptor binding in 
caudate but not in putamen.  
Reductions in caudate D2 receptor availability could reflect either disease 
progression or an effect of chronic exposure to dopaminergic therapy. However, these 
reductions were observed only in caudate and not in putamen whereas both these brain 
structures showed decreased D2 receptor availability in PD patients receiving DAs. 
Significant correlations between decreased D2 receptor binding in caudate and putamen 
and the total lifetime DA intake were also found, where no correlations were found with 
the duration of dopaminergic treatment (DA or L-DOPA) or motor disability. 
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These data suggest that exposure to DAs influences D2 binding by downregulating 
the receptors in both caudate and putamen while L-DOPA treatment does not seem to 
have this effect. Additionally, D2 receptors in caudate are linearly affected from disease 
progression possibly due to degeneration of dopamine terminals or loss of D2 binding 
sites. These observations may also explain previous PET findings demonstrating 
comparative data between PD patients on frequent medication and those that have 
completely discontinued, and showing a greater reduction in striatal D2 receptor 
availability as measured by RAC PET in the medicated patients (Thobois et al., 2004).    
 
 
3.2	  Evidence	  of	  Hypothalamic	  D2	  Receptor	  
Dysfunction	  	  
 
3.2.1	  Subjects	  	  
Fourteen patients (13 male) suffering from idiopathic PD were studied. Nine healthy 
volunteers (all men) were used as controls for this study. The participant characteristics 
are summarized in Table 11. All subjects undertook a RAC PET scan and 1.5T volumetric 
MRI scan in OFF medication condition. RAC BPND in hypothalamus and putamen was 
measured. The aims of this study are presented in Box 3. 
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Box 3 Aims: Evidence of Hypothalamic D2 Receptor Dysfunction  
To investigate the functional integrity of hypothalamic postsynaptic dopamine D2 
receptors. It is hypothesised that dysfunction of these receptors would be evident in 
idiopathic Parkinson’s disease patients possibly accounting in part for the non-motor 
symptomatology commonly seen in the clinical course of the disease.   
 
 
Table 11 Participant characteristics 
CHARACTERISTICS PD PATIENTS GROUP NORMAL CONTROLS 
Number of subjects 14 9 
Age (years ± SD) 55.6 ± 8.4 41.2 ± 5.5  
Disease duration (years ± SD)a  12.1 ± 5.3  - 
Hoehn and Yahr (H&Y) stage - OFF 
state (mean ± SD) 
2.8 ± 0.5  - 
UPDRS Part III – OFF state (mean ± 
SD) 
44.79 ± 19.17  - 
Daily LEDTOTAL (mg ± SD) 1185.33 ± 590.40   
aDisease duration has been accounted from the time of PD motor symptom initiation (not the time 
of diagnosis)    
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3.2.2	  Results	  
 
Region of interest analysis 
The mean RAC BPND was significantly decreased in the hypothalamus of PD patients in 
comparison to the group of normal controls (0.2714 ± 0.06 vs. 0.3861 ± 0.04; mean ± SD; 
p = 0.0005). A column graph detailing mean hypothalamic RAC BPND and SDs in PD 
patients and normal controls is depicted in Figure 49. In contrast, no significant difference 
in the mean putaminal RAC BPND between PD patients and normal controls (2.953 ± 0.49 
vs. 3.024 ± 0.46; mean ± SD; Figure 50) was found. 
Individual RAC BPND analyses were also performed for each subject. The normal 
range was defined as values falling within two SD of the normal volunteer RAC mean 
BPND. Nine out of 14 PD patients (64.29%) had significantly reduced hypothalamic RAC 
BPND (Figure 51). 
 
Statistical parametric mapping  
Analysis of mean RAC BPND differences at a voxel level between the PD and normal 
control groups masking out extra-hypothalamic regions confirmed the results obtained 
with ROI analysis. SPM categorical comparisons localized clusters of significant RAC 
BPND decreases (p < 0.01) in the right and left hypothalamus in PD group compared to the 
group of healthy controls (Figure 52 and Table 12). 
 
Correlations 
Individual PD patient values of hypothalamic RAC BPND did not correlate with the 
subject's age (r = − 0.11, p > 0.1), disease duration (r = 0.06, p > 0.1), disease severity as 
 166	  
measured by UPDRS motor scores in an OFF state (r = 0.25, p > 0.1) and daily LEDTOTAL 
(r = 0.18, p > 0.1). 
 
Figure 49 Mean hypothalamic 11C-raclopride binding potential values and standard deviation in the groups 
of Parkinson’s disease patients and normal controls. *p=0.0005 
 
Figure 50 Mean putaminal 11C-raclopride binding potential values and standard deviation in the groups of 
Parkinson’s disease patients and normal controls 
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Figure 51 Scatterplot showing individual hypothalamic 11C-raclopride binding potential values for all 
subjects in the two groups (normal controls and Parkinson’s disease patients). Dotted line represents normal 
control mean−2SD 	  
 
Figure 52 Coronal section of statistical parametric map. Yellow-red areas represent voxel clusters with 
significant decreases in 11C-raclopride binding within the hypothalamic region mask in Parkinson’s disease 
patients (n=14) compared with the group of normal controls (n=9). The color stripe indicates z values 
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Table 12 Bilateral significant decreases in hypothalamic 11C-raclopride binding potential in Parkinson’s 
disease patients compared with the group of normal controls 
Z SCORE MNI COORDINATES TAILAIRACH 
COORDINATES 
AREA 
 
p VALUE 
CORRECTED 
 x y z x y z   
4.28 5.22 -1.51 - 10.72 5.17 -1.91 - 8.92 Right 
hypothalamus 
< 0.01 
4.27 - 3.03 -2.62 - 10.88 - 3 -3 - 9 Left 
hypothalamus 
< 0.01 
 
 
3.2.3	  Discussion	  
This PET study provides further evidence that hypothalamic function is affected in PD, 
being the first in vivo functional imaging study to examine the postsynaptic dopaminergic 
system. The RAC PET findings indicate that the availability of postsynaptic dopamine D2 
and D3 receptors in the hypothalamus of PD patients is significantly reduced. The results 
were comparable using both ROI analysis and SPM categorical comparisons at a voxel 
level with extra-hypothalamic areas masked. 
Hypothalamic RAC BPND values did not correlate significantly with patient age, 
disease duration and severity or L-DOPA dosage suggesting that individual levels of 
reduced D2 and D3 binding in the hypothalamus are independent of integrity of 
nigrostriatal function and chronic exposure to dopaminergic treatment. Several studies 
have shown that in untreated early PD patients, there is a mild increase in putaminal RAC 
binding suggesting an increase in D2 receptor availability (Rinne et al., 1993; Sawle et al., 
1993; Turjanski et al., 1997). In this report, where the patients studied had been 
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chronically exposed to dopaminergic medication, there was no difference in putaminal 
RAC binding between idiopathic PD patients and normal controls. This finding is in 
agreement with previous studies and strengthens the theory that as the disease progresses 
and dopaminergic tone restored with therapy, RAC binding normalizes in the putamen 
(Brooks et al., 1992; Antonini et al., 1994; Turjanski et al., 1997; Dentresangle et al., 
1999). 
The increased putaminal RAC binding in untreated patients may simply reflect 
lack of occupancy by dopamine due to the deficiency state or represent a compensatory 
response involving receptor upregulation. The normalization of D2 binding in more 
advanced patients may reflect either disease progression or exposure to dopaminergic 
treatment. 
In this study, PD patients receiving dopaminergic therapy showed a significant 
reduction in RAC binding in the hypothalamus while putamen binding was normal. This 
differential finding suggests a greater susceptibility of D2 receptors in the hypothalamus 
than the putamen to PD progression, probably reflecting direct involvement of the 
hypothalamus by Lewy body pathology. It is less likely to be a consequence of chronic 
exposure to dopaminergic medication as D2/D3 receptor availability in the hypothalamus 
does not correlate with the level of treatment and putaminal D2 binding was similar in 
treated patients and untreated normal control subjects. However, as there are not 
hypothalamic RAC BPND data in de novo patients available, the treatment effect cannot be 
fully excluded. RAC binding in putamen is known to fall 0.6% (Antonini et al., 1993) per 
year with age. It is uncertain whether this is also true for hypothalamus but the PD cases 
studied here were on average 14 years older than the normal controls. 
The hypothalamus receives serotonergic projections from the median raphe 
nucleus and noradrenergic projections from the lateral medulla oblongata but also has its 
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own native dopaminergic neuronal network. This is divided into the TI and 
incertohypothalamic (IH) dopaminergic systems, periventricular–hypophysial 
dopaminergic (PHDA) neurons and periventricular (PeV) dopaminergic neurons. The 
density of D2 receptors in the hypothalamus is uniform across these regions while D3 
receptor density is more variable and lower than of D2 (Gurevich and Joyce, 1999). The 
RAC PET findings of uniformly reduced tracer BPND throughout the hypothalamus 
therefore suggest that it is primarily a marker of hypothalamic D2 rather than D3 receptors 
in this nucleus. 
The main pathological hallmark of PD, Lewy body formation, is found in the 
hypothalamic nuclei along with the nigra and other brainstem nuclei (Langston and Forno, 
1978). Lewy body pathology is likely to be responsible for the loss of dopaminergic 
neurons and postsynaptic dopamine receptors seen in PD hypothalamus but also for the 
loss of orexin neurons that interact with this dopaminergic network (Fronczek et al., 2007; 
Thannickal et al., 2007). Orexin (also known as Hert), is a neuropeptide involved in sleep 
regulation and metabolism and is almost exclusively located in the lateral hypothalamus 
(Siegel, 2004). Orexin neurons project to many parts of the brain and principally project 
and excite the noradrenergic locus coeruleus, the serotonergic raphe nuclei, the 
histaminergic tuberomammillary nucleus and the dopaminergic VTA (Nambu et al., 1999; 
Yamanaka et al., 2006). Both NA and dopamine regulate the function of orexin cells 
(Baldo et al., 2003; Alberto et al., 2006). D2 agonists probably activate orexin cells 
transsynaptically, as these cells do not appear to express dopamine receptors (Bubser et 
al., 2005). Whether D2 receptors directly or indirectly regulate orexin transmission is still 
unknown, however, the finding of reduced D2 availability in hypothalamus is likely to be 
associated with dysregulation of the orexin system and result in sleep disturbances 
(Thannickal et al., 2007). 
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This study did not formally evaluate the non-motor complaints of the PD subjects. 
In the future, studies searching for possible correlations between in vivo pathological 
findings and clinical characteristics could be of value in elucidating further the 
mechanisms underlying the clinical course of the disease. 
In conclusion, it is demonstrated in vivo with RAC PET significant loss of 
dopamine D2 receptor binding in PD hypothalamus. These postsynaptic receptor changes 
may reflect cellular loss or dysfunction in this region or alternatively be a response to the 
progressive decline of the dopaminergic network in the hypothalamus. Chronic treatment 
with dopaminergic drugs could also play a role though no correlation between D2 binding 
and drug dosage was found. It is likely that reduced hypothalamic D2 receptor function in 
PD patients leads in turn to dysregulation of the orexin system resulting in disturbances of 
sleep and other autonomic functions. 
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Serotonergic	  Dysfunction	  in	  
Parkinson’s	  Disease	  	  
4	  
 
 
4.1	  Staging	  of	  Serotonergic	  Dysfunction	  	  	  
	  
4.1.1	  Subjects	  	  
Thirty non-demented patients with idiopathic PD were studied. These subjects fulfilled the 
UK Brain Bank clinical criteria for PD (Hughes et al., 1992) and they were equally 
divided into three groups according to their disease duration forming early (disease 
duration 0 to 5 years), established (5-10 years) and advanced PD (more than 10 years of 
PD) groups. None of the subjects had a clinical history of depression nor had received any 
anti-depressant therapy in the past (according to referrals from the Movement Disorder 
Clinics in Charing Cross Hospital, London). Furthermore, they had not received any other 
medication with known action on the serotonergic system. Findings for PD subjects were 
compared to a group of 10 normal controls, all in good health and with no history of 
neurological or psychiatric illness and were not on any medication. All groups were 
matched for age and sex (Table 13). All subjects received one 11C-DASB PET and one 
1.5T volumetric MRI scan in OFF medication condition. The aims of this study are 
presented in Box 4. 
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Box 4 Aims: Staging of Serotonergic Dysfunction   
To provide an index of presynaptic serotonergic terminal dysfunction in different clinical 
stages of Parkinson’s disease and to correlate SERT binding changes with general disease 
disability scales. A secondary aim is to investigate the relationship between SERT 
binding and chronic exposure to dopaminergic therapy. 
 
Table 13 Participant Characteristics 
 NORMAL 
CONTROLS 
EARLY PD ESTABLISHED 
PD 
ADVANCED PD 
Disease Duration  
(range; mean ± SD) 
- 0-5 (3.4 ± 1.2) 6-10 (7.5 ± 0.9) 10+ (14.1 ± 3.9) 
No of Subjects 10 10 10 10 
Sex 8M/2F 8M/2F 8M/2F 8M/2F 
Age (years ± SD) 63.7 ± 7.2 65.7 ± 7.6 62.4 ± 9.7 67.2 ± 5.8 
H&Y stage - OFF state  
(mean ± SD) 
- 1.9±0.7 3.1±0.9 3.4±0.8* 
UPDRS Total - OFF state 
(mean ± SD) 
- 50.9±18.1 69.4±23.53 78.7±13.75 
Daily LEDTOTAL  
(mg ± SD) 
- 421.5 ± 89.2 823.3 ± 337.7 1103.4 ± 763.7¶ 
Lifetime LEDTOTAL  
(g ± SD) 
- 265.3 ± 159.0 1246.7 ± 983.4§ 2589.2 ± 1532.3§ 
Lifetime LEDDA  
(g ± SD) 
- 48.3 ± 77.6 341.8 ± 330.2 421.8 ± 490.1 
MMSE (mean ± SD) 29.4 ± 0.7 28.8 ± 1.7 28.2 ± 2.9 27.8 ± 3.0 
Disease duration has been accounted from the time of PD motor symptom initiation (not the time of 
diagnosis); M=male; F=female; SD=standard deviation; H&Y=Hoehn and Yahr; UPDRS=Unified 
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Parkinson’s Disease Rating Scale; DA=Dopamine Agonists; LED=Levodopa Equivalent Dose, similar to 
previous report (Parkin et al., 2002); LED (mg) = (1 X Levodopa) + (0.77 X Levodopa CR) + (1.43 X 
Levodopa + Entacapone) + (1.11 X Levodopa CR + Entacapone) + (20 X Ropinirole) + (20 X Ropinirole 
ER) + (100 X Pramipexole) + (30 X Rotigotine) + (10 X Bromocriptine) + (8 X Apomorphine) + (100 X 
Pergolide) + (67 X Cabergoline); LED formula, In Levodopa/Carbidopa or Benserazide hydrochloride: Only 
Levodopa is calculated. p value after one-way ANOVA is *0.0380, ¶0.0142 and §0.0002. 
 
4.1.2	  Results	  
 
General Characteristics  
Subjects were matched for sex, age and numbers in each group. Advanced PD patients 
were more disabled and receiving more dopaminergic medication than the early and 
established PD groups. Established and advanced PD patients received significantly more 
dopaminergic therapy in their life compared to early PD cases (Table 13). Repeated 
measures of ANCOVA showed no influence of temperate seasons, sunshine, humidity and 
temperature in 11C-DASB BPND values. 
 
Regional 11C-DASB binding 
Mean 11C-DASB BPND values for caudate nucleus, thalamus, hypothalamus and ACC 
were decreased across all stages of PD compared with the normal control group (Figure 
53). 11C-DASB BPND values were decreased in putamen, insular cortex, PCC and PFC in 
established and advanced but not early PD (Figure 54) while ventral striatal, caudal and 
rostral raphe nuclei, and amygdala 11C-DASB BPND values were reduced only in 
advanced PD (Figure 55). Raw mean 11C-DASB BPND values are reported in Table 14. 
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Figure 53 Regional 11C-DASB binding decreases that appear in the early Parkinson’s disease patients 
(disease duration range = 0-5 years) when compared with a group of normal controls. *p<0.05; **p<0.01; 
***p<0.001 
 
 
Figure 54 Regional 11C-DASB binding decreases that appear in the established Parkinson’s disease patients 
(disease duration range = 6-10 years) when compared with a group of normal controls. *p<0.05; **p<0.01; 
***p<0.001 
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Figure 55 Regional 11C-DASB binding decreases that appear in the advanced Parkinson’s disease patients 
(disease duration range = more than 10 years) when compared with a group of normal controls. *p<0.05; 
**p<0.01 
 
 
Table 14 Regional 11C-DASB binding potentials in Parkinson’s disease patients with Early, Established 
and Advanced disease 
REGION/GROUP NORMAL 
CONTROLS 
EARLY PD ESTABLISHED 
PD 
ADVANCED PD 
Amygdala 1.13 ± 0.19a 0.98 ± 0.25 0.94 ± 0.12 0.85 ± 0.15* 
Anterior Cingulate 
Cortex 
0.37 ± 0.09 0.25 ± 0.09* 0.26 ± 0.08* 0.26 ± 0.09* 
Caudal Raphe Nuclei 1.74 ± 0.30 1.49 ± 0.20 1.45 ± 0.32 1.41 ± 0.27* 
Caudate Nucleus 1.31 ± 0.06 0.94 ± 0.19** 0.92 ± 0.12** 0.86 ± 0.12*** 
Hypothalamus 1.21 ± 0.17 0.95 ± 0.16* 0.95 ± 0.19* 0.91 ± 0.20** 
Insular Cortex 0.36 ± 0.05 0.24 ± 0.12 0.21 ± 0.08* 0.16 ± 0.06*** 
Posterior Cingulate 
Cortex 
0.36 ± 0.09 0.28 ± 0.06 0.25 ± 0.08** 0.23 ± 0.08** 
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Prefrontal Cortex 0.20 ± 0.04 0.14 ± 0.06 0.12 ± 0.07* 0.12 ± 0.07* 
Putamen 1.35 ± 0.11 1.18 ± 0.16 1.04 ± 0.13** 0.95 ± 0.20*** 
Rostral Raphe Nuclei 2.44 ± 0.45 2.07 ± 0.37 2.05 ± 0.40 1.91 ± 0.34* 
Thalamus 1.43 ± 0.14 1.19 ± 0.11* 1.09 ± 0.19*** 1.02 ± 0.18*** 
Ventral Striatum 1.38 ± 0.13 1.20 ± 0.17 1.19 ± 0.14 0.95 ± 0.22** 
amean 11C-DASB BPND values ± SD; *p<0.05, **p<0.01, ***p<0.001  
 
Individual regional analyses of SERT binding for the caudate nucleus, putamen, 
and caudal and rostral raphe nuclei were also performed for each subject in all groups. 
Eight out of ten early PD subjects had significantly reduced caudate nucleus 11C-DASB 
BPND values two SD below the normal mean while this was true of all subjects in the 
established and advanced PD groups. Four out of 10 early PD subjects showed 
significantly reduced putamen 11C-DASB BPND values compared with eight established 
and eight advanced PD cases. None of the early PD subjects had abnormally reduced 
caudal raphe nuclei 11C-DASB BPND values while one of the established and two 
advanced PD patients fell below the normal control range. For the rostral raphe nuclei, one 
out of 10 early PD subjects showed abnormally reduced 11C-DASB BPND values, whereas 
only two and one subjects in the established and advanced PD groups fell below the 
normal control range, respectively. 
 
Relation of 11C-DASB BPND to Clinical parameters 
Individual and global 11C-DASB BPND reductions did not correlate with the duration of 
the disease (Figure 56A), the H&Y staging (Figure 56B), or UPDRS scores (Figure 56C). 
There were no significant correlations between global 11C-DASB BPND reductions and 
daily (r=0.0300, p=0.3610) and lifetime (r=0.0670, p=0.1669) total dopaminergic 
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medication intake (Figure 56D). Reductions of 11C-DASB BPND values showed no 
lateralisation. 
 Second level regional analysis between 11C-DASB BPND values and clinical 
parameters after setting the p threshold at <0.05 uncorrected, revealed correlations 
between 11C-DASB BPND reductions in thalamus and in ventral striatum, and disease 
duration. 
 
 
Figure 56 Relation of global 11C-DASB binding and clinical parameters. No significant correlations 
between Parkinson’s disease duration (r=-0.2763, p=0.1394), Hoehn and Yahr staging (r=-0.1855, 
p=0.3265), Unified Parkinson’s Disease Rating Scale scores (r=-0.1894, p=3160), lifetime dopamine agonist 
intake (r=0.007, p=0.9692) and global 11C-DASB BPND values 
	  
4.1.3	  Discussion	  
This PET study has used 11C-DASB to provide an index of presynaptic serotonergic 
terminal dysfunction in PD. It is demonstrated a general widespread decrease of 
presynaptic serotonergic terminal function in PD that does not correlate with the duration 
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of the disease or locomotor disability as rated with the UPDRS and H&Y staging. 
Furthermore, this study suggests that chronic exposure to dopaminergic therapy does not 
influence SERT binding in any of the brain regions investigated. 
11C-DASB uptake was decreased in caudate nucleus, thalamus, hypothalamus and 
ACC in early PD. 11C-DASB uptake was additionally reduced in the putamen, insular 
cortex, PCC and PFC in established disease while further reduced values were found in 
the ventral striatum, raphe nuclei and amygdala in the advanced cases. Reductions in 
caudate nucleus and putamen have been reported in two previous PET studies, recruiting a 
smaller sample of patients (Kerenyi et al., 2003; Guttman et al., 2007). Kerenyi and 
colleagues (2003) using a lower affinity SERT radioligand, have reported a correlation 
between these reductions and the clinical staging of their PD subjects.  
Here, using the more selective SERT marker 11C-DASB PET and a larger sample, 
we did not replicate this finding as the reductions of 11C-DASB uptake did not correlate 
with the duration, severity and clinical staging of PD. Post-hoc analysis revealed two 
significant correlations between 11C-DASB uptake in thalamus and ventral striatum, and 
duration of the disease. However, this result did not survive a correction for multiple 
comparisons. A larger study might be able to address whether these two regions show a 
linear decline of serotonergic function over the course of PD. The pattern of serotonergic 
degeneration observed in this study differs from that seen in the dopaminergic system. 
18F-DOPA and 18F-CFT uptake are most reduced in the posterior putamen and inversely 
correlate with the disease progression (Brooks et al., 1990; Vingerhoets et al., 1997; 
Nurmi et al., 2000) in contrast to 11C-DASB where putamen involvement occurs later. 
Also, reductions in 11C-DASB uptake did not show lateralization in any of the groups 
suggesting that loss of serotonergic function is not following the same pattern of unilateral 
predominance as seen in degeneration of the dopaminergic system. 
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 Braak staging (Braak et al., 2003) suggests that pathological changes start in the 
dorsal motor nucleus in presymptomatic stages and follow an ascending progression, with 
midbrain and forebrain structures affected later. Stage two sees Lewy body and neurite 
deposition occur within the raphe nuclei ahead of motor symptoms while stage three 
involves the substantia nigra, amygdala and hypothalamus. According to Braak staging, 
caudal brainstem serotonergic neurons are affected ahead of dopaminergic midbrain 
neurons while in the midbrain the two systems are affected simultaneously. This study’s in 
vivo findings indicate a relative preservation of serotonergic function in both caudal and 
rostral raphe nuclei until advanced clinical disease presents.  
A previous small PET series has also reported a relative preservation of 11C-
DASB uptake in these areas (Albin et al., 2008). Furthermore, in the present study 
serotonergic neurons in the caudate nucleus, thalamus, hypothalamus and ACC are 
affected early, while 5-HT neurons in putamen and other mesocortical and neocortical 
structures are affected later in the disease. A significant reduction in the amygdala was 
observed only in the advanced group. Very little is known about the density and functional 
effect of Lewy body and neurite deposition into 5-HT neurons in these areas. It could well 
be that alpha-synuclein accumulates into 5-HT neurons at an early stage of disease but is 
less toxic to these than for dopamine neurons. 
 Another important hypothesis that this study aimed to address was the effect of 
chronic exposure to dopaminergic therapy on SERT binding. SERT binding in these 
patients did not correlate with their chronic exposure to dopaminergic treatment 
suggesting that this does not influence SERT binding in the long run. However, preclinical 
findings have shown that L-DOPA can be converted to dopamine in 5-HT neurons and 
displace 5-HT content (Ng et al., 1970), which may result in alteration of SERT 
expression. Thus, interference of L-DOPA with serotonergic transmission could be a 
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confounding factor in advanced patients treated with L-DOPA where 5-HT neurons are 
playing a significant role in dopamine production (Navailles et al., 2010). The present 
study was not powered to compare patient populations receiving L-DOPA versus DAs 
alone – most were receiving polypharmacy. However, it would be highly interesting to 
perform such a comparison in the future. 
 Post-mortem observations have suggested preferential loss of 5-HT markers 
(including SERT) in caudate nucleus versus putamen in PD (Kish et al., 2008). In this 
study by staging the PD subjects it is shown that decreases in caudate SERT binding 
(early=28.2%, established=29.8% and advanced=34.4%) were higher than in putamen 
(early=13.3%, established=23.0% and advanced=30.0%) for all stages of PD studied. This 
loss of SERT binding is also in agreement with two previous studies (Kerenyi et al., 2003; 
Guttman et al., 2007). SERT binding in the caudate nucleus in all but two of the PD 
subjects fell below the normal control range. These reductions are comparable to the 
dopaminergic dysfunction found in caudate nucleus (~40% loss) but attenuated compared 
to the profound dopaminergic dysfunction observed in the posterior putamen (70-80%) 
with 18F-DOPA PET (Khan et al., 2002). In agreement with the study of Albin and 
colleagues (2008) no asymmetry of diminished SERT binding in dorsal striatum was 
observed.  
 In this study I have attempted to minimize the effects of potentially confounding 
factors. First, all scans were corrected for movement as some of the patients had tremor 
and OFF-period dystonia. Second, although not all the brain was analyzed, brain regions 
in which the 11C-DASB uptake could be reliably and validly measured, were chosen. 
Third, possible partial volume effects were accounted by standardizing the volumes across 
subjects. Finally, SERT studies can be confounded by seasonal changes, as SERT binding 
is sensitive to sunshine and humidity (Praschak-Rieder et al., 2008). In this study no 
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influence of these parameters to SERT binding was observed, possibly because the 
majority of the patients were scanned under cloudy and rainy weather and under 
comparable humidity levels.      
 In conclusion, this study indicates a non-linear loss of presynaptic serotonergic 
terminals across the clinical course of PD that is not related to disease disability or clinical 
staging. Furthermore, SERT binding is not influenced by the amount of chronic 
dopaminergic treatment.  
 
4.2	  Depressive	  Symptoms	  and	  SERT	  Binding	  	  
 
4.2.1	  Subjects	  	  
Thirty-four non-demented patients with idiopathic PD who were referred from a specialist 
movement disorder clinic (Charing Cross Hospital, London) with no past history of 
depression or any other psychiatric disorder (nor had received medication with a known 
action on the serotonergic system) were studied. Findings for PD subjects were also 
compared to those from a group of 10 normal controls, all in good health and with no 
history of neurological or psychiatric illness and were not on any medication (Table 15). 
All subjects received one 11C-DASB PET and one 1.5T volumetric MRI scan in OFF 
medication condition. The aims of this study are presented in Box 5. 
 
Box 5 Aims: Depressive symptoms and SERT binding    
To investigate the relationship between depressive symptoms and serotonin transporter 
availability. It is hypothesised that anti-depressant naive Parkinson’s disease patients with 
the highest Beck depression inventory – II and Hamilton rating scale of depression scores 
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would show relatively increased serotonin transporter availability, possibly reflecting 
lower extracellular serotonin levels. 
 
Table 15 Parkinson’s disease patient’s and healthy control’s characteristics 
Disease duration has been accounted from the time of PD motor symptom initiation (not the time of 
diagnosis); M=male; F=female; SD=standard deviation; H&Y=Hoehn and Yahr staging; UPDRS=Unified 
ALL PD     
 NON-
DEPRESSED PD 
DEPRESSED 
PD 
NORMAL 
CONTROLS 
No of Subjects 34 24 10 10 
Sex 26M/8F 20M/4F 6M/4F 8M/2F 
Age (years ± SD) 65.1 ± 7.8 66.8 ± 6.7 60.7 ± 9.1 63.7 ± 7.2 
Disease Duration (years ± 
SD) 
9.1 ± 4.8 8.6 ± 4.5 10.3 ± 5.4 - 
H&Y stage – OFF state 
(mean ± SD) 
2.7 ± 0.8  2.5 ± 0.8 3.1 ± 0.6 - 
UPDRS – OFF state 
(mean ± SD) 
66.8 ± 20.0 61.2 ± 18.5 81.9 ± 16.3 - 
Daily LEDTOTAL  (mg ± 
SD) 
794.1 ± 533.4 761.2 ± 582.1 881.9 ± 389.6 - 
Lifetime LEDTOTAL (g ± 
SD) 
1355.7 ± 1352.1 1289.1 ± 1422.1 1533.3 ± 1203.7 - 
MMSE (mean ± SD) 28.4 ± 2.5 28.3 ± 2.6 28.9 ± 1.97 29.4 ± 0.7 
BDI-II (mean ± SD and 
range) 
11.5 ± 6.0 (2-
20) 
9.1 ± 4.5 (2-16) 19.1 ± 1.4 (17-20) 3.5 ± 2.6 (0-7) 
HRSD (mean ± SD and 
range) 
9.7 ± 5.5 (2-22) 6.9 ± 3.1 (2-13) 17.0 ± 3.4 (14-22) 2.9 ± 2.8 (0-8) 
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Parkinson’s Disease Rating Scale; LED=Levodopa Equivalent, The dose is calculated similarly to previous 
report (Parkin et al., 2002), LED (mg) = (1 X Levodopa) + (0.77 X Levodopa CR) + (1.43 X Levodopa + 
Entacapone) + (1.11 X Levodopa CR + Entacapone) + (20 X Ropinirole) + (20 X Ropinirole ER) + (100 X 
Pramipexole) + (30 X Rotigotine) + (10 X Bromocriptine) + (8 X Apomorphine) + (100 X Pergolide) + (67 
X Cabergoline); LED formula, In Levodopa/Carbidopa or Benserazide hydrochloride: Only Levodopa is 
calculated; MMSE=Mini-Mental State Examination; BDI-II=Beck Depression Inventory Second Edition; 
HRSD=Hamilton Rating Scale for Depression.  
 
4.2.2	  Results	  
All PD patients scored under 20 on the BDI-II and under 22 on the HRSD scales. There 
was a significant correlation between individual PD patient BDI-II and HRSD scores 
(Spearman r=0.6622, p<0.0001). The 24 patients who scored < 16 with the BDI-II scored 
< 13 with the HRSD (70.6%), whereas the 10 patients scored > 17 with the BDI-II scored 
> 14 in HRSD (29.4%). Of the 10 high scorers, SCID-I screening revealed two cases 
(5.9% of total sample) with an anxiety disorder and three cases (8.8% of total sample) 
with both anxiety and mood disorders. The other five high scoring and 24 low scoring PD 
cases could not be classified according to SCID-I criteria. 
Individual 11C-DASB BPND values for the PD patients correlated with both HRSD 
(amygdala: r=0.3632, p=0.0441; hypothalamus: r=0.4214, p=0.0232; caudal raphe nuclei: 
r=0.3767, p=0.0448; PCC: r=0.3663, p=0.0360) and BDI-II ratings (Figure 57).  
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Figure 57 Relation of 11C-DASB binding to depression levels in Parkinson’s disease patients (n=34). 
Significant correlations (Pearson r) between 11C-DASB BPND values in (A) amygdala (r=0.4203, p=0.0133), 
(B) hypothalamus (r=0.4154, p=0.0146), (C) caudal raphe nuclei (r=0.4367, p=0.0098) and (D) posterior 
cingulate cortex (r=0.4280, p=0.0116) and Beck depression inventory – II scores 
 
 
The 24 patients with low (< 16 BDI-II and < 13 HRSD) depressive symptom 
scores had significantly lower 11C-DASB BPND values compared to 10 healthy controls in 
all regions sampled. The 10 PD patients with raised (> 17 BDI-II and  > 14 in HRSD) 
depressive scores had significantly lower 11C-DASB BPND values compared to 10 healthy 
controls in eight regions: ACC, caudate nucleus, insular cortex, PFC, putamen, rostral 
raphe nuclei, thalamus and ventral striatum. Their 11C-DASB BPND values in amygdala, 
hypothalamus, caudal raphe nuclei and posterior cingulate cortex, however, were 
significantly higher compared to PD patients with low depressive scores but not compared 
to healthy controls. The reduced 11C-DASB BPND values in ACC, caudate, insula, PFC, 
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putamen, rostral raphe nuclei, thalamus and ventral striatum were similar for the PD 
patients with raised and low depressive scores (One-way ANOVA with Tukey-Kramer 
multiple comparisons; Figure 58 and Table 16). 
 
 
Figure 58 11C-DASB binding in Parkinson’s disease patients with  < 16 Beck depression inventory – II and  
< 13 Hamilton Rating Scale for Depression scores (non-Depressed PD; n=24; white bars), > 17 Beck 
depression inventory – II and  > 14 in Hamilton Rating Scale for Depression scores (Depressed PD; n=10; 
black bars) and Healthy Controls (n=10; grey bars). Significantly increased 11C-DASB binding in 
Depressed Parkinson’s disease patients and Healthy Controls in (A) amygdala, (B) hypothalamus, (C) 
caudal raphe nuclei and (D) posterior cingulate cortex compared to non-Depressed Parkinson’s disease 
patients. One-way analysis of variance with Tukey-Kramer multiple comparisons test (*p<0.05, 
**p<0.01,***p<0.001) 	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Table 16 Regional 11C-DASB binding potentials in Non-Depressed and Depressed Parkinson’s disease 
patients and a group of Normal Controls.  
BRAIN REGIONS NON-
DEPRESSED 
PD 
DEPRESSED-
PD 
NORMAL 
CONTROLS 
NON-
DEPRESSED 
PD VS. 
DEPRESSED-
PD 
NON-
DEPRESSED 
PD VS. 
NORMAL 
CONTROLS 
DEPRESSED-
PD VS. 
NORMAL 
CONTROLS 
Amygdala 0.88 ± 0.18† 1.11 ± 0.18 1.13 ± 0.19 P<0.01¶ P<0.01 NS 
Anterior 
Cingulate Cortex 
0.25 ± 0.10 0.27 ± 0.08 0.37 ± 0.09 NS§ P<0.01 P<0.05 
Caudal Raphe 
Nuclei 
1.42 ± 0.25 1.61 ± 0.24  1.74 ± 0.30 P<0.05 P<0.01 NS 
Caudate Nucleus 0.91 ± 0.12 0.96 ± 0.16 1.31 ± 0.06 NS P<0.001 P<0.01 
Hypothalamus 0.96 ± 0.21 1.15 ± 0.14 1.21 ± 0.17 P<0.05 P<0.01 NS 
Insular Cortex 0.22 ± 0.09 0.24 ± 0.10 0.36 ± 0.05 NS P<0.001 P<0.01 
Posterior 
Cingulate Cortex 
0.23 ± 0.07 0.31 ± 0.07 0.36 ± 0.09 P<0.05 P<0.001 NS 
Prefrontal Cortex 0.14 ± 0.06 0.14 ± 0.07 0.20 ± 0.04 NS P<0.05 P<0.05 
Putamen 1.06 ± 0.12 1.07 ± 0.19 1.35 ± 0.11 NS P<0.001 P<0.001 
Rostral Raphe 
Nuclei 
2.00 ± 0.33 2.08 ± 0.40 2.44 ± 0.45 NS P<0.05 P<0.05 
Thalamus 1.18 ± 0.12 1.13 ± 0.18 1.43 ± 0.14 NS P<0.01 P<0.001 
Ventral Striatum 1.18 ± 0.12 1.22 ± 0.15 1.38 ± 0.13 NS P<0.01 P<0.05 
†mean ± SD ¶All P values after ANOVA with post-test; §NS, non-significant 
 
When the relationship between BDI-II and HRSD scores was interrogated, clinical 
characteristics (disease duration, H&Y staging and UPDRS scores), and dopaminergic 
medication intake (Daily and Lifetime LEDTOTAL and LEDDA), no significant correlations 
and no differences between PD patients with raised or low depressive symptoms were 
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found. Moreover, no correlation between temperate seasons, sunshine, humidity and 
temperature with 11C-DASB BPND values and BDI-II and HRSD scores was found. PD 
11C-DASB BPND values showed no lateralization in these subjects. 
 
4.2.3	  Discussion	  
The findings indicate that the level of depressive symptoms in anti-depressant naive PD 
patients correlates with higher SERT binding in median raphe nuclei and limbic structures. 
Patients with higher BDI-II and HRSD scores showed relatively increased SERT binding 
in these areas compared to PD patients with low scores, though not compared to healthy 
controls. SERT binding in all other regions under investigation was similarly reduced in 
PD patients whether they had low or raised depressive symptom scores. 
While most of the PD patients had depressive symptoms indentified by screening, 
these had gone unrecognized and untreated. Reported symptoms by the patients (BDI-II) 
were in agreement with those detected by the clinicians (HRSD) and revealed that 29.4% 
of the cases scored higher than the cutoff scores suggested to discriminate depression in 
PD (Leentjens et al., 2000; Silberman et al., 2006; Dissanayaka et al., 2007). However, 
only half of these patients could be diagnosed as having DSM-IV Axis I Disorders - 
mostly due to their “atypical” features. 
Depressive symptoms are common in PD but a formal diagnosis of depression is 
far less frequent because of the overlapping features between depression and parkinsonism 
(e.g. slowed movements, sleep disturbances, inability to work, fatigue, preoccupation with 
ill health, loss of desire, and reduction in libido) and the different symptom profile to 
endogenous depression. Up to 50% of PD patients with concurrent depression do not meet 
the DSM-IV criteria for endogenous depression or dysthymia (Gotham et al., 1986; 
Starkstein et al., 1990) although some of them can be classed under “subsyndromal 
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symptomatic depression” (Judd et al., 1994). PD patients with depression show higher 
associated rates of anxiety, sadness without guilt or self-blame, greater pessimism, loss of 
interest and hopelessness, brooding, social withdrawal, self-depreciation, and lower 
suicide rates despite high rates of suicidal thoughts (Taylor et al., 1986; McDonald, 2008). 
PD depression is often associated with increased disability, worse health-related quality of 
life measures, more rapid progression of motor impairment and increased mortality hazard 
ratio (Weintraub et al., 2004; Barbas, 2006). The findings from this study highlight the 
need to develop specific diagnostic criteria for PD depression. 
Relatively reduced serotonergic neurotransmission and consequent increased 
SERT availability could a play a primary role in the pathophysiology of PD depression. 
This study detected a relative increase of SERT binding in raphe nuclei and limbic 
structures such as amygdala, hypothalamus and the PCC in anti-depressant naive PD 
patients with more severe depressive symptoms compared to patients with mild depressive 
symptoms. In other non-limbic regions sampled the PD cases scoring high and low for 
depressive symptoms showed similar decreases of SERT binding. A previous report 
studying seven early-PD patients (Boileau et al., 2008), reported increased SERT binding 
in the OFC of depressed-PD patients compared to healthy controls. 
Combining the results of the Boileau study with this study’s findings it is likely 
that stage of disease influences regional levels of SERT binding in PD with depressive 
symptoms. In the present study, the PD patients were more advanced and are likely to 
have had a greater loss of serotonergic terminals than in the Boileau series. For this 
reason, the relatively increased SERT binding in the limbic regions and raphe of PD 
patients with higher depressive symptom scores was only evident when compared to 
similar-stage PD patients with low scores but not when compared to healthy controls. In 
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favor of this scenario, SERT binding in all other regions was similarly reduced in both 
cohorts of PD patients. 
Mood and neuroendocrine rhythms are modulated by the brainstem raphe 5-HT 
system and are distinctively altered in anxiety-related and affective disorders (Lesch and 
Gutknecht, 2005). Levels of synaptic 5-HT are maintained by the SERT. It has been 
shown that cerebrospinal fluid levels of 5-hydroxyindoleacetic acid, the main metabolite 
of 5-HT in the human body, are low in parkinsonian patients with major depression 
(Mayeux et al., 1986). Relatively increased SERT binding in a subgroup of PD cases 
could lead to greater clearance of 5-HT from the extracellular space and thus potentially 
exacerbate affective disorders. However, it cannot be excluded the possibility that the 
relative increase in SERT binding seen in PD patients with high depressive symptom 
scores results from a homeostatic mechanism to compensate for the disease-related loss of 
presynaptic serotonergic neurons. Depression in PD is more frequent than in non-PD 
population with similar age and sex (Robins, 1976; Veiga et al., 2009). This could be a 
result of a combined effect of serotonergic terminal loss together with inappropriate 
upregulation of SERT function. This view is supported by this study’s findings 
demonstrating relatively increased SERT binding only in raphe and limbic structures in 
the more depressive PD cases.  
The results of this study are in line with the hypothesis that PD patients become 
more prone to depression due to loss of serotonergic innervation, however, not all PD 
patients become depressed. It may be that inappropriately raised SERT binding is also 
necessary in limbic areas to cause depression due to an excessive clearance of synaptic 5-
HT. Such a situation would justify the use of SSRIs as anti-depressants in PD. Previous 
PET data, however, have indicated that loss of dopamine and NA innervation in the limbic 
system of depressed PD cases may also play a role (Remy et al., 2005). If this is the case 
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the use of non-selective tricyclic antidepressants (TCAs) would be more rational in PD 
patients with high BDI-II and HRSD scores.  
Several small open-label studies have shown that SSRI’s are well tolerated, have a 
favorable side effect profile and can help depressive symptomatology in depressed PD 
patients (Hauser et al., 1997; Ceravolo et al., 2000; Tesei et al., 2000; Dell'Agnello et al., 
2001; Rampello et al., 2002; Menza et al., 2004; Weintraub et al., 2005). The effectiveness 
of both SSRI’s and TCA’s in PD depression was confirmed by a placebo-controlled study, 
which showed significant decreases of depression scores with both drugs. SSRI’s showed 
better tolerability but delayed response compared to TCA’s (Devos et al., 2008). 
Superiority of TCA’s against SSRI’s on improving depression symptoms and depression 
response rates was also shown in a more recent placebo-controlled trial (Menza et al., 
2009). However, the results of these two trials should be taken cautiously (Okun and 
Fernandez, 2009). TCA’s are associated with a number of side effects (e.g. orthostatic 
hypotension, sedation, cognitive and anticholinergic effects) that may present problems. 
Recently, a placebo-controlled study has reported direct anti-depressant activity of the DA 
pramipexole in patients with PD (Barone et al., 2010). However, in our PD patients, 
depressive symptoms were not influenced by the amount of current or lifetime, L-DOPA 
or DA intake. Large and long duration clinical trials are needed to determine the 
applicability of the different anti-depressants in PD depression in order to help clinician 
for the optimal choice weighing between effectiveness and tolerability.  
In this study confounding factors were tried kept to a minimum although some 
issues need to be considered: (1) PET scans required movement correction as some of the 
patients had tremor and OFF-dystonia. (2) Not all the brain was analyzed. Brain regions, 
in which the 11C-DASB binding could be reliably and validly measured, were chosen. (3) 
Possible partial volume effects were minimized with sampling equal ROI volumes across 
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subjects. (4) Although BDI-II and HRSD are considered good scales for rating depressive 
symptoms in PD (Miyasaki et al., 2006; Schrag et al., 2007), rating scales should not be 
used to diagnose depression and their use should be limited to screen and measure its 
severity in patients and for determining the effects of treatments on the symptoms of the 
illness.  
In vivo SERT studies can be confounded by seasonal changes such as sunshine and 
humidity (Praschak-Rieder et al., 2008) and depression levels by longer disease duration 
and more severe motor disability (Veiga et al., 2009). In this study no influence of 
seasonal characteristics to SERT binding was observed, possibly because the majority of 
the patients were scanned under cloudy and rainy weather and under comparable humidity 
levels. Also, no influence to the PET results was observed by clinical characteristics such 
as disease duration, UPDRS scores and H&Y staging and daily and lifetime dopaminergic 
medication intake.  
 
4.3	  Body	  Mass	  Index	  and	  SERT	  Binding	  
	  
4.3.1	  Subjects	  	  
Thirty-four non-demented patients with idiopathic PD were studied. These patients were 
referred from specialist movement disorder clinics and had no past history of depression 
or any other psychiatric disorder (nor had received medication with a known action on the 
serotonergic system). In each subject, body weight in kg and height in meters were 
measured to perform the BMI calculation. BMI unit change over 12 months for all 
subjects was measured and PD patients were categorized into “High BMI change” or 
“Low BMI change” group depending if their BMI change was within or above the cut-off 
score that was set as two-times SD above mean BMI change of 10 normal controls (Figure 
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59).  All subjects had one 11C-DASB PET and one 1.5T volumetric MRI scan at the time 
of the second BMI assessment in OFF medication condition. The aims of this study are 
presented in Box 6 and the clinical characteristics of the participants in Table 17. 
 
Box 6 Aims: Body Mass Index and SERT    
To investigate the relationship between body mass index changes and serotonin 
transporter availability. It is hypothesised that Parkinson’s disease patients with the 
highest body mass index changes over the last year would show relatively altered 
serotonin transporter availability, possibly reflecting changes in extracellular serotonin 
levels. 
 
 
4.3.2	  Results	  
 
Body Mass Index  
Twenty-two PD patients lost BMI (2.0 ± 1.4; mean ± SD) and 12 gained BMI (1.5 ± 0.9; 
mean ± SD) over a 12-month period. Half (17 subjects) of the cohort had a higher than 
normal BMI change and half had a Low BMI change during the same period (Figure 59). 
 
BMI changes and 11C-DASB binding 
Individual BMI unit changes in PD patients were significantly correlated with 11C-DASB 
BPND values in rostral raphe nuclei (r=0.4282, p=0.0115), hypothalamus (r=0.3987, 
p=0.0195), caudate nucleus (r=0.5199, p=0.0016) and ventral striatum (r=0.3609, 
p=0.0360) (Figure 60). No significant associations between BMI changes and 11C-DASB 
 194	  
BPND values were found in amygdala, insula, thalamus, caudal raphe nuclei, ACC, PCC 
and PFC. 
  	  
Table 17 Parkinson’s disease patient’s and normal control’s characteristics 
ALL PD     
 PD-LOW BMI 
CHANGE 
PD-HIGH BMI 
CHANGE 
NORMAL 
CONTROLS 
(LOW BMI 
CHANGE) 
No of Subjects 34 17 17 10 
Sex 26M/8F 12M/5F 14M/3F 8M/2F 
Age (years ± SD) 65.1 ± 7.8 65.1 ± 7.8 66.0 ± 6.6 63.7 ± 7.2 
Disease Duration (years ± SD) 9.1 ± 4.8 10.1 ± 5.4 8.0 ± 3.9 - 
H&Y stage – “OFF” state (mean ± 
SD) 
2.7 ± 0.8  2.7 ± 1.0 2.6 ± 0.6 - 
UPDRS – “OFF” state (mean ± SD) 66.8 ± 20.0 66.9 ± 22.7 66.8 ± 17.5 - 
Daily LEDTOTAL  (mg ± SD) 794.1 ± 533.4 820.4 ± 650.6 766.3 ± 392.2 - 
Lifetime LEDTOTAL (g ± SD) 1355.7 ± 
1352.1 
1526.2 ± 1668.5 1174.6 ± 928.7 - 
MMSE (mean ± SD) 28.4 ± 2.5 28.5 ± 2.2 28.4 ± 2.8 29.4 ± 0.7 
BDI-II (mean ± SD) 11.5 ± 6.0  10.5 ± 6.1 12.6 ± 5.9 3.5 ± 2.6 (0-7) 
HRSD (mean ± SD) 9.7 ± 5.5  8.9 ± 6.0 10.2 ± 6.2 2.9 ± 2.8 (0-8) 
BMI (kg/m2) – Time of PET scan 
(mean ± SD)  
25.4 ± 3.9 24.8 ± 3.4 26.1 ± 4.4 28.1 ± 5.3 
BMI (kg/m2) – 12 months ago (mean 
± SD)  
26.2 ± 4.1 24.9 ± 3.2 27.5 ± 4.5 28.2 ± 5.1 
BMI (kg/m2) – Change (mean ± SD)  1.8 ± 1.2 0.8 ± 0.4 2.8 ± 1.0 0.7 ± 0.3 
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Disease duration has been accounted from the time of PD motor symptom initiation (not the time of 
diagnosis); M=male; F=female; SD=standard deviation; H&Y=Hoehn and Yahr staging; UPDRS=Unified 
Parkinson’s Disease Rating Scale; LED=Levodopa Equivalent, The dose is calculated similarly to previous 
report (Parkin et al., 2002), LED (mg) = (1 X Levodopa) + (0.77 X Levodopa CR) + (1.43 X Levodopa + 
Entacapone) + (1.11 X Levodopa CR + Entacapone) + (20 X Ropinirole) + (20 X Ropinirole ER) + (100 X 
Pramipexole) + (30 X Rotigotine) + (10 X Bromocriptine) + (8 X Apomorphine) + (100 X Pergolide) + (67 
X Cabergoline); LED formula, In Levodopa/Carbidopa or Benserazide hydrochloride: Only Levodopa is 
calculated; MMSE=Mini-Mental State Examination; BDI-II=Beck Depression Inventory Second Edition; 
HRSD=Hamilton Rating Scale for Depression; BMI=body mass index. 
 
 
BMI changes and 11C-DASB binding: group comparisons  
The High BMI change group had significantly higher 11C-DASB BPND values in rostral 
raphe nuclei (p=0.0009), hypothalamus (p=0.0003) caudate nucleus (p<0.0001) and 
ventral striatum (p<0.0001) compared to the Low BMI change group (Figure 61). No 
significant differences between the high and low BMI groups were found in any other ROI 
(Table 18). 
 
BMI change, 11C-DASB and clinical parameters 
There was no significant correlation between BMI changes and BDI-II and HRSD scores. 
Repeated measures ANCOVA showed no influence of clinical parameters (sex, age, 
disease duration, motor disability as measured with H&Y stage and UPDRS, and daily 
and lifetime dopaminergic medication intake) on BMI changes or regional 11C-DASB 
BPND values. Furthermore, no association between seasonal variation and 11C-DASB 
BPND values and BMI changes were found. 
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Figure 59 Body Mass Index unit change over 12 months for all subjects. Categorization for inclusion into 
either High BMI change or Low BMI change group was determined by obtaining the mean BMI unit change 
for normal controls +2 standard deviations. Subjects below the cut-off (normal mean +2SD=1.37 units; 
median= 1.49 units) were categorized as having a Low BMI change and those above had a High BMI 
change. Seventeen Parkinson’s disease patients had a High BMI change and 17 had a Low BMI change 
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Figure 60 Relation of 11C-DASB uptake to body mass index change in Parkinson’s disease patients. 
Significant positive correlations between body mass index change units and 11C-DASB BPND values in (A) 
rostral raphe nuclei, (B) hypothalamus, (C) caudate nucleus and (D) ventral striatum in 34 patients with 
Parkinson’s disease 
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Figure 61 11C-DASB BPND values in Parkinson’s disease patients with a Low BMI change,and High BMI 
change and Normal Controls with a Low BMI change. Significant difference between PD-Low BMI change 
and PD-High BMI change in (A) rostral raphe nuclei (PD-Low BMI vs PD-High BMI =1.87±0.28 vs 
2.24±0.37, p>0.05; PD-Low BMI vs Controls = 1.87±0.28 vs 2.44±0.45, p>0.01), (B) hypothalamus (PD-
Low BMI vs PD-High BMI =0.91±0.16 vs 1.11±0.2, p<0.01; PD-Low BMI vs Controls = 0.91±0.16 vs 
1.21±0.17, p<0.001), (C) caudate nucleus (PD-Low BMI vs PD-High BMI = 0.85±0.11 vs 0.1 ±0.14, 
p<0.01; PD-Low BMI vs Controls = 0.85±0.11 vs 1.31±0.06, p<0.001; PD-High BMI vs Controls = 
0.1±0.14 vs 1.31±0.06, p<0.001) and (D) ventral striatum (PD-Low BMI vs PD-High BMI = 1.04±0.22 vs 
1.2±0.13, p<0.05; PD_Low BMI vs Controls = 1.04±0.22 vs 1.38±0.13, p<0.001; PD-High BMI vs Controls 
= 1.2±0.13 vs 1.38±0.13, p<0.05). No significant differences were found between PD-High BMI change and 
Normal Controls for rostral raphe nuclei or hypothalamus 
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Table 18 Univariate group comparison of SERT binding in 12 Regions-of-Interest  
 PD-LOW BMI 
CHANGE 
PD-HIGH BMI 
CHANGE 
NORMAL 
CONTROLS 
(LOW BMI 
CHANGE) 
P VALUEß 
 
Amygdala 0.97 ± 0.18 1.02 ± 0.20 1.13 ± 0.19 NS – BMI¥ 
Anterior Cingulate Cortex 0.23 ± 0.09 0.27 ± 0.08 0.37 ± 0.09 NS – BMI 
Caudal Raphe Nuclei 1.44 ± 0.25 1.56 ± 0.25 1.74 ± 0.30 NS – BMI 
Caudate Nucleus 0.85 ± 0.11¶† 0.99  ± 0.14¶§ 1.31 ± 0.06†§ ¶<0.01** 
†<0.001*** 
§<0.001*** 
Hypothalamus 0.91 ± 0.16¶† 1.11 ± 0.2¶§ 1.21 ± 0.17†§ ¶ <0.01** 
†<0.001*** 
§ NS 
Insular Cortex 0.20 ± 0.10 0.21 ± 0.09 0.36 ± 0.05 NS – BMI 
Posterior Cingulate Cortex 0.23 ± 0.07 0.26 ± 0.08 0.36 ± 0.09 NS – BMI 
Prefrontal Cortex 0.12 ± 0.07 1.14 ± 0.06 0.20 ± 0.04 NS – BMI 
Putamen 1.01 ± 0.18 1.06 ± 0.14 1.35 ± 0.11 NS – BMI 
Rostral Raphe Nuclei 1.89 ± 0.28¶† 2.24 ± 0.37¶§ 2.44 ± 0.45†§ ¶<0.05* 
† <0.01** 
§ NS 
Thalamus 1.06 ± 0.22 1.12 ± 0.11 1.43 ± 0.14 NS – BMI 
Ventral Striatum 1.04 ± 0.22¶† 1.20 ± 0.13¶§ 1.38 ± 0.13†§ ¶ <0.05* 
†<0.001*** 
§<0.05* 
ßAll comparisons made with one-way ANOVA corrected with Tukey-Kramer Multiple Comparisons tests; 
§NS: Not significant; ¥ NS – BMI: Not significant difference between the two PD BMI groups 
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4.3.3	  Discussion	  
This is the first in vivo study investigating BMI changes in relation to SERT expression in 
a PD population. PD patients demonstrated a decrease of SERT binding in all regions 
compared to the group of normal controls, which had a Low BMI change. PD patients 
with a high BMI change demonstrated a relative increase of SERT binding compared to 
PD patients with a low BMI change but not compared to the healthy controls, denoting a 
dissociation of 5-HT neurotransmission within PD patients dependent upon BMI change 
and a possible insight in the pathophysiology of BMI change in PD.  
The results showed a positive correlation between SERT binding and BMI change 
over a 12-month period in PD patients in rostral raphe nuclei, hypothlamus, caudate 
nucleus and ventral striatum. Furthermore, PD patients determined to have a High BMI 
change compared to PD patients with a Low BMI change demonstrated significantly 
increased SERT binding in the same four regions. These findings are independent of 
possible effects of clinical parameters such as sex, age, disease duration, motor disability 
(H&Y and UPDRS), daily or lifetime dopaminergic medication or seasonal variations. 
Moreover, depression levels as measured by BDI-II and HRSD scales were not 
significantly associated with BMI changes and SERT binding in any region. No 
association between BMI change and SERT binding were found in amygdala, insula, 
thalamus, caudal raphe nuclei, ACC, PCC, PFC, and putamen for the entire PD group or 
when divided into High and Low BMI change groups.  
 BMI/weight gains and losses have been reported in PD, although the mechanism 
underlying the weight change is not clear. Clinical studies have suggested that alteration 
of food intake and energy expenditure levels is not primarily responsible for BMI change 
(Beyer et al., 1995; Gasparini et al., 1975; Macia et al, 2004). Moreover, it is proposed 
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that weight change is a continuous process, beginning several years prior to diagnosis 
(Chen et al., 2003).   
  There is evidence that 5-HT, when experimentally manipulated can alter the 
pattern of feeding behaviour and appetite regulation in rats. For example, lower SERT 
levels in rats result in an increase of food consumption (Breisch et al., 1976; Saller and 
Stricker, 1976; Waldbillig et al., 1981). Eating disorders have provided an insight into the 
serotonergic role in appetite regulation in humans. Obesity treatments aiming to augment 
5-HT activity have shown that inhibition of 5-HT re-uptake leads to weight loss in obese 
individuals (Bever and Perry, 1997). Depletion of 5-HT levels in individuals with bulimia 
nervosa was linked with an increase of food intake (Weltzin et al., 1995).   
Currently there is a small number of in vivo studies investigating the relationship 
between 5-HT and BMI in non-PD populations. These studies have utilized 18F-altanserin 
PET which binds to 5-HT2A receptors (presynaptically located G protein coupled receptor 
that mediates some actions of synaptic 5-HT), and 123I-nor-β-CIT SPECT and 11C-
DASB PET used as a specific marker of SERT in healthy and obese adult cohorts (Adams 
et al., 2004; Koskela et al., 2008; Matsumoto et al., 2008; Erritzoe et al., 2009; 2010). 
Findings from the 18F-altanserin PET studies found a positive correlation between 5-HT2A 
binding and BMI in both healthy and obese populations in several brain regions including, 
the left superior temporal cortex, left medial inferior temporal cortex, right dorsal lateral 
PFC, and right sensory motor cortex (Adams et al., 2004) and more recently, the addition 
of ACC, insula and the sub-cortical structure, hippocampus (Erritzoe et al., 2009). 
Increased 5-HT2A binding in those with a high BMI may reflect a direct role of the 5-HT2A 
receptor in appetite regulation or indirectly reflect low baseline levels of 5-HT possibly 
due to dysfunctional regulation of raphe innervation. Over one third of the Erritzoe and 
colleagues (2009) sample were classified as obese (BMI >30) and the authors suggest the 
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lower 5-HT levels in obese individuals result in increased food consumption, which in 
turn results in a compensatory upregulation of the 5-HT2A receptor density.  
Two studies have investigated SERT availability in relation to BMI and have 
reported conflicting findings. Erritzoe and colleagues (2010) in a recent 11C-DASB study 
reported a negative correlation between SERT binding and BMI in a group of healthy and 
obese individuals. Increase of SERT binding in those with a lower BMI compared to those 
with a higher BMI was found in several cortical areas, midbrain, striatum and thalamus. 
Conversely an 123I-nor-β-CIT SPECT study of monozygotic twins with intrapair 
differences in BMI found increased SERT binding in the twin with a higher BMI 
compared to the leaner twin (Koskela et al., 2008). It must be noted that this finding was 
not apparent in all twin pairs. Furthermore, a preliminary report in healthy adults provides 
support for the Erritzoe and colleagues (2010) findings of a negative correlation between 
SERT binding and BMI (Matsumoto et al., 2008). These results are supporting a 
serotonergic involvement in BMI although so far in vivo investigations have only 
measured BMI at a single point in time and have not attempted to assess BMI change over 
time.    
 Although the regions underpinning BMI modulation and how they interact, has yet 
to be established, the hypothalamus and brain stem have been identified as homeostatic 
sites responsible for the regulation of appetite (Morton et al, 2006; Schwartz et al, 2000). 
The rostral raphe nuclei whose main neuronal components are 5-HT neurons, possess 
projections to the hypothalamus and has been demonstrated to play an important role in 
food intake (Carlini et al., 2004). In the present study it is shown a relative decreased 
SERT binding in the PD cohort compared to normal controls. This finding may reflect 
dysfunctional raphe innervation regulation and may have a knock on effect to other 
regions possibly involved in BMI regulation and other functions related to eating 
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behaviour, which are currently unknown. PD patients with High BMI changes showed 
increased SERT binding in hypothalamus, rostral raphe nuclei, caudate nucleus and 
ventral striatum compared to the Low BMI change group. This dissociation of 11C-DASB 
binding in these regions, subject to the degree of BMI change may provide an insight into 
the regions involved in the pathophysiology of BMI change specifically in PD and what 
role each region may play in BMI change.  
It is thought that cognitive, emotional and sensory factors also play important roles 
in human eating behaviour (Kelley et al, 2005). As yet it is not known which regions are 
responsible for these functions or how they are integrated in order to function together. 
Our finding of increased SERT binding in the high BMI change group compared to the 
low BMI change group for the caudate nucleus and ventral striatum could indicate a 
possible cognitive or emotional role of these regions in relation to BMI modulation. The 
raphe nuclei cytoarchitectonic boundaries are poorly defined, however, anatomical studies 
have demonstrated a major serotonergic projection between the rostral raphe nucleus and 
the striatum (Morris et al., 1988). Furthermore, the rostral raphe nucleus provides 
significant serotonergic projections to the ventral striatum compared the dorsal striatum 
(Morris et al., 1988; Vertes, 1991). It has been suggested that on the basis of this 
connection, the dorsal striatum is involved in cognitive functions and the ventral striatum 
likely to be a site for limbic information integration (Conrad et al., 1974).  
fMRI studies have shown that the striatum is activated in response to visual 
exposure to palatable food images and food craving (Rothemund et al., 2007; Stoeckel et 
al., 2008), therefore is proposed that the striatum may be involved in encoding the reward 
value of food (Gottfried et al., 2003). A recent fMRI study has shown that the ventral 
striatum is involved in feeding behaviour, particularly following a period of fasting 
(Goldstone et al., 2009). Furthermore measurements of the peptide YY3-36 , a physiological 
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gut-derived satiety signal, have shown to be activated in the ventral striatum (Batterham et 
al, 2007). Moreover, it has been proposed that the nucleus accumbens is well positioned as 
an input station between the brainstem and hypothalamic projections to cortical regions 
for higher function and as a site for the integration of homeostatic signals following 
findings this region responds to leptin and ghrelin (Abizaird et al., 2006; Fulton et al., 
2006). 
 It is interesting to consider the impact of a possible dopamine with 5-HT 
interaction on BMI in PD. Evidence relating to eating disorders may provide insight into 
this notion in relation to eating behaviour and/or appetite regulation. Animal studies have 
demonstrated that 5-HT2C receptors tonically inhibit dopamine neurons (De Deurwaedere 
et al., 2004) and a PET study reported a positive correlation between dopamine D2/D3 
receptors and SERT in the ventral striatum and caudate in individuals following recovery 
of eating disorders (noted in Kaye et al., 2009). It has been hypothesized that serotonergic 
activity may be a crucial substrate for motivational systems and oppose the dopamine 
related appetitive system (Daw et al., 2002).  
Depression is one of the most common non-motor symptoms in PD with 
approximately 40-50% of patients affected (Starkstein et al., 1990; Dooneef et al., 1992; 
Cummings et al., 1999. The DSM-IV criteria for major depression disorder include a 
significant increase or decrease in appetite or body weight and there is evidence 
supporting the association between depression and BMI (Carpenter et al., 2000). 5-HT has 
also been purported as possessing a role in the pathophysiology of depressive symptoms 
(Wurtmann, 1992). No association between levels of depression with BMI change was 
found in this cohort of PD patients. This could indicate that the BMI change in this cohort 
was not a consequence of depressive symptomatology such as an increase or decrease of 
food intake and decrease in energy expenditure i.e due to apathy. However, the symptom 
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profile of depression in PD varies from that of endogenous depression with approximately 
50% of PD patients exhibiting depressive symptomatology not meeting the DSM-IV 
criteria for endogenous depression or dysthymia (Starkstein et al., 1990; Gotham et al., 
1996). Depression in PD usually displays higher levels of anxiety, hopelessness and lower 
suicide rates despite more suicidal thoughts (Taylor et al., 1986; McDonald, 2008), and as 
such may possess a different pathophysiology, which was not detected in this study.   
While the hypothalamus and raphe nuclei have been directly associated with 
appetite regulation and 5-HT previously, the caudate nucleus and ventral striatum have 
been shown to possess functional roles related with cognition and emotion. Human eating 
behaviour is likely to involve these functions as well as other physiological factors and the 
findings from this study may be indicative of dysfunctional serotonergic innervation, 
starting from median raphe nuclei then spreading to hypothalamus and other anatomically 
connected regions such as the striatum. Serotonergic pathways in the associative (caudate) 
and limbic (ventral striatum) parts of the striatum could be modulating cognitive and 
emotional aspects of eating behaviour and upon dysfunction, may in part be responsible 
for BMI changes.   
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5.1.1	  Subjects	  	  
Sixty-eight non-demented patients with idiopathic PD and 12 normal controls were 
studied. The PD patients were categorized into two groups depending on having (38 
subjects) or not having (30 subjects) LIDs. All subjects undertook a RAC PET scan and 
1.5T volumetric MRI scan in OFF medication condition. RAC BPND in caudate and 
putamen was examined between the different groups. The aims of this study are presented 
in Box 7 and the clinical characteristics of the participants in Table 19. 
 
Box 7 Aims: Postsynaptic Dopamine D2 Receptors in Levodopa-Induced Dyskinesia 
To investigate the integrity of striatal postsynaptic dopamine D2 receptors in levodopa-
induced dyskinesia in patients with Parkinson’s disease.  
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Table 19 Participants Clinical Characteristics 
 PD 
DYSKINETICS 
PD NON-
DYSKINETICS 
NORMAL 
CONTROLS 
Number 38 30 12 
Sex 28M / 10F 24M / 6F 10M / 2F 
Age (years ± SD) 62.43 ± 9.17 63.21 ± 9.21 63.31 ± 7.00 
Disease Duration (years ± SD) 13.45 ± 6.67a 7.25 ± 3.80 - 
H&Y OFF (mean ± SD) 3.14 ± 0.86b 2.37 ± 0.86 - 
UPDRS III – OFF (mean ± SD) 45.34 ± 10.57 37.87 ± 14.69 - 
UPDRS III – ON (mean ± SD) 
(% change) 
23.21 ± 7.66c  
(44.4 %) 
17.77 ± 9.43 
(53.1 %) 
- 
MMSE (mean ± SD) 29.08 ± 1.48 29.37 ± 1.25 29.42 ± 0.67 
BDI-II (mean ± SD) 14.78 ± 8.63 12.46 ± 8.67 3.08 ± 2.57 
Daily LEDL-DOPA (mean ± SD) 964.63 ± 847.80d 453.17 ± 411.36 - 
Daily LEDDA (mean ± SD) 184.62 ± 208.80 160.10 ± 138.76 - 
Daily LEDTOTAL (mean ± SD) 1149.25 ± 834.48 609.27 ± 382.04b - 
ap< 0.0001; bp<0.0005; cp<0.05; dp<0.01 
 
5.1.2	  Results	  
	  
Clinical Characteristics 
PD and normal control groups were matched for sex and age (one-way ANOVA with 
Tukey-Kramer post-test, p = 0.9216). PD dyskinetics had longer PD duration (Mann-
Whitney two-tail, p < 0.0001), were more disabled in terms of motor symptoms (H&Y 
OFF: Mann-Whitney two-tail, p = 0.0004; UPDRS III – OFF: Mann-Whitney two-tail, p = 
0.0762; UPDRS III – ON: Mann-Whitney two-tail, p = 0.0234) and received more L-
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DOPA (Daily LEDL-DOPA: Mann-Whitney two-tail, p = 0.0006; Daily LEDTOTAL: Mann-
Whitney two-tail, p = 0.0001) than the group of PD non-dyskinetics (Table 19).  
 All subjects were non-demented (all subjects ≥ 27 in MMSE; MMSE: Kruskal-
Wallis test with Dunn post test, p = 0.5344) and non-depressed - though the PD groups 
had higher amount of depressive scores from normal controls but no difference between 
those with and without LIDs (BDI-II: Kruskal-Wallis test with Dunn post test, p < 0.0001; 
both PD groups against normal controls, p < 0.0001; no difference between the two PD 
groups, p > 0.1). There was no difference in the amount of DA intake between the PD 
dyskinetic and non-dyskinetic group (Daily LEDDA: Mann-Whitney two-tail, p = 0.9348) 
(Table 19).  
 
D2 Receptor Binding 
Caudate RAC BPND was found significantly decreased in the PD dyskinetic group 
(p <0.001) and PD non-dyskinetic group (p<0.05) compared to the normal control group 
(one-way ANOVA with Tukey-Kramer post-test, p < 0.0001). Although PD dyskinetics 
showed less caudate RAC BPND than the PD non-dyskinetics (Mann-Whitney two-tail, p = 
0.0031), the comparison did not survive p value correction (Tukey-Kramer post-test, p < 
0.05) (Table 20 and Figure 62).  
Putamen RAC BPND was no different between the PD dyskinetic group, the PD 
non-dyskinetic group and the normal control group (one-way ANOVA with Tukey-
Kramer post-test, p < 0.05) (Table 20 and Figure 63). 
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Table 20 Caudate nucleus and putamen 11C-raclopride BPND values in a group of Parkinson’s 
disease dyskinetics, Parkinson’s disease non-dyskinetics and Normal Controls 
 PD DYSKINETICS 
(n=38) 
PD NON-
DYSKINETICS 
(n=30) 
NORMAL 
CONTROLS (n=12) 
Caudate 1.78 ± 0.36a 2.03 ± 0.31 2.27 ± 0.24 
Putamen 2.59 ± 0.53 2.76 ± 0.41 2.58 ± 0.24 
aAll caudate and putamen values = mean 11C-raclopride BPND values ± SD 
 
 
 
 
Figure 62 Significant decreases in 11C-raclopride RAC BPND in Caudate in the group of PD non-dyskinetics 
and PD dyskinetics compared to a group of Normal Controls (*p<0.05; ***p<0.001) 
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Figure 63 No differences in 11C-raclopride RAC BPND in Putamen in the group of PD non-dyskinetics and 
PD dyskinetics compared to a group of Normal Controls 
 
5.1.3	  Discussion	  
The findings demonstrate that there are no significant differences in caudate and putamen 
D2 receptor binding between dyskinetic and non-dyskinetic PD patients when the p values 
were corrected for multiple comparisons with a group of normal controls. However, 
caudate D2 receptor binding in the group of PD dyskinetics was reduced compared to the 
group of non-dyskinetics PD (uncorrected result). Clinical data showed that PD 
dyskinetics had more advanced disease, were more disabled while received more L-DOPA 
but not DA medication compared to a group of PD non-dyskinetics. 
 Post mortem studies have shown normal (Pierot et al., 1988), reduced (Rinne et al., 
1991) or increased (Bokobza et al., 1984) D2 binding in the putamen of L-DOPA treated 
PD patients. Previous animals studies have suggested that LIDs arise as a result of changes 
in the binding properties of striatal D2 receptors and that their occurrence requires both 
loss of dopamine terminals and priming with L-DOPA (Boyce et al., 1990; Bedard et al., 
1992; Graham et al., 1993). In vivo PET and SPECT studies have shown that the raised 
putamen D2 binding seen in untreated PD patients returns to normal after exposure to L-
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DOPA (Hagglund et al., 1987; Shinotoh et al., 1993; Antonini et al., 1994). A previous 
PET study demonstrated that D2 receptor availability in the putamen was similar between 
dyskinetic and non-dyskinetic PD and within the normal range when compared to a group 
of normal controls, and that D2 receptor availability in the caudate was similarly reduced 
to about 15% in both PD groups (Turjanski et al., 1997). Although it was initially 
postulated that dyskinesias were caused by supersensitivity of striatal D2 receptors, our 
findings are in agreement with the data from the aforementioned PET study and show no 
difference of striatal D2 receptors between PD dyskinetic and non-dyskinetic groups. 
 It was previously shown in this thesis (Chapter 3.1) that longer PD duration 
correlates with decreased D2 receptor availability in caudate but not in putamen, reflecting 
mostly disease progression, and also that motor disability and L-DOPA treatment do not 
affect D2 binding while exposure to DAs does affect the binding. In this study, PD 
dyskinetics showed reduced D2 binding in the caudate (p value not corrected for multiple 
comparisons) but not in the putamen when compared to the PD non-dyskinetic group. 
Moreover, PD dyskinetics had more advanced disease and motor disability, and were 
receiving more L-DOPA but not more DAs compared to the PD non-dyskinetic group. 
Taken together these data suggest that the difference in caudate D2 binding between 
dyskinetic and non-dyskinetic PD reflect differences in the stage of PD rather than the 
presence of dyskinesias.  
 In conclusion, the results indicate that dyskinesias in PD are not associated to 
selective changes in putamen dopamine D2 receptor binding. Similarly dyskinesias are 
unlikely to arise from a primary abnormality of caudate dopamine D2 receptor binding. 
However, the occurrence of rapid changes in receptor affinity configuration following 
dopaminergic medication cannot be excluded. 
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5.2	  The	  Role	  of	  Striatal	  Serotonergic	  Terminals	  in	  
Levodopa-­‐Induced	  Dyskinesia	  
	  
5.2.1	  Subjects	  	  
Thirty-six non-demented, non-depressed patients, with idiopathic PD survived screening 
to form three groups: (a) PD patients with stable response to L-DOPA treatment (12 
subjects), (b) PD patients with peak-dose LIDs (16 subjects) and (c) PD patients with 
motor complications but no LIDs (eight subjects). All PD patients were on L-DOPA 
treatment during the time of the study. Their findings were compared to a group of 12 
normal controls, all in good health and with no history of neurological or psychiatric 
illness that were not on any medication. None of the subjects had received anti-depressant 
therapy in the past or any other medication with known action on the serotonergic system. 
The clinical characteristics of the subjects are shown in Table 21 and the aims of this 
study are presented in Box 8. 
All groups were matched for sex and age (one-way ANOVA with Tukey-Kramer 
post test, p = 0.3868) and MMSE scores (Kruskal-Wallis test with Dunn post-test, p = 
0.1498). PD groups were also matched for motor disability (UPDRS motor scores in OFF 
medication condition: one-way ANOVA with Tukey-Kramer post test, p = 0.5048), daily 
DA intake (Daily LEDDA: Kruskal-Wallis test with Dunn post-test, p = 0.4993) and 
depression symptoms (BDI-II scores: one-way ANOVA with Tukey-Kramer post test, p = 
0.9657; HRSD scores: one-way ANOVA with Tukey-Kramer post test, p = 06127). PD 
groups with from motor complications were further matched for disease duration (Dunn 
post-test, p > 0.05), total UPDRS scores (Tukey-Kramer post test, p > 0.05), duration of 
DA treatment (Tukey-Kramer post test, p > 0.05), duration of L-DOPA treatment (Tukey-
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Kramer post test, p > 0.05), daily L-DOPA intake (Daily LEDL-DOPA: Tukey-Kramer post 
test, p > 0.05), lifetime L-DOPA intake (Lifetime LEDL-DOPA: Tukey-Kramer post test, p > 
0.05), lifetime DA intake (Lifetime LEDDA: Dunn post-test, p > 0.05), weight (Tukey-
Kramer post test, p > 0.05) and BMI (Tukey-Kramer post test, p > 0.05).  
 
Box 8 Aims: The Role of Striatal Serotonergic Terminals in Levodpa-Induced Dyskinesia 
To investigate the role of striatal serotonergic terminals in levodopa-induced dyskinesia in 
patients with Parkinson’s disease. It is hypothesised that Parkinson’s patients with 
levodopa-induced dyskinesias will not show differences in levels of integrity of striatal 
serotonergic terminals in comparison to Parkinson’s patients with stable response to 
levodopa. Furthermore, a bolus dose of the serotonin receptor 1A agonist, buspirone, will 
attenuate the high synaptic dopamine levels generated after administration of levodopa in 
Parkinson’s patients with levodopa-induced dyskinesias and will consequently, reduce the 
dyskinesia severity without increasing Parkinson’s symptoms. 
 
 
The PD subjects received: (a) one 11C-DASB PET scan in OFF medication 
condition, (b) three RAC PET scans (OFF medication, 60 mins after 250mg L-DOPA / 
25mg Carbidopa administration, and after 75 mins of buspirone and 60 mins of 250mg L-
DOPA / 25mg Carbidopa administration) and (c) an 1.5T volumetric MRI scan. They also 
undertook two clinical visits consisting of clinical assessments and two 150-min 
medication challenges with L-DOPA, and with L-DOPA and buspirone preceding 15 mins 
the administration of L-DOPA.  
 The normal controls received: (a) one 11C-DASB PET scan in OFF medication 
condition, (b) two RAC PET scans (RAC PET scan in OFF medication condition and 
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RAC PET scan 75 mins after buspirone administration) and (c) an 1.5T volumetric MRI 
scan. They also had a clinical visit where they undertook clinical assessments.  
 
Table 21 Clinical characteristics of three groups of Parkinson’s disease patients (with stable response to 
levodopa treatment, with other motor complications but not levodopa-induced dyskinesias and with peak-
dose levodopa-induced dyskinesias) and a group of Normal Controls 
CHARACTERISTICS NORMAL 
CONTROLS 
PD STABLE PD MF – NO 
DYSKINESIAS 
PD PEAK-DOSE 
LIDs 
 
Number of subjects 12 12 8 16 
Sex 10M/2F 10M/2F 6M/2F 12M/2F 
Age (years ± SD)i 63.31 ± 7.0 66.6 ± 7.2 61.3 ± 6.5 65.4 ± 8.0 
Disease duration (years ± SD)ii,iii - 5.58±3.52 9.81±2.59 11.52±4.33 
UPDRS ALL OFF state (mean ± 
SD)iv 
- 54.8 ± 18.4 75.3 ± 24.9 71.9 ± 12.6 
UPDRS ALL ON best state (mean 
± SD)v,vi and % improvementvii 
- 27.3 ± 12.2 
(52%) 
48.0 ± 20.4 (38%) 42.8 ± 9.9 (40%) 
UPDRS Part III – OFF state  
(mean ± SD)viii 
- 38.5 ± 13.1 44.0 ± 12.8 42.3 ± 7.7 
UPDRS Part III – ON best state 
(mean ± SD)ix,x and % 
improvementixi 
- 15.0 ± 7.2 
(63%) 
24.6 ± 10.3 (46%) 20.1 ± 3.8 (52%) 
Hoehn and Yahr (H&Y) stage - 
OFF state (mean ± SD)xii 
- 2.40±0.76 3.19±0.74 3.09±0.72 
Hoehn and Yahr (H&Y) stage - 
ON state  
- 1.54±0.61 2.41±0.58 2.14±0.61 
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(mean ± SD)xiii  
On PD Medication Duration 
(years ± SD)xiv 
- 3.89±3.61 6.99±3.13 9.96±3.53 
On DA Duration (years ± SD)xv - 2.32±4.11 4.85±3.39 6.91±2.60 
On L-DOPA Duration (years ± 
SD)xvi 
- 2.13±1.24 4.88±2.82 8.09±4.27 
Daily LEDTOTAL (mg ± SD)xvii, xviii - 443.3±97.5 920.3±291.7 1036.3±651.7 
Daily LEDDA (mg ± SD)xix - 94.58±114.9 146.3±123.6 165.5±210.3 
Daily LEDL-DOPA (mg ± SD)xx - 348.75±114.7
1 
774.0±265.4 870.8±468.5 
Lifetime LEDTOTAL (g ± SD)xxi - 404.0±431.0 1339.7±980.9 2185.2±1446.1 
Lifetime LEDDA (g ± SD)xxii - 202.6±451.0 382.6±359.9 452.7±423.0 
Lifetime LEDL-DOPA (g ± SD)xxiii - 201.4±158.8 957.1±743.2 1732.5±1253.6 
MMSE – OFF state (mean ± 
SD)xxiv 
29.42± 0.67 29.0 ± 1.60 28.5±2.63 28.75±2.52 
MMSE – ON state (mean ± SD)xxv - 29.67±0.65 29.25±1.25 29.19±1.47 
Beck Depression Inventory (BDI-
II) (mean ± SD)xxvi 
3.08±2.57 11.83±4.84 11.25±7.42 11.25±6.55 
Hamilton Rating Scale for 
Depression (HRSD) (mean ± 
SD)xxvii 
2.58±2.68 8.33±3.50 10.88±8.18 10.0±6.06 
Weight (kg ± SD)xxviii 92.45 ±19.79 79.1±11.4 79.3±14.0 69.53±14.56 
BMI (units ± SD)xxiv 29.15±5.45 25.65±3.08 26.95±4.0 24.34±4.59 
iOne-way ANOVA with Tukey-Kramer post test, p = 0.3868; iiDisease duration has been accounted from the 
time of PD motor symptom initiation (not the time of diagnosis) – time of first appearance of PD motor 
symptoms; iiiKruskal-Wallis test with Dunn post-test, p = 0.0002 (Stable vs Dysk p < 0.001; Stable vs MC 
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no Dysk p < 0.05; Dysk vs MC no Dysk p > 0.05); ivOne-way ANOVA with Tukey-Kramer post test, p = 
0.0224 (Stable vs Dysk p < 0.05; Stable vs MC no Dysk p < 0.05; Dysk vs MC no Dysk p > 0.05); vFor 
calculation of Total UPDRS ON scores, the best ON Part III motor scores has taken during the period t=0 
and t=150 after L-DOPA challenge; viOne-way ANOVA with Tukey-Kramer post test, p = 0.0031 (Stable vs 
Dysk p < 0.05; Stable vs MC no Dysk p < 0.01; Dysk vs MC no Dysk p > 0.05); viiOne-way ANOVA with 
Tukey-Kramer post test, p = 0.0007 (Stable vs Dysk p < 0.001; Stable vs MC no Dysk p < 0.05; Dysk vs 
MC no Dysk p > 0.05); viiiOne-way ANOVA with Tukey-Kramer post test, p = 0.5048; ixThe best ON Part 
III motor scores has taken during the period t=0 and t=150 after L-DOPA challenge; xOne-way ANOVA 
with Tukey-Kramer post test, p = 0.0133 (Stable vs Dysk p > 0.05; Stable vs MC no Dysk p < 0.05; Dysk vs 
MC no Dysk p > 0.05); xiOne-way ANOVA with Tukey-Kramer post test, p < 0.0001 (Stable vs Dysk p < 
0.01; Stable vs MC no Dysk, p < 0.001; Dysk vs MC no Dysk p > 0.05); xiiOne-way ANOVA with Tukey-
Kramer post test, p = 0.0299 (Stable vs Dysk p < 0.05; Stable vs MC no Dysk p > 0.05; Dysk vs MC no 
Dysk p > 0.05); xiiiOne-way ANOVA with Tukey-Kramer post test, p = 0.0073 (Stable vs Dysk p < 0.05; 
Stable vs MC no Dysk p < 0.01; Dysk vs MC no Dysk p > 0.05); xivOne-way ANOVA with Tukey-Kramer 
post test, p = 0.0003 (Stable vs Dysk p < 0.001; Stable vs MC no Dysk p > 0.05; Dysk vs MC no Dysk p > 
0.05); xvOne-way ANOVA with Tukey-Kramer post test, p = 0.0042 (Stable vs Dysk p < 0.01; Stable vs MC 
no Dysk p > 0.05; Dysk vs MC no Dysk p > 0.05); xviOne-way ANOVA with Tukey-Kramer post test, p = 
0.0001(Stable vs Dysk p <0.001; Stable vs MC no Dysk p > 0.05; Dysk vs MC no Dysk p > 0.05); xviiLED 
(mg) = (1 X Levodopa) + (0.77 X Levodopa CR) + (1.43 X Levodopa + Entacapone) + (1.11 X Levodopa 
CR + Entacapone) + (20 X Ropinirole) + (20 X Ropinirole ER) + (100 X Pramipexole) + (30 X Rotigotine) 
+ (10 X Bromocriptine) + (8 X Apomorphine) + (100 X Pergolide) + (67 X Cabergoline). Levodopa with 
Carbidopa or Benserazide hydrochloride; In Levodopa/Carbidopa or Benserazide hydrochloride: Only 
Levodopa is calculated; xviiiOne-way ANOVA with Tukey-Kramer post test, p = 0.0064 (Stable vs Dysk p < 
0.01; Stable vs MC no Dysk p > 0.05; Dysk vs MC no Dysk p > 0.05); xixKruskal-Wallis test with Dunn 
post-test, p = 0.4993; xxOne-way ANOVA with Tukey-Kramer post test, p = 0.0012 (Stable vs Dysk p < 
0.01; Stable vs MC no Dysk p < 0.05; Dysk vs MC no Dysk p > 0.05); xxiOne-way ANOVA with Tukey-
Kramer post test, p = 0.0008 (Stable vs Dysk p < 0.001; Stable vs MC no Dysk p > 0.05; Dysk vs MC no 
Dysk p > 0.05); xxiiKruskal-Wallis test with Dunn post-test, p = 0.0211 (Stable vs. Dysk p < 0.05; Stable vs. 
MC no Dysk p > 0.05; Dysk vs. MC no Dysk p > 0.05); xxiiiOne-way ANOVA with Tukey-Kramer post test, 
p = 0.0005 (Stable vs Dysk p < 0.001; Stable vs MC no Dysk p > 0.05; Dysk vs MC no Dysk p > 0.05); 
xxivKruskal-Wallis test with Dunn post-test, p = 0.1498; xxvKruskal-Wallis test with Dunn post-test, p = 
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0.3150; xxviOne-way ANOVA with Tukey-Kramer post test, p = 0.0007 (Stable vs Dysk p > 0.05; Stable vs 
MC no Dysk p > 0.05; Stable vs NC p < 0.01; Dysk vs MC no Dysk p > 0.05; Dysk vs NC p < 0.01; MC no 
Dysk vs NC p < 0.05); xxviiKruskal-Wallis test with Dunn post-test, p = 0.0012 (Stable vs. Dysk p > 0.05; 
Stable vs. MC no Dysk p > 0.05; Stable vs. NC p < 0.05; Dysk vs. MC no Dysk p > 0.05; Dysk vs. NC p < 
0.01; MC no Dysk vs. NC p < 0.05); xxviiiOne-way ANOVA with Tukey-Kramer post test, p = 0.0039 (Stable 
vs Dysk p < 0.01; Stable vs MC no Dysk p > 0.05; Stable vs NC p > 0.05; Dysk vs MC no Dysk p > 0.05; 
Dysk vs NC p > 0.05; MC no Dysk vs NC p > 0.05); xxixOne-way ANOVA with Tukey-Kramer post test, p = 
0.0481 (Stable vs Dysk p > 0.05; Stable vs MC no Dysk p > 0.05; Stable vs NC p > 0.05; Dysk vs MC no 
Dysk p > 0.05; Dysk vs NC p < 0.05; MC no Dysk vs NC p > 0.05) 
	  
5.2.2	  Results	  
 
PD patients Clinical Characteristics 
PD patients with motor complications (both groups) had longer disease duration (Kruskal-
Wallis test with Dunn post-test, p = 0.0002), had higher UPDRS total OFF medication 
state score (one-way ANOVA with Tukey-Kramer post test, p = 0.0224), had worse motor 
response after L-DOPA challenge (UPDRS motor score % improvement: one-way 
ANOVA with Tukey-Kramer post test, p < 0.0001) and were currently receiving more L-
DOPA (one-way ANOVA with Tukey-Kramer post test, p = 0.0012) compared to PD 
patients with stable response to L-DOPA.   
 PD patients with LIDs were on DA for a longer period of time (one-way ANOVA 
with Tukey-Kramer post test, p = 0.0042) and L-DOPA (one-way ANOVA with Tukey-
Kramer post test, p = 0.0001), had received higher amounts of DA (Lifetime LEDDA: 
Kruskal-Wallis test with Dunn post-test p = 0.021) and L-DOPA (Lifetime LEDL-DOPA: 
one-way ANOVA with Tukey-Kramer post test, p = 0.0005) in their lifetime, and had less 
body weight (one-way ANOVA with Tukey-Kramer post test, p = 0.0039) and BMI (one-
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way ANOVA with Tukey-Kramer post test, p = 0.0481) in their body compared to PD 
patients with stable response to L-DOPA (Table 21).   
 The PD groups had higher depressive scores compared to normal controls (BDI-II; 
one-way ANOVA with Tukey-Kramer post test, p = 0.0007; HRSD: Kruskal-Wallis test 
with Dunn post-test, p = 0.0012) but their values were not higher than the cut-off scores 
for clinical depression. 
 
Buspirone and D2 receptor binding: Decision of Dose 
The 12 normal controls were divided into two groups of six and had the second RAC PET 
scan with either 0.20mg/kg (~ 15mg) (Low Dose Group) or 0.35mg/kg (~30mg) (High 
Dose Group) bolus dose of buspirone, 75 mins preceding the RAC infusion. The two 
groups were matched for sex, age, weight, BMI, MMSE and depression scores (BDI-II 
and HRSD) (Table 22). This assessment was performed in order to explore whether 
buspirone affects D2 receptor binding and also to establish the side-effect profile in two 
different doses of the drug. 
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Table 22 Clinical characteristics of the two Normal Control subgroups that underwent the trial 
with low (0.20mg/kg) and high (0.35mg/kg) bolus dose of Buspirone 
 LOW DOSE GROUP  
0.20 mg/kg BUSPIRONE 
HIGH DOSE GROUP  
0.35 mg/kg BUSPIRONE 
Subjects 6 6 
Sex 5M / 1F 5M / 1F 
Age (years ± SD) 62.85±6.06  63.77±8.40  
Weight (Kg ± SD) 92.0 ± 14.47 92.9 ± 25.53 
BMI (units ± SD) 28.78± 4.57 29.52± 6.64 
MMSE (mean ± SD) 29.17 ± 0.75 29.67 ± 0.52 
BDI-II (mean ± SD) 2.83 ± 2.14 3.33 ± 3.14 
HRSD (mean ± SD) 2.5 ± 1.87 2.66 ± 3.50 
 
 
The findings demonstrate that in normal control subjects there were no significant 
difference in caudate and putamen RAC BPND between the baseline scans and the scans 
after low (0.20mg/kg) or high (0.35mg/kg) bolus dose of buspirone (paired t tests, p > 
0.1). Hence there was no difference in RAC BPND between the low and the high buspirone 
groups (unpaired t tests, p > 0.1) (Figure 64; Tables 23 and 24). 
Six out of 12 normal subjects reported at least one side-effect (50%). There were 
five different side-effects (drowsiness, dizziness, nausea, vomiting and feeling 
lightheaded) reported after buspirone challenge in the normal control groups. Three 
subjects in each low and high dose group reported side-effects whereas three subjects in 
each group reported no side-effects. There was no difference in the amount of side-effects 
reported by the low or high dose group (Table 25). 
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 The findings of this buspirone trial in normal control subjects have shown that 
there is no influence of buspirone in striatal D2 binding neither with low or high dose. 
Furthermore, the results show no difference in the side-effect profile of low or high bolus 
doses of buspirone. According to these results, it was decided to use the high buspirone 
dose (0.35mg/kg) in the PD trial aiming to achieve a more complete block of serotonergic 
terminals and attenuate the dopamine levels released from these neurons and therefore, 
attenuate dyskinesia severity.   
 
 
 
Figure 64 No significant differences in caudate and putamen 11C-raclopride BPND mean values in normal 
control subjects between baseline 11C-raclopride PET scans (blue bars) and 11C-raclopride PET scans 
following low (0.20 mg/kg) or high bolus doses (0.35 mg/kg) (red bars) of buspirone. Error Bars: +1 
Standard Deviation(s) 
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Table 23 Caudate and Putamen 11C-raclopride BPND mean values in a group of six normal 
controls at baseline and following low (0.20 mg/kg) doses of Buspirone   
 BASELINE LOW DOSE BUSPIRONE 
Caudatea 2.59 ± 0.18c 2.43 ± 0.09 
Putamenb 2.94 ± 0.16 2.88 ± 0.07 
aCaudate: Paired t test. Two-tail p value = 0.2188; bPutamen: Paired t test. Two-tail p value = 
0.3102; cmean 11C-raclopride RAC BPND values ± SD 
 
Table 24 Caudate and Putamen 11C-raclopride BPND mean values in a group of six normal 
controls at baseline and following high (0.35 mg/kg) doses of Buspirone   
 Baseline HIGH DOSE BUSPIRONE 
Caudatea 2.58 ± 0.34c 2.55 ± 0.23 
Putamenb 2.91 ± 0.27 2.78 ± 0.13 
a Caudate: Paired t test. Two-tail p value = 0.6424; bPutamen: Paired t test. Two-tail p value = 
0.1601; cmean 11C-raclopride RAC BPND values ± SD 
 
Table 25 Side-effect Profile after administration of low (0.20 mg/kg) and high bolus dose of 
Buspirone (0.35 mg/kg) in normal control subjects 
NUMBER OF SUBJECTS SIDE-EFFECT 
LOW DOSE GROUP HIGH DOSE GROUP TOTAL 
Drowsy 3 1 4 
Dizziness 1 0 1 
Nausea 1 0 1 
Vomited 1 0 1 
Lightheaded 0 2 2 
None 3 3 6 
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Buspirone and L-DOPA Medication Challenges in Parkinson’s patients with L-
DOPA-induced dyskinesias: Clinical Results – Severity of Dyskinesias  
PD patients with LIDs showed significantly decreased (paired t tests, two tailed p values) 
total AIMS scores at 60 (p<0.05), 75 (p<0.01), 90 (p<0.01) and 105 (p<0.05) mins after L-
DOPA administration in the challenge where buspirone preceded the administration of L-
DOPA compared to the challenge with L-DOPA only (Figure 65). 
 
 
Figure 65 Total Abnormal Involuntary Movement Scale scores (presented as % of 40 points maximum) 
after levodopa (blue line) and after 0.35mg/kg buspirone preceding the administration of levodopa  (red line) 
in a group of 16 Parkinson’s patients with peak-dose levodopa -induced dyskinesias. The time period 
recorded was 150 minutes after levodopa administration. OFF represents the administration of levodopa. 
Buspirone administration took place 15 minutes before the administration of levodopa on the second 
medication challenge. Error Bars = ± 1 standard error of mean 
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PD patients with LIDs showed significantly decreased (paired t tests, two tailed p 
values) facial and oral AIMS scores at 60 (p<0.05) and 75 (p<0.05) mins after L-DOPA 
administration in the challenge where buspirone preceded the administration of L-DOPA 
compared to the challenge with L-DOPA only (Figure 66). 
 
 
 
Figure 66 Facial and Oral Abnormal Involuntary Movement Scale scores (presented as % of 16 points 
maximum) after levodopa (blue line) and after 0.35mg/kg buspirone preceding the administration of 
levodopa (red line) in a group of 16 Parkinson’s patients with peak-dose levodopa-induced dyskinesias. The 
time period recorded was 150 minutes after levodopa administration. OFF represents the administration of 
levodopa. Buspirone administration took place 15 minutes before the administration of levodopa on the 
second medication challenge. Error Bars = ± 1 standard error of mean 
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PD patients with LIDs showed significantly decreased (paired t tests, two tailed p 
values) extremity AIMS scores at 75 (p<0.01), 90 (p<0.01) and 105 (p<0.01) mins after L-
DOPA administration in the challenge where buspirone preceded the administration of L-
DOPA compared to the challenge with L-DOPA only (Figure 67). 
 
 
 
Figure 67 Extremity Abnormal Involuntary Movement Scale scores (presented as % of 8 points maximum) 
after levodopa (blue line) and after 0.35mg/kg buspirone preceding the administration of levodopa (red line) 
in a group of 16 Parkinson’s patients with peak-dose levodopa-induced dyskinesias. The time period 
recorded was 150 minutes after levodopa administration. OFF represents the administration of levodopa. 
Buspirone administration took place 15 minutes before the administration of levodopa on the second 
medication challenge. Error Bars = ± 1 standard error of mean 
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PD patients with LIDs showed significantly decreased (paired t tests, two tailed p 
values) trunk AIMS scores at 75 (p<0.01), 90 (p<0.05) and 105 (p<0.05) mins after L-
DOPA administration in the challenge where buspirone preceded the administration of L-
DOPA compared to the challenge with L-DOPA only (Figure 68). 
 
 
 
Figure 68 Trunk Abnormal Involuntary Movement Scale scores (presented as % of 4 points maximum) after 
levodopa (blue line) and after 0.35mg/kg buspirone preceding the administration of levodopa (red line) in a 
group of 16 Parkinson’s patients with peak-dose levodopa-induced dyskinesias. The time period recorded 
was 150 minutes after levodopa administration. OFF represents the administration of levodopa. Buspirone 
administration took place 15 minutes before the administration of levodopa on the second medication 
challenge. Error Bars = ± 1 standard error of mean 
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PD patients with LIDs showed significantly decreased (paired t tests, two tailed p 
values) global judgments AIMS scores at 60 (p<0.01), 75 (p<0.05), 90 (p<0.05) and 105 
(p<0.05) mins after L-DOPA administration in the challenge where buspirone preceded 
the administration of L-DOPA compared to the challenge with L-DOPA only (Figure 69). 
 
 
 
Figure 69 Global Judgments Abnormal Involuntary Movement Scale scores (presented as % of 12 points 
maximum) after levodopa (blue line) and after 0.35mg/kg buspirone preceding the administration of 
levodopa (red line) in a group of 16 Parkinson’s patients with peak-dose levodopa-induced dyskinesias. The 
time period recorded was 150 minutes after levodopa administration. OFF represents the administration of 
levodopa. Buspirone administration took place 15 minutes before the administration of levodopa on the 
second medication challenge. Error Bars = ± 1 standard error of mean 
 
 
 
 
 
 227	  
Buspirone and L-DOPA Medication Challenges in Parkinson’s patients with L-
DOPA-induced dyskinesias: Clinical Results – Parkinson’s Symptoms  
PD patients with LIDs showed significantly decreased improvement at 30 (p<0.01) and 75 
(p<0.01) mins and significantly increased improvement at 150 mins (p<0.05) in total 
UPDRS motor scores after L-DOPA administration in the challenge where buspirone 
preceded the administration of L-DOPA compared to the challenge with L-DOPA only 
(paired t tests, two tailed p values) (Figure 70). 
 
 
Figure 70 Total Unified Parkinson’s Disease Rating Scale Part III motor scores (presented as % 
improvement from OFF medication condition; worst score = 108) after levodopa (blue line) and after 
0.35mg/kg buspirone preceding the administration of levodopa (red line) in a group of 16 Parkinson’s 
patients with peak-dose levodopa-induced dyskinesias. The time period recorded was 150 minutes after 
levodopa administration. OFF represents the administration of levodopa. Buspirone administration took 
place 15 minutes before the administration of levodopa on the second medication challenge. Error Bars = ± 
1 standard error of mean 
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Buspirone and L-DOPA Medication Challenges in Parkinson’s patients with L-
DOPA-induced dyskinesias: Imaging Results 
No significant differences were found in caudate (Figure 71) and putamen (Figure 72) 
11C-DASB BPND between PD patients with peak-dose LIDs and PD patients with stable 
response to L-DOPA. No correlation was found between caudate 11C-DASB BPND and 
maximum (Pearson r=-0.1438, p=0.5951) and average (Pearson r=-0.1463, p=0.5887) 
AIMS scores during the 150-min medication challenge with L-DOPA in PD patients with 
peak-dose LIDs. Similarly, no correlation was found between putamen 11C-DASB BPND 
and maximum (Pearson r=-0.06842, p=0.8012) and average (Pearson r=-0.03518, 
p=0.8971) AIMS scores during the 150-min medication challenge with L-DOPA in PD 
patients with peak-dose LIDs. 
 
 
 
 
 
 
 
 
 229	  
 
Figure 71 Caudate 11C-DASB BPND mean values in a group of Parkinson’s disease patients with stable 
response to levodopa (n=12; BPND = 0.954) and a group of Parkinson’s disease patients with peak-dose 
levodopa-induce dyskinesias (n=16; BPND = 0.884). Unpaired t test with Welch correction, two-tailed P 
value is 0.2675. Error Bars = + 1 Standard Deviation(s) 
 
 
Figure 72 Putamen 11C-DASB BPND mean values in a group of Parkinson’s disease patients with stable 
response to levodopa (n=12; BPND = 1.061) and a group of Parkinson’s disease patients with peak-dose 
levodopa-induce dyskinesias (n=16; BPND = 0.992). Unpaired t test with Welch correction, two-tailed P 
value is 0.2762. Error Bars = + 1 Standard Deviation(s) 
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PD patients with LIDs showed a significant reduction (paired t test, two tailed p 
value = 0.0499) in caudate RAC BPND mean percentage reductions from RAC PET OFF 
medication scans, in the challenge where buspirone preceded the administration of L-
DOPA compared to the challenge with L-DOPA only. PD patients with stable response to 
L-DOPA showed no significant differences (paired t test, two tailed p value = 0.1021) in 
caudate RAC BPND mean percentage reductions from RAC PET OFF medication scans, in 
the challenge where buspirone preceded the administration of L-DOPA compared to the 
challenge with L-DOPA only (Figure 73). 
 
 
Figure 73 Estimated levodopa-induced changes in caudate synaptic levels of dopamine after a challenge 
with levodopa only (blue bars) and a challenge with 0.35mg/kg buspirone preceding the administration of 
levodopa (red bars) in a group of Parkinson’s patients with stable response to levodopa (n=12) and a group 
of Parkinson’s patients with peak-dose levodopa-induced dyskinesias (n=16). Values are expressed as % 
reduction from baseline caudate 11C-raclopride BPND. Error Bars = + 1 Standard Error(s) of mean. *p<0.05 	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PD patients with LIDs showed a significant reduction (paired t test, two tailed p 
value = 0.0499) in putamen RAC BPND mean percentage reductions from RAC PET OFF 
medication scans, in the challenge where buspirone preceded the administration of L-
DOPA compared to the challenge with L-DOPA only. PD patients with stable response to 
L-DOPA showed no significant differences (paired t test, two tailed p value = 0.3148) in 
putamen RAC BPND mean percentage reductions from RAC PET OFF medication scans, 
in the challenge where buspirone preceded the administration of L-DOPA compared to the 
challenge with L-DOPA only (Figure 74). 
 
 
Figure 74 Estimated levodopa-induced changes in putamen synaptic levels of dopamine after a challenge 
with levodopa only (blue bars) and a challenge with 0.35mg/kg buspirone preceding the administration of 
levodopa (red bars) in a group of Parkinson’s patients with stable response to levodopa (n=12) and a group 
of Parkinson’s patients with peak-dose levodopa-induced dyskinesias (n=16). Values are expressed as % 
reduction from baseline putamen 11C-raclopride BPND. Error Bars = + 1 Standard Error(s) of mean. *p<0.05 
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Categorization of Parkinson’s disease patients with L-DOPA-induced dyskinesias 
in mild to moderate and moderate to severe dyskinetic groups 
Subjects in the group of PD patients with peak-dose LIDs were further divided at the mean 
and median for severity of dyskinesias over 150 mins following administration with L-
DOPA to form two groups of: (i) PD patients with mild to moderate peak-dose LIDs 
(eight subjects; below mean and median severity of dyskinesias over 150 mins following 
L-DOPA challenge) and (ii) PD patients with moderate to severe peak-dose LIDs (eight 
subjects; below mean and median severity of dyskinesias over 150 mins following L-
DOPA challenge) (Figure 75).  
 
 
Figure 75 Individual total Abnormal Involuntary Movement Scale scores of Parkinson’s disease patients 
with peak-dose levodopa-induced dyskinesias over 150 minutes following administration of levodopa. Eight 
subjects were below (grey lines) and eight subjects were above (black lines) the discriminating mean (blue 
dotted line) and median (red dotted line) cut-off for categorisation into mild to moderate and moderate to 
severe dyskinetic groups 
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Buspirone and L-DOPA Medication Challenges in Parkinson’s patients with mild 
to moderate L-DOPA-induced dyskinesias: Clinical Results – Severity of Dyskinesias  
PD patients with mild to moderate LIDs showed significantly decreased (paired t tests, 
two tailed p values) total AIMS scores at 60 (p<0.05), 75 (p<0.05), 90 (p<0.05) and 105 
(p<0.05) mins after L-DOPA administration in the challenge where buspirone preceded 
the administration of L-DOPA compared to the challenge with L-DOPA only (Figure 76). 
 
 
Figure 76 Total Abnormal Involuntary Movement Scale scores (presented as % of 40 points maximum) 
after levodopa (blue line) and after 0.35mg/kg buspirone preceding the administration of levodopa (red line) 
in a group of 8 Parkinson’s patients with mild to moderate peak-dose levodopa-induced dyskinesias. The 
time period recorded was 150 minutes after levodopa administration. OFF represents the administration of 
levodopa. Buspirone administration took place 15 minutes before the administration of levodopa on the 
second medication challenge. Error Bars = ± 1 standard error of mean 
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PD patients with mild to moderate LIDs showed significantly decreased (paired t 
tests, two tailed p values) facial and oral AIMS scores at 60 (p<0.05), 75 (p<0.05) and 90 
(p<0.05) mins after L-DOPA administration in the challenge where buspirone preceded 
the administration of L-DOPA compared to the challenge with L-DOPA only (Figure 77). 
 
 
 
Figure 77 Facial and Oral Abnormal Involuntary Movement Scale scores (presented as % of 16 points 
maximum) after levodopa (blue line) and after 0.35mg/kg buspirone preceding the administration of 
levodopa (red line) in a group of 8 Parkinson’s patients with mild to moderate peak-dose levodopa-induced 
dyskinesias. The time period recorded was 150 minutes after levodopa administration. OFF represents the 
administration of levodopa. Buspirone administration took place 15 minutes before the administration of 
levodopa on the second medication challenge. Error Bars = ± 1 standard error of mean 
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PD patients with mild to moderate LIDs showed significantly decreased (paired t 
tests, two tailed p values) extremity AIMS scores at 75 (p<0.05), 90 (p<0.05) and 105 
(p<0.05) mins after L-DOPA administration in the challenge where buspirone preceded 
the administration of L-DOPA compared to the challenge with L-DOPA only (Figure 78). 
 
 
 
Figure 78 Extremity Abnormal Involuntary Movement Scale scores (presented as % of 8 points maximum) 
after levodopa (blue line) and after 0.35mg/kg buspirone preceding the administration of levodopa (red line) 
in a group of 8 Parkinson’s patients with mild to moderate peak-dose levodopa-induced dyskinesias. The 
time period recorded was 150 minutes after levodopa administration. OFF represents the administration of 
levodopa. Buspirone administration took place 15 minutes before the administration of levodopa on the 
second medication challenge. Error Bars = ± 1 standard error of mean 
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PD patients with mild to moderate LIDs showed significantly decreased (paired t 
tests, two tailed p values) trunk AIMS scores at 75 mins (p<0.05) after L-DOPA 
administration in the challenge where buspirone preceded the administration of L-DOPA 
compared to the challenge with L-DOPA only (Figure 79). 
 
 
 
 
Figure 79 Trunk Abnormal Involuntary Movement Scale scores (presented as % of 4 points maximum) after 
levodopa (blue line) and after 0.35mg/kg buspirone preceding the administration of levodopa (red line) in a 
group of 8 Parkinson’s patients with mild to moderate peak-dose levodopa-induced dyskinesias. The time 
period recorded was 150 minutes after levodopa administration. OFF represents the administration of 
levodopa. Buspirone administration took place 15 minutes before the administration of levodopa on the 
second medication challenge. Error Bars = ± 1 standard error of mean 
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PD patients with mild to moderate LIDs showed significantly decreased (paired t 
tests, two tailed p values) global judgments AIMS scores at 75 (p<0.05), 90 (p<0.05) and 
105 (p<0.05) mins after L-DOPA administration in the challenge where buspirone 
preceded the administration of L-DOPA compared to the challenge with L-DOPA only 
(Figure 80). 
 
 
 
 
Figure 80 Global Judgments Abnormal Involuntary Movement Scale scores (presented as % of 12 points 
maximum) after levodopa (blue line) and after 0.35mg/kg buspirone preceding the administration of 
levodopa (red line) in a group of 8 Parkinson’s patients with mild to moderate peak-dose levodopa-induced 
dyskinesias. The time period recorded was 150 minutes after levodopa administration. OFF represents the 
administration of levodopa. Buspirone administration took place 15 minutes before the administration of 
levodopa on the second medication challenge. Error Bars = ± 1 standard error of mean 
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Buspirone and L-DOPA Medication Challenges in Parkinson’s patients with mild 
to moderate L-DOPA-induced dyskinesias: Clinical Results – Parkinson’s Symptoms  
PD patients with mild to moderate LIDs showed significantly decreased improvement at 
30 mins (p<0.05) and significantly increased improvement at 120 (p<0.01), 135 (p<0.01) 
and 150 (p<0.05) mins in total UPDRS motor scores after L-DOPA administration in the 
challenge where buspirone preceded the administration of L-DOPA compared to the 
challenge with L-DOPA only (paired t tests, two tailed p values) (Figure 81). 
 
 
Figure 81 Total Unified Parkinson’s Disease Rating Scale Part III motor scores (presented as % 
improvement from OFF medication condition; worst score = 108) after levodopa (blue line) and after 
0.35mg/kg buspirone preceding the administration of levodopa (red line) in a group of 8 Parkinson’s patients 
with mild to moderate peak-dose levodopa-induced dyskinesias. The time period recorded was 150 minutes 
after levodopa administration. OFF represents the administration of levodopa. Buspirone administration took 
place 15 minutes before the administration of levodopa on the second medication challenge. Error Bars = ± 
1 standard error of mean 
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Buspirone and L-DOPA Medication Challenges in Parkinson’s patients with 
moderate to severe L-DOPA-induced dyskinesias: Clinical Results – Severity of 
Dyskinesias  
PD patients with moderate to severe LIDs showed significantly decreased (paired t tests, 
two tailed p values) total AIMS scores at 75 mins (p<0.05) after L-DOPA administration 
in the challenge where buspirone preceded the administration of L-DOPA compared to the 
challenge with L-DOPA only (Figure 82). 
 
 
Figure 82 Total Abnormal Involuntary Movement Scale scores (presented as % of 40 points maximum) 
after levodopa (blue line) and after 0.35mg/kg buspirone preceding the administration of levodopa (red line) 
in a group of 8 Parkinson’s patients with moderate to severe peak-dose levodopa-induced dyskinesias. The 
time period recorded was 150 minutes after levodopa administration. OFF represents the administration of 
levodopa. Buspirone administration took place 15 minutes before the administration of levodopa on the 
second medication challenge. Error Bars = ± 1 standard error of mean 
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PD patients with moderate to severe LIDs showed no significant differences 
(paired t tests, two tailed p values) in facial and oral AIMS scores in the challenge where 
buspirone preceded the administration of L-DOPA compared to the challenge with L-
DOPA only (Figure 83). 
 
 
 
Figure 83 Facial and Oral Abnormal Involuntary Movement Scale scores (presented as % of 16 points 
maximum) after levodopa (blue line) and after 0.35mg/kg buspirone preceding the administration of 
levodopa (red line) in a group of 8 Parkinson’s patients with moderate to severe peak-dose levodopa-
induced dyskinesias. The time period recorded was 150 minutes after levodopa administration. OFF 
represents the administration of levodopa. Buspirone administration took place 15 minutes before the 
administration of levodopa on the second medication challenge. Error Bars = ± 1 standard error of mean 
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PD patients with moderate to severe LIDs showed significantly decreased (paired t 
tests, two tailed p values) extremity AIMS scores at 75 (p<0.01) and 90 (p<0.05) mins 
after L-DOPA administration in the challenge where buspirone preceded the 
administration of L-DOPA compared to the challenge with L-DOPA only (Figure 84). 
 
 
 
Figure 84 Extremity Abnormal Involuntary Movement Scale scores (presented as % of 8 points maximum) 
after levodopa (blue line) and after 0.35mg/kg buspirone preceding the administration of levodopa (red line) 
in a group of 8 Parkinson’s patients with moderate to severe peak-dose levodopa-induced dyskinesias. The 
time period recorded was 150 minutes after levodopa administration. OFF represents the administration of 
levodopa. Buspirone administration took place 15 minutes before the administration of levodopa on the 
second medication challenge. Error Bars = ± 1 standard error of mean 
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PD patients with moderate to severe LIDs showed significantly decreased (paired t 
tests, two tailed p values) trunk AIMS scores at 75 mins (p<0.05) after L-DOPA 
administration in the challenge where buspirone preceded the administration of L-DOPA 
compared to the challenge with L-DOPA only (Figure 85). 
 
 
 
Figure 85 Trunk Abnormal Involuntary Movement Scale scores (presented as % of 4 points maximum) after 
levodopa (blue line) and after 0.35mg/kg buspirone preceding the administration of levodopa (red line) in a 
group of 8 Parkinson’s patients with moderate to severe peak-dose levodopa-induced dyskinesias. The time 
period recorded was 150 minutes after levodopa administration. OFF represents the administration of 
levodopa. Buspirone administration took place 15 minutes before the administration of levodopa on the 
second medication challenge. Error Bars = ± 1 standard error of mean 
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PD patients with moderate to severe LIDs showed significantly decreased (paired t 
tests, two tailed p values) global judgments AIMS scores at 60 mins (p<0.05) after L-
DOPA administration in the challenge where buspirone preceded the administration of L-
DOPA compared to the challenge with L-DOPA only (Figure 86). 
 
 
 
Figure 86 Global Judgments Abnormal Involuntary Movement Scale scores (presented as % of 12 points 
maximum) after levodopa (blue line) and after 0.35mg/kg buspirone preceding the administration of 
levodopa (red line) in a group of 8 Parkinson’s patients with moderate to severe peak-dose levodopa-
induced dyskinesias. The time period recorded was 150 minutes after levodopa administration. OFF 
represents the administration of levodopa. Buspirone administration took place 15 minutes before the 
administration of levodopa on the second medication challenge. Error Bars = ± 1 standard error of mean 
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Buspirone and L-DOPA Medication Challenges in Parkinson’s patients with 
moderate to severe L-DOPA-induced dyskinesias: Clinical Results – Parkinson’s 
Symptoms  
PD patients with moderate to severe LIDs showed no significant differences in total 
UPDRS motor scores in the challenge where buspirone preceded the administration of L-
DOPA compared to the challenge with L-DOPA only (paired t tests, two tailed p values) 
(Figure 87). 
 
 
Figure 87 Total Unified Parkinson’s Disease Rating Scale Part III motor scores (presented as % 
improvement from OFF medication condition; worst score = 108) after levodopa (blue line) and after 
0.35mg/kg buspirone preceding the administration of levodopa (red line) in a group of 8 Parkinson’s patients 
with moderate to severe peak-dose levodopa-induced dyskinesias. The time period recorded was 150 
minutes after levodopa administration. OFF represents the administration of levodopa. Buspirone 
administration took place 15 minutes before the administration of levodopa on the second medication 
challenge. Error Bars = ± 1 standard error of mean 
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Buspirone and L-DOPA Medication Challenges in Parkinson’s patients’ 
subgroups: Imaging Results 
PD patients’ subgroups (MF without dyskinesias, n=8; moderate to severe peak-dose 
LIDs, n=8; mild to moderate peak-dose LIDs, n=8; stable response to L-DOPA, n=12) 
showed no differences in caudate 11C-DASB BPND (Kruskal-Wallis with Dunn’s multiple 
comparisons tests: all p>0.05). All PD subgroups showed significantly reduced caudate 
11C-DASB BPND compared to a group of 12 normal controls (Kruskal-Wallis with Dunn’s 
multiple comparisons tests: MF without dyskinesias, p<0.001; moderate to severe peak-
dose LIDs, p<0.001; mild to moderate peak-dose LIDs, p<0.05; stable response to L-
DOPA, p<0.01) (Figure 88). 
 
 
 
Figure 88 Caudate 11C-DASB BPND mean values in groups of Parkinson’s disease patients with: motor 
fluctuations but no dyskinesias (n=8; BPND = 0.746), moderate to severe levodopa-induced dyskinesias (n=8; 
BPND = 0.843), mild to moderate peak-dose levodopa-induced dyskinesias (n=8; BPND = 0.925), stable 
response to levodopa (n=12; BPND = 0.954) and normal controls (n=12; BPND = 1.364). Kruskal-Wallis with 
Dunn post test, p<0.0001. The graph shows statistical comparisons between each group with the group of 
Parkinson’s disease patients with motor fluctuations but no dyskinesias. Error Bars = + 1 Standard 
Deviation(s). ***p<0.001 
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PD patients with MF but no dyskinesias showed significantly reduced putamen 
11C-DASB BPND compared to PD patients with mild to moderate peak-dose LIDs 
(p<0.05) and compared to PD patients with stable response to L-DOPA (p<0.01). All 
other comparisons between PD subgroups showed no differences in putamen 11C-DASB 
BPND (one-way ANOVA with Tukey-Kramer multiple comparisons tests). All PD 
subgroups showed significantly reduced putamen 11C-DASB BPND compared to a group 
of 12 normal controls (one-way ANOVA with Tukey-Kramer multiple comparisons tests: 
all p<0.001) (Figure 89). 
 
 
 
Figure 89 Putamen 11C-DASB BPND mean values in groups of Parkinson’s disease patients with: motor 
fluctuations but no dyskinesias (n=8; BPND = 0.811), moderate to severe levodopa-induced dyskinesias (n=8; 
BPND = 0.955), mild to moderate peak-dose levodopa-induced dyskinesias (n=8; BPND = 1.028), stable 
response to L-DOPA (n=12; BPND = 1.061) and normal controls (n=12; BPND = 1.360). Kruskal-Wallis with 
Dunn post test, p<0.0001. The graph shows statistical comparisons between each group with the group of 
Parkinson’s disease patients with motor fluctuations but no dyskinesias. Error Bars = + 1 Standard 
Deviation(s). p<0.05 ,*p<0.01 ***p<0.001 	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No correlation was found between caudate 11C-DASB BPND and maximum and 
average AIMS scores during the 150-min medication challenge with L-DOPA in PD 
patients with mild to moderate peak-dose LIDs (maximum: Pearson r=0.6650, p=0.0719; 
average: Pearson r=0.6075, p=0.1101) and PD patients with moderate to severe peak-dose 
LIDs (maximum: Pearson r=0.04765, p=0.9108; average: Pearson r=-0.1161, p=0.7843). 
There was a significant correlation between putamen 11C-DASB BPND and 
maximum (Pearson r=0.8361, p=0.0097; Figure 90) and average (Pearson r=0.8293, 
p=0.0109; Figure 91) AIMS scores during the 150-min medication challenge with L-
DOPA in the group of PD subjects with mild to moderate peak-dose LIDs. No correlation 
was found between putamen 11C-DASB BPND and maximum (Pearson r=-0.1388, 
p=0.7431) and average (Pearson r=-0.1874, p=0.6567) AIMS scores during the 150-min 
medication challenge with L-DOPA in PD patients moderate to severe peak-dose LIDs.  
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Figure 90 Significant correlation between individual putamen 11C-DASB BPND values and maximum 
dyskinesias scores during 150 minutes after levodopa administration in Parkinson’s disease patients with 
mild to moderate peak-dose levodopa-induced dyskinesias 
 
 
 
Figure 91 Significant correlation between individual putamen 11C-DASB BPND values and average 
dyskinesias scores during 150 minutes after levodopa administration in Parkinson’s disease patients with 
mild to moderate peak-dose levodopa-induced dyskinesias 
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PD patients with mild to moderate LIDs showed a significant reduction (p = 
0.0391) in caudate RAC BPND mean percentage reductions from RAC PET OFF 
medication scans, in the challenge where buspirone preceded the administration of L-
DOPA compared to the challenge with L-DOPA only. There were no significant 
differences in the groups of PD patients with: stable response to L-DOPA (p = 0.1021), 
moderate to severe LIDs (p = 0.4672) and MF but no dyskinesias (p = 0.357) in caudate 
RAC BPND mean percentage reductions from RAC PET OFF medication scans, in the 
challenge where buspirone preceded the administration of L-DOPA compared to the 
challenge with L-DOPA only (paired t test, two tailed p values) (Figure 92). 
 
 
 
Figure 92 Estimated levodopa-induced changes in caudate synaptic levels of dopamine after a challenge 
with levodopa only (blue bars) and a challenge with 0.35mg/kg buspirone preceding the administration of 
levodopa (red bars) in Parkinson’s patients with: stable response to levodopa (n=12), mild to moderate peak-
dose levodopa-induced dyskinesias (n=8), moderate to severe peak-dose levodopa-induced dyskinesias 
(n=8) and motor fluctuations but not dyskinesias (n=8). Values are expressed as % reduction from baseline 
caudate 11C-raclopride BPND. Error Bars = + 1 Standard Error(s) of mean. *p<0.05 
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PD patients with mild to moderate LIDs showed a significant reduction (p = 
0.0072) in putamen RAC BPND mean percentage reductions from RAC PET OFF 
medication scans, in the challenge where buspirone preceded the administration of L-
DOPA compared to the challenge with L-DOPA only. There were no significant 
differences in the groups of PD patients with: stable response to L-DOPA (p = 0.3148), 
moderate to severe LIDs (p = 0.4596) and MF but no dyskinesias (p = 0.253) in putamen 
RAC BPND mean percentage reductions from RAC PET OFF medication scans, in the 
challenge where buspirone preceded the administration of L-DOPA compared to the 
challenge with L-DOPA only (paired t test, two tailed p values) (Figure 93). 
 
 
 
Figure 93 Estimated levodopa-induced changes in putamen synaptic levels of dopamine after a challenge 
with levodopa only (blue bars) and a challenge with 0.35mg/kg buspirone preceding the administration of 
levodopa (red bars) in Parkinson’s patients with: stable response to levodopa (n=12), mild to moderate peak-
dose levodopa-induced dyskinesias (n=8), moderate to severe peak-dose levodopa-induced dyskinesias 
(n=8) and motor fluctuations but not dyskinesias (n=8). Values are expressed as % reduction from baseline 
putamen 11C-raclopride BPND. Error Bars = + 1 Standard Error(s) of mean. **p<0.01 
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Side Effects 
Sixteen out of 36 PD subjects reported at least one side-effect (44%). There were eight 
different side-effects (drowsiness, dizziness, nausea, vomiting, feeling lightheaded, 
excessive sweating, stomach upset and confusion) reported after the buspirone challenge. 
In the group of PD patients with stable response to L-DOPA, four subjects reported side-
effects whereas eight reported no side-effects. In the group of PD patients with mild to 
moderate LIDs, five subjects reported side-effects whereas three reported no side-effects. 
In the group of PD patients with moderate to severe LIDs, two subjects reported side-
effects whereas six reported no side-effects. In the group of PD patients with MF but no 
dyskinesias, three subjects reported side-effects whereas five reported no side-effects 
(Table 26). 
 
 
Table 26 Side-effect Profile after administration of 0.35 mg/kg bolus dose of Buspirone in Parkinson’s 
disease patients 
NUMBER OF SUBJECTS SIDE-EFFECT 
STABLE MM LIDs MS LIDs MF NON-DYSK TOTAL 
Drowsy 1 4 2 3 10 
Dizziness 1 1 1 1 4 
Nausea 1 0 0 0 1 
Vomited 1 0 0 0 1 
Lightheaded 1 0 0 0 1 
Excessive Sweating 1 0 0 0 1 
Stomach Upset 1 0 0 0 1 
Confusion 0 1 1 0 2 
None 8 3 6 5 22 
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5.2.3	  Discussion	  
The findings of this study demonstrate the active role of striatal serotonergic terminals in 
the development of peak-dose LIDs in PD patients. Administration of a high bolus dose of 
the 5-HT1A agonist, buspirone, resulted in significant attenuation of dyskinesia severity 
and significant reduction of the high synaptic dopamine levels generated after 
administration of L-DOPA, in a group of PD patients with LIDs. 
 Twelve normal controls were divided into two equally sized groups (matched for 
age and sex) and received either a low or a high bolus dose of buspirone in order to assess 
the influence of the drug in D2 receptor binding. Data showed no difference in D2 binding 
between normal controls receiving 0.20mg/kg or 0.35mg/kg bolus dose of buspirone. 
Furthermore, the two groups showed a similar adverse effect profile with 50% of the 
subjects in each group reporting at least one minor side-effect. Consequently it was 
decided to use the high buspirone dose in PD trial aiming to achieve a more complete 
block of serotonergic terminals and attenuate the dopamine levels released from these 
neurons and therefore, attenuate dyskinesia severity.   
 PD patients with LIDs showed significant reductions in the severity of their 
dyskinesias during their peak 60 to 105 mins following challenge with L-DOPA) when 
buspirone preceded the administration of L-DOPA for a recorded time of 150 mins. Facial 
and oral (at 60 and 75 mins), extremities (at 75-105 mins), trunk (at 75-105 mins) and 
overall severity (at 60-105 mins) dyskinesia subscores were all found reduced after the 
buspirone challenge. Improvement in total UPDRS motor scores was reduced at 30 and 75 
mins and increased at 150 mins after L-DOPA in the medication challenge where 
buspirone preceding the administration of L-DOPA compared to the challenge where 
patients received L-DOPA only.  
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There was no difference in caudate or putamen SERT binding between PD patients 
with stable response to L-DOPA and PD patients with LIDs. Moreover, caudate or 
putamen SERT binding did not correlate with peak or average dyskinesia scores during 
the recorded 150 mins following L-DOPA administration. Administration of buspirone 
before L-DOPA resulted in significant reductions of estimated levels of synaptic 
dopamine in both caudate (14.1% to 9.6%; stable responders = 6.1% reductions in RAC 
BPND) and putamen (18.0% to 12.6%; stable responders = 8.0% reductions in RAC BPND) 
in the group of PD patients with LIDs. 
 5-HT neurons are able to take up dopamine from the extracellular space via SERT 
(Schmidt and Lovenberg, 1985; Saldaña and Barker, 2004; Kannari et al., 2006), convert 
L-DOPA to dopamine, and store and release it in an activity-dependent manner (Ng et al., 
1970; 1971; Tanaka et al., 1999; Maeda et al., 2005). Animal studies have shown that 5-
HT1A receptor agonists (including buspirone) can block the false release of dopamine from 
the serotonergic neurons by activating the inhibitory 5-HT autoreceptors (Carta et al., 
2007; Eskow et al., 2007). The results from this study demonstrate that administration of 
buspirone before L-DOPA results in significant attenuation of peak-dose LIDs and also in 
reductions of the high synaptic dopamine levels expressed in the striatum of PD patients 
with LIDs. These results justify the active role of striatal serotonergic terminals in the 
development of LIDs in PD and suggest that the lack of normal autoregulatory feedback 
that results in non-physiological release of dopamine and abnormal swings in synaptic 
dopamine levels can be reversed with administration of high bolus 5-HT1A receptor 
agonists. 
 Buspirone when preceded administration of L-DOPA influenced the improvement 
of motor symptoms compared to L-DOPA only administration in PD patients with LID’s 
in three out of 10 assessment points. Buspirone administration is not affecting motor 
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scores in PD patients with stable response to L-DOPA (data not shown) and PD patients 
with peak-dose LIDs characteristically respond with variations in motor performance 
(high and lows) that are accompanied with high striatal synaptic dopamine levels after 
challenge with L-DOPA. It seems reasonable to assume that the significant differences 
seen in this study are related to normalization of striatal synaptic dopamine levels that 
produces a smoother response to L-DOPA when buspirone is preceding its administration.  
 Furthermore, this study intended to explore the role of striatal serotonergic 
terminals in the development of LIDs in groups with different dyskinesia severity. The PD 
group with LIDs was divided into two equally sized subgroups at the mean and median for 
severity of dyskinesias over 150 mins following administration with L-DOPA to form a 
group with mild to moderate and a group with moderate to severe dyskinesia severity.  
PD patients with mild to moderate LIDs showed significant reductions in the 
severity of their dyskinesias during their peak 60 to 105 mins following challenge with L-
DOPA) when buspirone preceded the administration of L-DOPA for a recorded time of 
150 mins. Facial and oral (at 60-90 mins), extremities (at 75-105 mins), trunk (at 75 mins) 
and overall severity (at 75-105 mins) dyskinesia subscores were all found reduced after 
the buspirone challenge. Improvement in total UPDRS motor scores was reduced at 30 
mins and increased at 120, 135 and 150 mins after L-DOPA in the medication challenge 
where buspirone preceding the administration of L-DOPA compared to the challenge 
where patients received L-DOPA only.  
PD patients with moderate to severe LIDs showed significant reductions in the 
severity of their dyskinesias (75 mins following challenge with L-DOPA) when buspirone 
preceded the administration of L-DOPA for a recorded time of 150 mins. Extremities (at 
75-90 mins), trunk (at 75 mins) and overall severity (at 60 mins) dyskinesia subscores 
were all found reduced after the buspirone challenge. No changes were observed in facial 
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and oral dyskinesia scores. Moreover, no changes in total UPDRS scores were observed 
after L-DOPA in the medication challenge where buspirone preceding the administration 
of L-DOPA compared to the challenge where patients received L-DOPA only. 
 There were no differences in caudate SERT binding between PD patients with 
stable response to L-DOPA, PD patients with mild to moderate LIDs, PD patients with 
moderate to severe LIDs and PD patients with MF but no dyskinesias, though all these 
groups had reduced caudate SERT binding compared to normal controls. PD patients with 
stable response to L-DOPA and PD patients with mild to moderate LIDs showed 
relatively increased putamen SERT binding compared to PD patients with MF but no 
dyskinesias. All PD subgroups had reduced SERT binding compared to normal controls. 
Caudate SERT binding did not correlate with peak or average dyskinesia scores during the 
recorded 150 mins following L-DOPA administration in both PD LIDs subgroups. SERT 
binding in putamen correlated with both peak and average dyskinesia scores during the 
recorded 150 mins following L-DOPA administration in the group of PD patients with 
mild to moderate LIDs but not in the group of PD patients with moderate to severe LIDs. 
Administration of buspirone before L-DOPA resulted in significant reductions of 
estimated levels of synaptic dopamine that came close to that of stable responders to L-
DOPA in both caudate (12.6% to 6.8%; stable responders = 6.1% reductions in RAC 
BPND) and putamen (15.9% to 8.8%; stable responders = 8.0% reductions in RAC BPND) in 
the group of PD patients with mild to moderate LIDs. Administration of buspirone before 
L-DOPA resulted in no significant reductions of estimated levels of synaptic dopamine in 
both caudate (15.6% to 13.2%; stable responders = 6.1% reductions in RAC BPND) and 
putamen (20.1% to 16.3%; stable responders = 8.0% reductions in RAC BPND) in the 
group of PD patients with moderate to severe LIDs. No significant influence of buspirone 
in estimated levels of striatal synaptic dopamine was observed in the groups of PD 
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patients with stable response to L-DOPA and with MF but no dyskinesias. At least one 
minor adverse effect, related to buspirone administration, was reported from 44% of PD 
subjects who completed this trial. No life threatening side-effects were reported from any 
subjects.  
The data of this study suggest that striatal serotonergic terminals play a primary 
role in the development of LIDs in PD patients with mild to moderate dyskinesia severity. 
After the loss of dopaminergic terminals and the dysregulated release of dopamine at the 
synapse, serotonergic terminals through the relatively preserved SERT influence the 
dopamine levels. This results in uncontrolled swings and consequently in the development 
of dyskinesias. PD patients with mild to moderate LIDs respond well to administration of 
high bolus dose of the 5-HT1A agonist buspirone, which normalises the estimate levels of 
dopamine and therefore significantly diminishes peak and average severity of dyskinesias. 
The effect of buspirone in LIDs in more severe dyskinetic PD patients, though beneficial, 
is less robust than the milder cases. PD patients with moderate to severe LIDs may benefit 
from the development and use of more selective 5-HT1A or 5-HT1B agonists. It is also 
conceivable that the involvement of other, non-serotonergic complementary mechanisms 
may contribute to the lesser effect of buspirone in more severe cases. Overall, the results 
of this study prove the active role of striatal serotonergic terminals in the development of 
LIDs in PD and justify the use of 5-HT1A agonists for their management.    
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Graft-­‐Induced	  Dyskinesia	  in	  
Parkinson’s	  Patients	  with	  
Neural	  Transplants	  	  
6	  
 
 
 
6.1	  Subjects	  	  
Twelve non-demented, non-depressed patients with advanced idiopathic PD fulfilling the 
UK Brain Bank clinical criteria for PD (Hughes et al., 1992) and experiencing motor and 
non-motor complications, 12 normal controls matched for age and sex, and patients 7 and 
15 from the Lund series with fetal VM grafts and GIDs (Box 9) were studied. Subjects 
underwent a series of clinical assessments, 1.5T volumetric MRI scan, 11C-DASB PET, 
18F-DOPA and two RAC PET scans (methamphetamine challenge vs. placebo). PD 
patients with fetal VM grafts also undertook a double blind trial with the 5-HT1A agonist 
buspirone and placebo. The clinical characteristics of the subjects are shown in Table 27 
and the aims of this study are presented in Box 10. 
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Box 9 Graft-Induced Dyskinesias  
Graft-induced dyskinesias refer to involuntary movements in the absence of dopaminergic 
medication (OFF-phase dyskinesias) and differ from ON-phase peak-dose dyskinesias, 
which appear when brain and plasma concentrations of levodopa and dopamine are high. 
 
 
Box 10 Aims: Serotonergic Neurons Mediate Dyskinesia Side Effects in Parkinson’s 
Patients with Neural Transplants  
To investigate the role of serotonergic neurons within intrastriatal grafts in the 
development of graft-induced dyskinesias in two Parkinson’s disease patients who had 
shown recovery of motor function after intrastriatal fetal ventral mesencephalic tissue 
transplantation. It is hypothesized that a dense serotonergic network will be responsible 
for generating dysregulated synaptic levels of dopamine and that low repeated doses of 
the serotonin receptor 1A agonist, buspirone, will normalize synaptic dopamine levels and 
consequently, reduce dyskinesia severity without increasing Parkinson’s symptoms. 
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Table 27 Participant characteristics 
 NORMAL 
CONTROLS 
(n=12) 
ADVANCED PD 
(n=12) 
PATIENT 7 PATIENT 15 
Sex 10M/2F 10M/2F Male Male 
Age (years ± SD) 63.3 ± 7.0 67.1 ± 7.2 65 66 
UPDRS Part III 
OFF  
(mean ± SD) 
- 44.5 ± 10.2 13 7 
UPDRS Total OFF  
(mean ± SD) 
- 77.5 ± 16.8 37 17 
PD Duration  
(years ± SD) 
- 12.5 ± 3.7 26  25 
Daily LED  
(mean ± SD) 
- 1087 ± 692 0 0 
MMSE  
(mean ± SD) 
29.42 ± 0.7 28.50 ± 2.0 29 29 
PD, Parkinson’s disease; M, male; F, female; SD, standard deviation; UPDRS, Unified Parkinson’s Disease 
Rating Scale; OFF, OFF-medication; LED, levodopa-equivalent-dose; MMSE, mini-mental state 
examination; UPDRS part III (motor score) worst score is 108; UPDRS total worst score is 199; LED was 
calculated as LED(mg)=(1 X Levodopa) + (0.77 X Levodopa CR) + (1.43 X Levodopa + Entacapone) + 
(1.11 X Levodopa CR + Entacapone) + (20 X Ropinirole) + (20 X Ropinirole ER) + (100 X Pramipexole) + 
(30 X Rotigotine) + (10 X Bromocriptine) + (8 X Apomorphine) + (100 X Pergolide) + (67 X Cabergoline),  
 
 Details for the tissue preparation and neurosurgical procedure have been previously 
described in detail (Lindvall et al., 1992; Wenning et al., 1997; Brundin et al., 2000) 
(Table 28). Briefly, dissociated VM tissue was implanted by using CT- and MRI- guided 
stereotaxic neurosurgery along five trajectories in the putamen (patients 7 and 15) and two 
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trajectories in the head of the caudate nucleus (patient 15). The tissue was procured from 
dead human fetuses aged six to eight weeks after conception and was obtained from 
routine suction abortions. Both patients were given immunosuppressive treatment 
(Lindvall et al., 1989). 
 
Table 28 Transplantation characteristics of Patients 7 and 15 
Patient NO 7 15 
Year of Transplantation 1993 
1994 
1996 
Location of implanted sites  L Put  
R Put  
L Put + Caud/ R Put + Caud 
 
Number of implant sites 5  
5 
5 + 2/5 + 2 
Number of donors 5 
5 
4/4 
Size of the donors  L Put: mean size 22 mm (range 
14-26 mm) 
R Put: mean size 18 mm (range 
14-22 mm) 
L Put and L Caud: mean size 20 
mm  
(range: 15-26 mm) 
R Put and R Caud: mean size 19 
mm  
(range 13-23 mm) 
Amount of implanted tissue  L Put: 5 VM  
R Put: 5 VM  
 
L Put: 2.9 VM  
L Caud: 1.1 VM 
R Put: 2.9 VM 
R Caud: 1.1 VM 
Time from abortion to 
implantation  
L Put: mean time 7h 15min 
(range 5.5-9h) 
R Put: mean time 5h 30min 
L Put: mean time 5 h  
(range 3.5-6.5h)* 
L Caud: mean time 6h 45min  
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(range: 3.5-7.5h) (range 6-7.5h)* 
R Put: mean time 4h 15min  
(range 2.5-6h)* 
R Caud: mean time 6h  
(range 5-7h)* 
L, left; R, right; Put, Putamen; Caud, Caudate nucleus; VM, ventral mesencephalon; *Exposed to the 
lazaroid tirilazad mesylate during storage and dissociation; patient given lazaroid for 3 days (Brundin et al., 
2000)   
 
 
6.2	  Results	  	  
Patient 7 reported PD-related symptoms since 1980, and he is currently 26 years post-
diagnosis. Preoperatively, after a five-year “honeymoon-period” in which he experienced 
a good response to L-DOPA treatment, he developed severe motor complications 
including diphasic and peak-dose LIDs, ON-OFF fluctuations and wearing-OFF 
phenomena without any OFF-phase dyskinesias. He had bilateral intraputaminal 
transplantation of fetal VM tissue 16 years ago (Wenning et al., 1997; Hagell et al., 1999) 
(Tables 27 and 28). After transplantation and for the following three years, his motor 
symptoms were moderately improved and OFF-periods were shorter and less severe while 
ON-period dyskinesias were reduced. From the fourth postoperative year, his 
parkinsonism was significantly improved, and he no longer required dopaminergic 
medication (Figure 94A). Currently, he has no OFF-periods but experiences GID, which 
are insufficiently relieved by amantadine (a glutamate NMDA receptor antagonist used for 
treating dyskinesias). GIDs are present almost constantly causing disability. His 
dyskinesia phenotype includes involuntary movements, mainly of the trunk and lower and 
upper extremities, although facial and oral involuntary movements are also detected.  
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 18F-DOPA and RAC PET showed dopaminergic neuron restoration and dopamine 
release after transplantation, which rose to normal values in the grafted putamen (Figure 
94A). Using 11C-DASB PET, excessive serotonergic innervation in the grafted putamen 
was found. 11C-DASB binding was 172% and 285% higher than mean values in healthy 
normal individuals and advanced PD patients, respectively. In contrast, 11C-DASB 
binding in the non-grafted caudate nucleus was reduced by 29.4% compared to that in 
normal individuals and was similar to the mean values in patients with advanced PD 
(Figure 95A-C and E-G). The ratio of serotonergic to dopaminergic innervation in the 
grafted putamen, estimated as the 11C-DASB/18F-DOPA binding ratio, was increased by 
230% compared to the ratio in normal people (356 vs. 108).  
 Patient 15 reported PD-related symptoms since 1982, and he is currently 25 years 
post-diagnosis. Preoperatively, after a six-year period with good response to L-DOPA 
treatment he developed severe motor complications including diphasic and peak-dose 
LIDs, ON-OFF fluctuations and wearing-OFF phenomena without OFF-phase 
dyskinesias. He had received bilateral VM tissue transplants in the caudate and putamen 
13 years earlier (Brundin et al., 2000) (Tables 27 and 28). For three years after surgery he 
did not experience any improvement in his motor symptoms, although the amount of 
administered L-DOPA was reduced and ON-period dyskinesias were slightly reduced. 
From the fourth postoperative year, motor symptoms gradually improved, OFF-periods 
faded out, and 8 years ago all dopaminergic medications were stopped (Figure 94B). 
Currently, he has no OFF periods but has developed GIDs, which are poorly controlled 
with amantadine. His dyskinesias are moderately disabling and are evident most of the 
time. His dyskinesias include involuntary movements mainly of the lower extremities, 
although trunk and upper extremity involuntary movements are also seen.  
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 18F-DOPA and RAC PET imaging in this patient has shown restoration of 
dopamine neurons and dopamine release to normal values in the grafted putamen (Figure 
94B). 11C-DASB PET revealed excessive binding of the radiotracer in both grafted parts 
of the striatum (caudate nucleus: 123% and 252%; putamen 77% and 150%; increase 
compared to normal and advanced PD mean values, respectively) (Figure 95A,B and D-
G). The 11C-DASB/18F-DOPA binding ratio in the grafted putamen was 146% increased 
compared to normal (266 vs. 108). 
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Figure 94 Fetal mesencephalic grafts provide long-lasting major relief of motor symptoms and restore 
dopamine innervation and release in the grafted striatum. (A) Patient 7 and (B) patient 15 from the Lund 
series. Motor examination scores of the Unified Parkinson’s Disease Rating Scale (UPDRS, worst possible 
score = 108) (mean ± 95% confidence interval) in the OFF-phase (open squares) and 18F-DOPA Ki values 
in the grafted putamen (filled circles), preoperatively and at various time points after transplantation. 
Comparative data on 18F-DOPA Ki values in the putamen (mean ± 2 SD) are given on the right for a group 
of 16 healthy volunteers. Percentage reduction of 11C-raclopride binding values (upper right corner) in the 
grafted putamen after methamphetamine administration at postoperative year 9 and year 7 for patient 7 and 
patient 15, respectively, and in the putamen of a group of 6 healthy volunteers (mean ± 2 SD). 18F-DOPA 
Ki values and UPDRS scores up to 2.5 years postoperatively for patient 7 (Hagell et al., 1999) and during 
the first year after transplantation for patient 15 (Brundin et al., 2000) were reported previously. BPND, 
binding potential of the specifically bound radioligand relative to the nondisplaceable radioligand in tissue; 
Ki, influx rate constant; Preop, preoperative; UPDRS motor score, part III of the Unified Parkinson’s 
Disease Rating Scale; SD, standard deviation. 
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 Our in vivo 11C-DASB and 18F-DOPA PET imaging data indicate serotonergic 
hyperinnervation in the grafted caudate nucleus and putamen that gives rise to high 
serotonergic relative to dopaminergic innervation in these areas. We hypothesized that this 
excess of serotonergic innervation could contribute to GID by releasing dopamine as a 
false transmitter. Therefore, we investigated whether administering a 5-HT1A agonist in 
low, repeated doses would dampen the activity of 5-HT neurons, inhibit their transmitter 
release, and thereby attenuate GID. Fifteen mg of the 5-HT1A agonist, buspirone, given in 
three doses of 5mg at 30 min intervals, significantly attenuated the severity of GID in both 
patients 7 and 15 for 4 hours when compared to no-drug or to placebo administration 
(Figure 95H and I). The UPDRS motor scores remained unchanged after buspirone 
administration (13 for patient 7; 7 for patient 15), and there were no side effects.  
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Figure 95 Serotonergic hyperinnervation in the grafted striatum causes dyskinesias, which are effectively 
suppressed by a 5-HT1A agonist. Summed 11C-DASB PET images co-registered and fused with 1.5 Tesla 
MRI images at the level of the dorsal basal ganglia for: (A) A 64-year-old healthy male. 11C-DASB binding 
(BPND) mean values are 1.27 for caudate nucleus, 1.42 for putamen and 1.31 for thalamus (B) A 65-year-old 
male with advanced Parkinson’s disease since 16 years experiencing motor and non-motor complications 
(BPND mean values: 0.82 for caudate, 0.82 for putamen and 1.21 for thalamus), (C) Patient 7, a 65-year-old 
male who received bilateral intraputaminal transplantation 16 years ago showing bilateral increases in 
putaminal 11C-DASB binding (BPND mean values: 0.96 for caudate, 3.70 for putamen and 1.07 for 
thalamus) (D) Patient 15, a 66-year-old male with bilateral intraputaminal and intracaudate grafts for 13 
years, showing bilateral increases in putaminal and caudate 11C-DASB binding (BPND mean values: 3.03 for 
caudate, 2.39 for putamen and 1.04 for thalamus). (E) Caudate nucleus, (F) putamen and (G) thalamus mean 
11C-DASB BPND values for patient 7 (P7) and patient 15 (P15) and mean 11C-DASB BPND values (± 2 SD) 
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for a group of 12 normal controls (NC) and a group of 12 age and sex matched, advanced PD patients (PD) 
(see also Table 27 and Box 11). Dyskinesia scores, rated with the Abnormal Involuntary Movement Scale 
(AIMS), for patient 7 (H) and patient 15 (I) after a double-blind acute challenge with three repeated 5mg 
doses of the 5-HT1A agonist buspirone or three repeated doses of placebo. Comparative AIMS scores in the 
absence of a drug challenge are also shown. AIMS, Abnormal Involuntary Movement Scale; BPND, binding 
potential of the specifically bound radioligand relative to the nondisplaceable radioligand in tissue; NC, 
normal controls; PD, Parkinson’s disease; P7, patient 7 from the Lund series; P15, patient 15 from the Lund 
series. 
 
Box 11 Supplementary Imaging Data 
11C-DASB PET Binding (BPND):  
Patient 7: Right putamen = 3.65 and left putamen = 3.75. Right caudate nucleus = 1.17 
and left caudate nucleus = 0.75 (Fig. 2C and E,F).  
Patient 15: Right putamen = 2.32 and left putamen = 2.46. Right caudate nucleus = 2.95 
and left caudate nucleus = 3.11. 
In advanced Parkinson’s disease cases, 11C-DASB BPND is decreased 36.8 % in caudate 
nucleus (p<0.0001), 29.4% in putamen (p<0.0001) and 31.3% in thalamus when 
compared to group of normal controls. 
 
	  
6.3	  Discussion	  	  
The data demonstrated striatal serotonergic hyperinnervation in two patients with PD who 
had received fetal neural transplants. This excess of 5-HT neurons was visualized with 
non-invasive PET imaging of serotonergic neurons and is most likely derived from the 
graft as PD patients lose about 30% of their endogenous striatal serotonergic innervation 
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(Box 11), and the excess of 11C-DASB signal was confined to those areas implanted with 
VM tissue (putamen in patient 7; caudate and putamen in patient 15). Supporting a 
causative role between the serotonergic hyperinnervation in the grafted putamen and the 
development of GID, patient 7 with more severe GID than patient 15 showed greater 11C-
DASB binding and higher serotonergic/dopaminergic innervation ratio in the grafted 
putamen. This finding is compatible with studies on LIDs in animal models of PD 
(Carlsson et al., 2007; 2009), which suggest that a high, graft-derived, 
serotonergic/dopaminergic innervation ratio is associated with the development of 
dyskinesias. The most likely explanation for the higher putaminal serotonergic innervation 
in patient 7 than in patient 15 is that he received 42% more VM tissue in each putamen 
(Table 28).   
 The crucial role of serotonergic neurons in causing GID was confirmed when 
administration of repeated doses of the 5-HT1A agonist buspirone dramatically attenuated 
dyskinesia severity in both transplanted patients. 5-HT neurons can take up dopamine 
from the extracellular space via SERT, where it competes with 5-HT for vesicular storage 
and release (Schmidt and Lovenberg, 1985; Saldaña and Barker, 2004; Kannari et al., 
2006). Also, 5-HT1A receptor agonists (including buspirone) can block the false release of 
dopamine from the serotonergic neurons by activating the inhibitory 5-HT autoreceptors 
(Carta et al., 2007; Eskow et al., 2007). We propose that GIDs are caused by dysregulated 
release of dopamine from the dense graft-derived serotonergic innervation. The high 
SERT-to-DAT ratio in the grafted putamen (a result of serotonergic hyperinnervation and 
reduced expression or loss-of-function of DAT [as seen in vivo (Cochen et al., 2003) and 
at post mortem (Kordower et al., 2008a; 2008b)] would exacerbate this situation. Due to 
lack of normal autoregulatory feedback, the non-physiological release of dopamine from 
serotonergic terminals is dysregulated and abnormal swings will result in GID. In 
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addition, excess 5-HT release can act directly on the dopamine terminals to induce an 
activity-independent, amphetamine-like release of dopamine, probably via reversal of the 
DAT (Jacocks and Cox, 1992; Yeghiayan and Kelley, 1995; Yeghiayan et al., 1997), and 
may further enhance the dysregulation of dopamine release, worsening GID. The 
attenuation of GID that we observed is thus readily explained by the ability of 5-HT1A 
agonists to dampen serotonergic neurotransmission by activation of the inhibitory 
autoreceptors. 
 Whether GIDs and LIDs in non-grafted PD patients share the same pattern of 
dopamine release from the serotonergic terminals is unknown. Both patients 7 and 15 
showed viable dopaminergic grafts and in the absence of administration of exogenous L-
DOPA, the serotonergic neuron-derived irregular swings in synaptic dopamine levels 
could be a phenomenon with prolonged duration and lower intensity compared to the 
sharp, short-term increase in synaptic dopamine levels when large doses of L-DOPA are 
administered orally and reach the extensively denervated striatum (as observed in LID). In 
patients 7 and 15, GIDs were attenuated after small, repeated doses of the 5-HT1A agonist 
buspirone, which supports this scenario.  
 The very limited availability of PD patients with neural transplants influenced 
patient selection for this study. For example, out of five transplanted patients in the UK, 
two have died and one is bedridden and unable to participate in research. However, based 
on the data reported here, it is conceivable that also other grafted PD patients with GID 
showing high serotonergic/dopaminergic innervation ratio in their putamen (compared to 
normal controls) should respond to 5-HT1A agonist treatment. Other 5-HT1A agonists are 
not tested because buspirone was the only one with license for human use in UK. The 
action of buspirone may be limited by its short t1/2 and diurnal, repeated administration of 
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this drug may give rise to adverse effects. This study’s results support the use and 
development of new 5-HT1A agonists with prolonged duration for the treatment of GID. 
 The findings have direct implications for the development of a clinically competitive 
cell replacement therapy in PD by indicating how the occurrence of GID might be 
prevented or minimized. First, the dissection of the VM, which contains both 
dopaminergic and serotonergic progenitors (Braak and Del Tredici, 2008), could be 
performed in such a way as to minimize the serotonergic component in the graft tissue. In 
rodents, this strategy leads to maximum functional restoration with minimum LIDs 
(Carlsson et al., 2007). Second, it needs to be determined that storage of tissue prior to 
implantation does not change the proportion of serotonergic and dopaminergic 
components. Storage and culture of the tissue are expected to alter its composition in 
favour of non-dopaminergic cells (Fawcett et al., 1995), and it has been reported that 
patients who received tissue that had been stored for long periods developed more 
pronounced GID than patients implanted with fresh tissue (Freed et al., 2001; Hagell et al., 
2002). Third, serotonergic neurons contaminating dopaminergic neuron populations 
generated from stem cells should be kept to a minimum, or removed by cell sorting. If, 
however, GID develop in future neural transplantation trials despite these preventive 
measures, it is shown here that they can be effectively treated with systemic 
administration of 5HT1A agonists. 
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  Dopaminergic	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7	  
	  
 
 
7.1	  Subjects	  	  
Six PD patients on enteral L-DOPA/carbidopa gel infusion (Duodopa®) (2g/0.5g for 100 
ml in the same ratio 4:1 as common oral formulations) underwent clinical assessments and 
a series of RAC PET scans. All subjects had advanced PD with motor and non-motor 
complications. The PET paradigm consisted of one RAC PET scan performed when the 
infusion was switched off and the patient in an OFF medication state and two RAC PET 
scans one and four hours after the infusion has been started with the patient in ON 
medication state (see Figure 37 in Methodology). In two cases, the second and third RAC 
PET scans were performed seven and 10 hours after the infusion has been started. The 
subjects’ clinical characteristics before and after induction of enteral L-DOPA/carbidopa 
gel infusion are shown in Table 29 (general and motor) and Table 30 (non-motor) and the 
aims of the study are presented in Box 12. Medication and clinical history are shown in 
Tables 31 and 32. 
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Box 12 Aims: Dopaminergic Stimulation in Parkinson’s Disease  
To investigate the ability of enteral levodopa/carbidopa gel infusion (Duodopa®) to 
produce steady striatal levels of dopamine and to correlate these levels with motor and 
non-motor symptoms. It is hypothesised that enteral levodopa/carbidopa gel infusion 
(Duodopa®) by providing stable and prolonged levodopa delivery will also result in more 
stable and prolonged synaptic levels of dopamine within the brain and possibly generate a 
significant clinical improvement.  
 
Table 29 General and Motor Clinical characteristics of Parkinson’s disease patients before and after enteral 
Levodopa/Carbidopa gel infusion (Duodopa®)  
 SUBJECT 
1  
SUBJECT 
2 
SUBJECT 
3 
SUBJECT 
4 
SUBJECT 
5 
SUBJECT 
6 
Sex F M M M M M 
Age (years) 58 57 61 54 69 41 
Disease Duration (years) 16 14 23 18 14 13 
H&Y OFF 4 4 5 4 4 4 
H&Y ON Before DD 2 2 5 2 4 4 
H&Y ON After DD 2 2 3 2 2 2 
UPDRS III OFF 62 58 75 53 43 29 
UPDRS III ON Before 
DD 
32 45 30 28 18 15 
UPDRS III ON After DD 14 7 21 9 10 7 
UPDRS IV Before DD 7 15 5 8 6 10 
UPDRS IV After DD 3 5 4 4 3 3 
PDQ – 8 Before DD 15 14 18 14 22 18 
PDQ – 8 After DD 12 10 13 8 18 8 
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Table 30 Non-Motor Clinical characteristics of Parkinson’s disease patients before and after enteral 
Levodopa/Carbidopa gel infusion (Duodopa®)  
NMS SUBJECT 
1  
SUBJECT 
2 
SUBJECT 
3 
SUBJECT 
4 
SUBJECT 
5 
SUBJECT 
6 
Cardiovascular Before 
DD 
2 4 0 9 0 6 
Cardiovascular After DD 2 6 5 4 0 0 
Sleep / Fatigue Before 
DD 
10 39 6 62 16 12 
Sleep / Fatigue After DD 4 16 24 25 14 7 
Mood / Cognition Before 
DD 
9 25 7 26 20 28 
Mood / Cognition After 
DD 
2 22 32 39 20 18 
Perceptual problems / 
hallucinations Before DD 
0 0 4 4 8 0 
Perceptual problems / 
hallucinations After DD 
0 0 0 13 8 0 
Attention / Memory 
Before DD 
4 12 12 21 32 18 
Attention / Memory After 
DD 
6 4 20 17 32 12 
Gastrointestinal Tract 
Before DD 
12 24 10 18 13 7 
Gastrointestinal Tract 
After DD 
10 0 7 12 13 8 
Urinary Before DD25 6 13 10 18 24 8 
Urinary After DD 2 0 5 9 20 7 
Sexual Function Before 
DD 
6 8 6 9 10 0 
Sexual Function After 0 8 0 14 10 0 
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DD 
Miscellaneuous Before 
DD 
12 28 12 24 27 32 
Miscellaneuous After DD 20 15 14 14 20 16 
 
 
Table 31 Medication and Clinical history before and after the induction of enteral Levodopa/Carbidopa gel infusion 
(Duodopa®) in Parkinson’s disease subjects 1, 2 and 3 
 SUBJECT 1  SUBJECT 2 SUBJECT 3 
Daily Medication Before 
Duodopa 
 
Cabergoline 8mg 
Sinemet plus 3hrly 
Apomorphine 5mg per hr 
 
Stalevo 200mg 2hrly 
Pergolide 4mg 
Rotigitine patch 16mg 
Madopar dispersible  
Madopar 125mg qds 
Apomorphine 5mg per hr 
Rotigitine patch 16mg 
Entacapone qds 
Previous Medication 
Levodopa Equivalent Dose 
(LED) mg /day 
1800 2680 1480 
Most Common complaints 
of previous medication  
Freezes 
Long OFF periods 
High anxiety Dyskinesias  
Weight loss 
DDS 
Psychosis 
Paranoia  
DDSa/ICDb 
Freezes  
Long OFF periods 
Dyskinesias 
Motor Fluctuations 
Freezes  
Long OFF periods 
Psychosis  
Paranoia 
Falls 
Duodopa doses Morning: 7 ml  
Continuous: 6 ml/hour  
Bolus: 3 ml  
Morning: 10 ml 
Continuous: 9 ml/hour  
Bolus: 3 ml 
Morning: 10 ml 
Continuous: 7 ml/hour   
Bolus: 3 ml  
Duodopa Levodopa 
Equivalent Dose (LED) mg 
/day 
1980 3120 2320 
Hours on Duodopa 12 14 14 
Clinical effect of Duodopa Reduced dyskinesias 
Reduced freezes and OFF 
Less freezes 
Less psychosis but this still 
More ON time 
Less freezes 
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periods 
Remains anxious 
Remains DDS 
remains as does DDS/ICD 
No dyskinesias 
Improved mobility 
Less fluctuations 
Increased mobility 
Less psychosis 
Less hallucinations 
Still falls 
Complications  Inner tube out x 1 
Oozing wound site 
Over boosting causing 
psychosis and dyskinesias 
Oozing wound site and 
developed a site fistula 
DDS/ICD remain 
Over boosting 
Manic  
Inner tube removed x 2 
Increasingly apathetic 
Side Effects  Hypersexual 
DDS 
Mood swings 
Hypersexual 
Mood swings  
DDS/ICD 
Increasing anger when over 
boosted 
Increasing Apathy 
aDDS = Dopamine Dysregulation Syndrome; bICD=Impulse Control Disorder(s) 
 
 
Table 32 Medication and Clinical history before and after the induction of enteral Levodopa/Carbidopa gel infusion 
(Duodopa®) in Parkinson’s disease subjects 4, 5 and 6 
 SUBJECT 4 SUBJECT 5 SUBJECT 6 
Daily Medication Before 
Duodopa 
 
Apomorphine 5mg 
Half Sinemet CR x 6  
Stalevo 50mg x 6 Madopar 
125mg x 4  
 
Rotigitne patch 16mg 
Sinemet Plus 2hrly 
Sinemet CR x 2 Nocte 
Sinemet plus qds 
Entacapone qds 
Pramipexole 1.5mg tds 
Sinemet CR BD 
Rotigitine Patch 16mg 
Apomorphine 5mg per hour 
Previous Medication 
Levodopa Equivalent Dose 
(LED) mg /day 
2600 1800 2600 
Most Common complaints 
of previous medication  
Freezes 
Immobility 
Wheelchair dependent  
Decreased mobility 
Increasing dementia 
problems 
Full body dystonia 
OFF pain and long OFF 
periods 
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Wearing-OFF 
DDSa/ICDb 
Mood swings 
Hallucinations 
Falls 
Freezes 
Anxiety 
Dyskinesias  
Fluctuations 
Mood swings 
Duodopa doses Morning: 10 ml  
Continuous: 7.5 ml/hour  
Bolus: 3 ml  
Morning: 6 ml   
Continuous: 5 ml/hour   
Bolus: 2 ml  
Morning: 10 ml 
Continuous: 7 ml/hour   
Bolus: 3 ml 
Duodopa Levodopa 
Equivalent Dose (LED) mg 
/day 
2780 1750 2680 
Hours on Duodopa 24 14 18 
Clinical effect of Duodopa Mobile  
No freezes 
Independent 
DDS/ICD remain  
Psychosis when boosted 
Mood swings remain 
Mood swings 
Increased dementia issues 
Less off time and more 
mobile 
No falls 
Mood swings remain 
Less Dystonia 
Less OFF time 
Less anxious 
Less fluctuations 
ICD 
Complications  Inner tube removed x 2 
ICD/DDS not improved 
Over boosting Worsening 
mood swings 
None Inner tube removed x 2 
Mood swings remain 
Anxiety worse when he has 
over boosted 
ICD remains 
Side Effects  ICD/DDS 
Mood swings 
Increasing anger when over 
boosted 
Depression 
Apathy 
Increasing mood swings  
Anger out bursts 
DDS 
ICD 
aDDS = Dopamine Dysregulation Syndrome; bICD=Impulse Control Disorder(s) 
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7.2	  Results	  
 
Individual Results 
Subject 1, 58-years old female, had PD for 16 years and suffered from motor blocks, 
prolonged OFF periods, dyskinesias, anxiety and dopamine dysregulation syndrome 
(DDS). She also had sleep problems, experienced sustained fatigue and had 
gastrointestinal and urinary symptoms and impaired sexual function. 
  After the induction of duodopa, she experienced a significant improvement on her 
motor symptoms, dyskinesias, sleep, fatigue and sexual problems, gastrointestinal and 
urinary symptoms and overall quality of life. However, anxiety and DDS did not improve 
while she also developed impulse control disorder (ICD) and mood swings (Tables 29, 30 
and 31). 
 RAC PET results showed robust and sustained dopamine release in SMST (Figures 
96 and 97), LS (Figures 98 and 99) and AST (Figures 100 and 101).  
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Figure 96 Duodopa-induced changes in sensorimotor striatum (SMST) 11C-raclopride (RAC) binding 
potential (BPND) in Subject 1, at baseline (2.763), 1 (2.157) and 4 (2.294) hours after the initiation of pump 
infusion 
 
 
 
Figure 97 Estimated duodopa-induced changes in the sensorimotor striatum (SMST) synaptic levels of 
dopamine. Values are expressed as percentage reduction from baseline of SMST 11C-raclopride binding 
potential (BPND) at both 1 (20.96%) and 4 (16.13%) hours after the initiation of pump infusion 
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Figure 98 Duodopa-induced changes in limbic striatum (LS) 11C-raclopride (RAC) binding potential 
(BPND) in Subject 1, at baseline (1.753), 1 (1.489) and 4 (1.515) hours after the initiation of pump infusion 
 
 
 
Figure 99 Estimated duodopa-induced changes in the limbic striatum (LS) synaptic levels of dopamine. 
Values are expressed as percentage reduction from baseline of LS 11C-raclopride binding potential (BPND) 
at both 1 (14.91%) and 4 (12.88%) hours after the initiation of pump infusion 
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Figure 100 Duodopa-induced changes in associative striatum (AST) 11C-raclopride (RAC) binding 
potential (BPND) in Subject 1, at baseline (2.120), 1 (1.762) and 4 (1.768) hours after the initiation of pump 
infusion 
 
 
 
Figure 101 Estimated duodopa-induced changes in the associative striatum (AST) synaptic levels of 
dopamine. Values are expressed as percentage reduction from baseline of AST 11C-raclopride binding 
potential (BPND) at both 1 (16.67%) and 4 (15.65%) hours after the initiation of pump infusion 
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Subject 2, 57-years old male, had PD for 14 years and suffered from motor blocks, 
prolonged OFF periods, MF and dyskinesias, psychosis, ICDs and DDS. He also had 
problems with his attention, memory, sleep, experienced sustained fatigue and had 
gastrointestinal and urinary symptoms and impaired sexual function. 
  After the induction of duodopa, he experienced a significant improvement on his 
motor symptoms, MF and dyskinesias, sleep and fatigue problems, attention and memory 
problems, gastrointestinal and urinary symptoms and overall quality of life. However, 
sexual function, psychosis, ICDs and DDS did not improve (Tables 29, 30 and 31). 
 RAC PET results showed robust and sustained dopamine release in SMST (Figures 
102 and 103), LS (Figures 104 and 105) and AST (Figures 106 and 107).  
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Figure 102 Duodopa-induced changes in sensorimotor striatum (SMST) 11C-raclopride (RAC) binding 
potential (BPND) in Subject 2, at baseline (2.753), 1 (2.290) and 4 (2.348) hours after the initiation of pump 
infusion 
 
 
 
Figure 103 Estimated duodopa-induced changes in the sensorimotor striatum (SMST) synaptic levels of 
dopamine. Values are expressed as percentage reduction from baseline of SMST 11C-raclopride binding 
potential (BPND) at both 1 (16.51%) and 4 (14.68%) hours after the initiation of pump infusion 
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Figure 104 Duodopa-induced changes in limbic striatum (LS) 11C-raclopride (RAC) binding potential 
(BPND) in Subject 2, at baseline (1.506), 1 (1.298) and 4 (1.298) hours after the initiation of pump infusion 
 
 
 
Figure 105 Estimated duodopa-induced changes in the limbic striatum (LS) synaptic levels of dopamine. 
Values are expressed as percentage reduction from baseline of LS 11C-raclopride binding potential (BPND) 
at both 1 (13.67%) and 4 (13.54%) hours after the initiation of pump infusion 
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Figure 106 Duodopa-induced changes in associative striatum (AST) 11C-raclopride (RAC) binding 
potential (BPND) in Subject 2, at baseline (1.782), 1 (1.519) and 4 (1.520) hours after the initiation of pump 
infusion 
 
 
 
Figure 107 Estimated duodopa-induced changes in the associative striatum (AST) synaptic levels of 
dopamine. Values are expressed as percentage reduction from baseline of AST 11C-raclopride binding 
potential (BPND) at both 1 (14.67%) and 4 (14.67%) hours after the initiation of pump infusion 
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Subject 3, 61-years old male, had PD for 23 years and suffered from motor blocks, 
long OFF periods, MF and psychosis. He also had sleep problems, experienced sustained 
fatigue and had gastrointestinal and urinary symptoms and impaired sexual function. 
  After the induction of duodopa, he experienced a significant improvement on his 
motor symptoms, MF, gastrointestinal and urinary symptoms, sexual function, perceptual 
problems and overall quality of life. However, sleep and fatigue problems did not improve 
and he showed increasing apathy (Tables 29, 30 and 31). 
 RAC PET results showed robust and sustained dopamine release in SMST (Figures 
108 and 109) and LS (Figures 110 and 111) but low dopamine release in AST (Figures 
112 and 113).  
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Figure 108 Duodopa-induced changes in sensorimotor striatum (SMST) 11C-raclopride (RAC) binding 
potential (BPND) in Subject 3, at baseline (2.751), 1 (2.426) and 4 (2.550) hours after the initiation of pump 
infusion 
 
 
 
Figure 109 Estimated duodopa-induced changes in the sensorimotor striatum (SMST) synaptic levels of 
dopamine. Values are expressed as percentage reduction from baseline of SMST 11C-raclopride binding 
potential (BPND) at both 1 (11.60%) and 4 (7.28%) hours after the initiation of pump infusion 
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Figure 110 Duodopa-induced changes in limbic striatum (LS) 11C-raclopride (RAC) binding potential 
(BPND) in Subject 3, at baseline (1.516), 1 (1.417) and 4 (1.443) hours after the initiation of pump infusion 
 
 
 
Figure 111 Estimated duodopa-induced changes in the limbic striatum (LS) synaptic levels of dopamine. 
Values are expressed as percentage reduction from baseline of LS 11C-raclopride binding potential (BPND) 
at both 1 (6.53%) and 4 (4.87%) hours after the initiation of pump infusion 
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Figure 112 Duodopa-induced changes in associative striatum (AST) 11C-raclopride (RAC) binding 
potential (BPND) in Subject 3, at baseline (1.763), 1 (1.704) and 4 (1.713) hours after the initiation of pump 
infusion 
 
 
 
Figure 113 Estimated duodopa-induced changes in the associative striatum (AST) synaptic levels of 
dopamine. Values are expressed as percentage reduction from baseline of AST 11C-raclopride binding 
potential (BPND) at both 1 (3.35%) and 4 (2.81%) hours after the initiation of pump infusion 
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Subject 4, 54-years old male, had PD for 18 years and suffered from motor blocks, 
prolonged OFF periods, was wheelchair dependent, had MF, hallucinations, ICDs and 
DDS. He also had problems with his attention, memory, mood, cognition, sleep, 
experienced sustained fatigue and had gastrointestinal and urinary symptoms and impaired 
sexual function. 
  After the induction of duodopa, he experienced a significant improvement on his 
motor symptoms, MF, sleep and fatigue problems, attention and memory problems, 
gastrointestinal and urinary symptoms, overall quality of life and became independent not 
needing the wheelchair assistance. However, mood, cognition and sexual function did not 
improve while hallucinations, ICDs and DDS worsened (Tables 29, 30 and 32). 
 RAC PET results showed robust and sustained dopamine release in SMST (Figures 
114 and 115), LS (Figures 116 and 117) and AST (Figures 118 and 119).  
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Figure 114 Duodopa-induced changes in sensorimotor striatum (SMST) 11C-raclopride (RAC) binding 
potential (BPND) in Subject 4, at baseline (2.351), 4 (1.999) and 7 (1.988) hours after the initiation of pump 
infusion 
 
 
 
Figure 115 Estimated duodopa-induced changes in the sensorimotor striatum (SMST) synaptic levels of 
dopamine. Values are expressed as percentage reduction from baseline of SMST 11C-raclopride binding 
potential (BPND) at both 4 (14.63%) and 7 (15.08%) hours after the initiation of pump infusion 
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Figure 116 Duodopa-induced changes in limbic striatum (LS) 11C-raclopride (RAC) binding potential 
(BPND) in Subject 4, at baseline (1.616), 4 (1.314) and 7 (1.347) hours after the initiation of pump infusion 
 
 
 
Figure 117 Estimated duodopa-induced changes in the limbic striatum (LS) synaptic levels of dopamine. 
Values are expressed as percentage reduction from baseline of LS 11C-raclopride binding potential (BPND) 
at both 4 (18.47%) and 7 (16.33%) hours after the initiation of pump infusion 
 292	  
 
Figure 118 Duodopa-induced changes in associative striatum (AST) 11C-raclopride (RAC) binding 
potential (BPND) in Subject 4, at baseline (1.488), 4 (1.234) and 7 (1.262) hours after the initiation of pump 
infusion 
 
 
 
Figure 119 Estimated duodopa-induced changes in the associative striatum (AST) synaptic levels of 
dopamine. Values are expressed as percentage reduction from baseline of AST 11C-raclopride binding 
potential (BPND) at both 4 (16.96%) and 7 (15.39%) hours after the initiation of pump infusion 
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Subject 5, 69-years old male, had PD for 14 years and suffered from motor blocks, 
MF, falls and cognitive decline. He also had problems with his mood, attention, sleep, 
experienced sustained fatigue, perceptual problems and had gastrointestinal and urinary 
symptoms and impaired sexual function. 
  After the induction of duodopa, he experienced a significant improvement on his 
motor symptoms, MF, falls, attention, perceptual problems, sexual function and overall 
quality of life. Sleep and fatigue complaints were slightly improved while gastrointestinal 
symptoms, mood and cognitive function did not improve (Tables 29, 30 and 32).  
 RAC PET results showed robust and sustained dopamine release in SMST (Figures 
120 and 121), LS (Figures 122 and 123) but low dopamine release in AST (Figures 124 
and 125).  
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Figure 120 Duodopa-induced changes in sensorimotor striatum (SMST) 11C-raclopride (RAC) binding 
potential (BPND) in Subject 5, at baseline (2.840), 4 (2.377) and 7 (2.379) hours after the initiation of pump 
infusion 
 
 
 
Figure 121 Estimated duodopa-induced changes in the sensorimotor striatum (SMST) synaptic levels of 
dopamine. Values are expressed as percentage reduction from baseline of SMST 11C-raclopride binding 
potential (BPND) at both 4 (15.84%) and 7 (15.58%) hours after the initiation of pump infusion 
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Figure 122 Duodopa-induced changes in limbic striatum (LS) 11C-raclopride (RAC) binding potential 
(BPND) in Subject 5, at baseline (1.811), 4 (1.655) and 7 (1.657) hours after the initiation of pump infusion 
 
 
 
Figure 123 Estimated duodopa-induced changes in the limbic striatum (LS) synaptic levels of dopamine. 
Values are expressed as percentage reduction from baseline of LS 11C-raclopride binding potential (BPND) 
at both 4 (8.55%) and 7 (8.01%) hours after the initiation of pump infusion 
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Figure 124 Duodopa-induced changes in associative striatum (AST) 11C-raclopride (RAC) binding 
potential (BPND) in Subject 5, at baseline (2.066), 4 (1.975) and 7 (1.975) hours after the initiation of pump 
infusion 
 
 
 
Figure 125 Estimated duodopa-induced changes in the associative striatum (AST) synaptic levels of 
dopamine. Values are expressed as percentage reduction from baseline of AST 11C-raclopride binding 
potential (BPND) at both 4 (4.33%) and 7 (4.34%) hours after the initiation of pump infusion 
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Subject 6, 41-years old male, had PD for 13 years and suffered from prolonged 
OFF periods, MF, dyskinesias and dystonia, anxiety and mood swings. He also had 
problems with his attention, memory, cognition, sleep, and experienced sustained fatigue 
and had gastrointestinal and urinary symptoms. 
  After the induction of duodopa, he experienced a significant improvement on his 
motor symptoms, MF and dyskinesias, sleep and fatigue problems, cognition, anxiety and 
overall quality of life. Urinary problems were slightly improved while gastrointestinal 
symptoms and mood swings did not improved and this patient also developed ICDs and 
DDS (Tables 29, 30 and 32). 
 RAC PET results showed robust and sustained dopamine release in SMST (Figures 
126 and 127), LS (Figures 128 and 129) and AST (Figures 130 and 131).  
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Figure 126 Duodopa-induced changes in sensorimotor striatum (SMST) 11C-raclopride (RAC) binding 
potential (BPND) in Subject 6, at baseline (2.853), 7 (2.419) and 10 (2.407) hours after the initiation of pump 
infusion 
 
 
 
Figure 127 Estimated duodopa-induced changes in the sensorimotor striatum (SMST) synaptic levels of 
dopamine. Values are expressed as percentage reduction from baseline of SMST 11C-raclopride binding 
potential (BPND) at both 7 (15.42%) and 10 (15.81%) hours after the initiation of pump infusion 
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Figure 128 Duodopa-induced changes in limbic striatum (LS) 11C-raclopride (RAC) binding potential 
(BPND) in Subject 6, at baseline (1.532), 7 (1.315) and 10 (1.305) hours after the initiation of pump infusion 
 
 
 
Figure 129 Estimated duodopa-induced changes in the limbic striatum (LS) synaptic levels of dopamine. 
Values are expressed as percentage reduction from baseline of LS 11C-raclopride binding potential (BPND) 
at both 7 (14.13%) and 10 (14.76%) hours after the initiation of pump infusion 
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Figure 130 Duodopa-induced changes in associative striatum (AST) 11C-raclopride (RAC) binding 
potential (BPND) in Subject 6, at baseline (1.830), 7 (1.653) and 10 (1.670) hours after the initiation of pump 
infusion 
 
 
 
Figure 131 Estimated duodopa-induced changes in the associative striatum (AST) synaptic levels of 
dopamine. Values are expressed as percentage reduction from baseline of AST 11C-raclopride binding 
potential (BPND) at both 7 (9.64%) and 10 (8.62%) hours after the initiation of pump infusion 
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 Group Results 
The six PD patients who currently undertake treatment with duodopa were also examined 
as a group to investigate changes in clinical scores before and after the induction of 
duodopa. There were significant improvements in UPDRS III, UPDRS IV, PDQ-8 and 
non-motor urinary scores. Several other clinical scores were also improved though not 
reaching statistical significance. Mood and cognition, and perceptual and hallucinations 
scores deteriorated though not statistically significant. Overall subjects’ clinial scores 
showed significant improvement after the induction of duodopa (Table 33).  
 RAC PET data showed robust levels of dopamine release up to 10 hours post 
initiation of the pump infusion in SMST (Figure 132), LS (Figure 133) and AST (Figure 
134). Second level analysis showed sustained dopamine release between one and four 
hours (Figure 135), four and seven hours (Figure 136) and seven and 10 hours (Figure 
137) in SMST after initiation of the duodopa pump infusion.  Furthermore, dopamine 
release in LS was also sustained between one and four hours (Figure 138), four and seven 
hours (Figure 139) and seven and 10 hours (Figure 140) after initiation of the duodopa 
pump infusion. Similarly, PD subjects showed sustained dopamine release in AST 
between one and four hours (Figure 141), four and seven hours (Figure 142) and seven 
and 10 hours (Figure 143) after initiation of the duodopa pump infusion. Figure 144 shows 
an example of RAC PET summed images with reductions in striatal RAC binding, 
corresponding to dopamine release, before and after initiation of the duodopa pump 
infusion. 
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Table 33 Percentage Improvement and Statistical Differences in Motor and Non-Motor Clinical Scales 
Before and After Induction of Enteral Levodopa/Carbidopa Gel Infusion (Duodopa®) in Six Parkinson’s 
disease patients  
CLINICAL SCALES PRE-DDb AFTER-DD IMPROVEMENT P VALUEc 
H&Y (mean+SD) 3.2±1.3  2.2±0.4  31.3% 0.0756 
UPDRS III (mean+SD) 28.0±10.8  11.3±5.4  47.5% 0.0169* 
UPDRS IV (mean+SD) 8.5±3.6  3.7±0.8  56.5% 0.0138* 
PDQ – 8 (mean+SD) 16.8±3.1  11.5±3.8  31.5% 0.0034** 
NMSa-Cardiovascular (mean+SD) 3.5±3.6  2.8±2.6  20.0% 0.7121 
NMS-Sleep/Fatigue (mean+SD) 24.2±21.9  15.0±8.6  38.0% 0.2878 
NMS-Mood /Cognition (mean+SD) 19.2±9.1  22.2±12.7  -15.6% 0.6070 
NMS-Perceptual 
problems/hallucinations (mean+SD) 
2.7±3.3  3.5±5.6  -29.6% 0.6557 
NMS-Attention/Memory 
(mean+SD) 
16.5±9.6  15.1±10.3  8.5% 0.6030 
NMS-Gastrointestinal Tract 
(mean+SD) 
14.0±6.1  8.3±4.7  40.7% 0.1962 
NMS-Urinary (mean+SD) 13.2±6.8  7.2±7.1  45.5% 0.0187* 
NMS-Sexual Function (mean+SD) 6.5±3.6  5.3±6.2  18.5% 0.5279 
NMS-Miscellaneuous (mean+SD) 22.5±8.5  16.5±2.8  26.7% 0.1722 
Overall Score (mean+SD) 178.7±53.4 124.7±42.8 30.2% 0.0264d 
a NMS = non-motor symptoms; b DD = duodopa; c Paired t tests, two-tail p value; d Wilcoxon matched pairs 
test 
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Figure 132 Estimated duodopa-induced changes in the sensorimotor striatum (SMST) synaptic levels of 
dopamine. Values are expressed as percentage reduction from baseline of SMST 11C-raclopride binding 
potential (BPND) at 1 (data from 3 subjects; 16.36%), 4 (data from 5 subjects; 13.71%), 7 (data from 3 
subjects; 15.36%) and 10 hours (data from 1 subject; 15.81%) after the initiation of pump infusion 
 
 
Figure 133 Estimated duodopa-induced changes in the limbic striatum (LS) synaptic levels of dopamine. 
Values are expressed as percentage reduction from baseline of LS 11C-raclopride binding potential (BPND) 
at 1 (data from 3 subjects; 11.70%), 4 (data from 5 subjects; 11.66%), 7 (data from 3 subjects; 12.82%) and 
10 hours (data from 1 subject; 14.76%) after the initiation of pump infusion 
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Figure 134 Estimated duodopa-induced changes in the associative striatum (AST) synaptic levels of 
dopamine. Values are expressed as percentage reduction from baseline of SMST 11C-raclopride binding 
potential (BPND) at 1 (data from 3 subjects; 11.56%), 4 (data from 5 subjects; 10.89%), 7 (data from 3 
subjects; 9.79%) and 10 hours (data from 1 subject; 8.62%) after the initiation of pump infusion 
 
 
 
Figure 135 Estimated duodopa-induced changes in the sensorimotor striatum (SMST) synaptic levels of 
dopamine. Values are expressed as percentage reduction from baseline of SMST 11C-raclopride binding 
potential (BPND) at both 1 (16.36%) and 4 (12.70%) hours (data from 3 subjects) after the initiation of pump 
infusion 
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Figure 136 Estimated duodopa-induced changes in the sensorimotor striatum (SMST) synaptic levels of 
dopamine. Values are expressed as percentage reduction from baseline of SMST 11C-raclopride binding 
potential (BPND) at both 4 (15.23%) and 7 (15.33%) hours (data from 2 subjects) after the initiation of pump 
infusion 
 
 
Figure 137 Estimated duodopa-induced changes in the sensorimotor striatum (SMST) synaptic levels of 
dopamine. Values are expressed as percentage reduction from baseline of SMST 11C-raclopride binding 
potential (BPND) at both 7 (15.42%) and 10 (15.81%) hours (data from 1 subject) after the initiation of pump 
infusion 
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Figure 138 Estimated duodopa-induced changes in the limbic striatum (LS) synaptic levels of dopamine. 
Values are expressed as percentage reduction from baseline of LS 11C-raclopride binding potential (BPND) 
at both 1 (11.70%) and 4 (10.43%) hours (data from 3 subjects) after the initiation of pump infusion 
 
 
Figure 139 Estimated duodopa-induced changes in the limbic striatum (LS) synaptic levels of dopamine. 
Values are expressed as percentage reduction from baseline of LS 11C-raclopride binding potential (BPND) 
at both 4 (13.51%) and 7 (12.17%) hours (data from 2 subjects) after the initiation of pump infusion 
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Figure 140 Estimated duodopa-induced changes in the limbic striatum (LS) synaptic levels of dopamine. 
Values are expressed as percentage reduction from baseline of LS 11C-raclopride binding potential (BPND) 
at both 7 (14.13%) and 10 (14.76%) hours (data from 1 subject) after the initiation of pump infusion 
 
 
 
Figure 141 Estimated duodopa-induced changes in the associative striatum (AST) synaptic levels of 
dopamine. Values are expressed as percentage reduction from baseline of AST 11C-raclopride binding 
potential (BPND) at both 1 (11.56%) and 4 (11.04%) hours (data from 3 subjects) after the initiation of pump 
infusion 
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Figure 142 Estimated duodopa-induced changes in the associative striatum (AST) synaptic levels of 
dopamine. Values are expressed as percentage reduction from baseline of AST 11C-raclopride binding 
potential (BPND) at both 4 (10.65%) and 7 (9.87%) hours (data from 2 subjects) after the initiation of pump 
infusion 
 
 
Figure 143 Estimated duodopa-induced changes in the associative striatum (AST) synaptic levels of 
dopamine. Values are expressed as percentage reduction from baseline of AST 11C-raclopride binding 
potential (BPND) at both 7 (9.64%) and 10 (8.62%) hours (data from 1 subject) after the initiation of pump 
infusion 
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Figure 144 11C-raclopride summed images before (A. B, C) and after enteral Levodopa/Carbidopa gel 
infusion (Duodopa®) infusion showing significant dopamine release in the striatum 
 
	  
7.3	  Discussion	  
 
The main results from this study demonstrate that duodopa can provide a stable and 
prolonged L-DOPA delivery with sustained dopamine synaptic levels for a period up to 10 
hours after the pump initiation.  
 The six advanced PD patients on duodopa showed significant improvement on 
their motor symptoms and motor complications in comparison to their previous treatment. 
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OFF periods became shorter and MF and dyskinesias less intense. Measures of the overall 
quality of life showed improvement as well. Non-motor symptoms and particularly sleep 
problems, fatigue, and gastrointestinal and urinary complaints improved as well after these 
patients started to receive treatment with duodopa. On the other hand, mood, cognition, 
perceptual and hallucinations symptoms did not show improvement. DDS and ICDs were 
also not improved; in two PD patients remained constant; in one PD patient became worse 
and in a further one, DDS and ICDs first developed after he was started on duodopa.  
PET with RAC is an indirect marker of extracellular dopamine increases following 
pharmacological challenges, as evidenced by decreases in D2 receptor availability (Piccini 
et al., 1999; 2003; 2005; de la Fuente -Fernandez et al., 2001; 2004). Previous PET studies 
have shown that in advanced PD patients with dyskinesias and MF after oral standard 
release L-DOPA 250/carbidopa 25 there was a 17.2% decrease in putaminal D2 binding 
after the first hour of administration in PD subjects with peak-dose dyskinesias and other 
fluctuations and 6.64% in PD subjects with wearing-OFF fluctuations. During the fourth 
hour, putaminal D2 binding was reduced to 7.8% in PD patients with peak-dose 
dyskinesias and other fluctuations and to baseline values in PD subjects with wearing-OFF 
fluctuations (de la Fuente-Fernández et al., 2001; 2004).  
The results from this study show similar reductions in advanced PD with motor 
complications in SMST RAC PET binding for the first hour after initiation of the duodopa 
pump, however, RAC binding remains mostly stable up to 10 hours thereafter (16.4% in 
one hour to 15.9% after 10 hours). Similar results were observed for the LS and AST parts 
of the striatum with RAC binding reductions remaining stable up to 10 hours after 
initiation of the duodopa pump.  
 Whilst the increased and sustained dopamine release in SMST can readily explain 
the improvement in PD motor symptoms and complications, high dopamine release in LS 
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could explain the compulsive behaviour observed in these patients. A previous PET study 
has shown that PD patients with DDS are linked to sensitized ventral striatal dopamine 
transmission (Evans et al., 2006). In the present study the four subjects that had 
considerably higher dopamine release in the limbic part of the striatum were the ones with 
ICDs and DDS. It needs to be noted that Subject 4 now experiences more severe ICDs and 
DDS and that Subject 6 developed ICDs and DDS after started treatment with duodopa. 
The two patients with the lowest dopamine release in AST were the ones with mostly 
impaired cognitive function. However, this could be persisted from before the start of 
treatment with duodopa as the other four patients showed good and sustained release in 
this part of the striatum.  
In conclusion, by studying six advanced PD patients on duodopa, it is shown that 
duodopa produces sustained striatal dopamine levels for at least up to 10 hours of the 
pump initiation improving motor and non-motor symptoms and overall quality of life. The 
results of this study also suggest that patients with a history or tendency to impulsive 
behaviours should be excluded as potential candidates for this type of treatment as it can 
contribute to the development or exacerbation of DDS or ICDs. 
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Conclusions	  and	  Review	  of	  
Major	  Findings	  	  
8	  
	  
 
PET imaging techniques when accompanied with clinical observations, can provide an 
objective approach to assess different aspects of PD. They can be used to investigate 
subclinical disease, assist in the differential diagnosis, improve the understanding of motor 
and non-motor complications, monitor disease progression, aid to management, and 
evaluate restorative approaches and new therapeutic developments. PET imaging has an 
increasing role in clarifying the unknown pathophysiology of the disease.  
 The studies included in this thesis have generated a series of findings, which 
contribute to the elucidation of pathophysiological mechanisms underlying the 
development of motor and non-motor complications such as LIDs, depression and weight 
changes commonly seen in the clinical course of PD. Also, they have shown that the main 
adverse effect of striatal transplantation of human fetal cells, namely GIDs, can be 
prevented or treated making this therapeutic approach safer. Morever, evidence is 
provided for the use of continuous dopaminergic stimulation in the management of PD.  
More specifically in Chapter 3, it is shown that exposure to DAs influences striatal 
D2 binding by downregulating the receptors in both caudate and putamen while L-DOPA 
treatment does not seem to have this effect. Caudate D2 receptors are linerly reduced with 
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disease progression possibly due to degeneration of dopamine terminals or loss of D2 
binding sites. Moreover, it is demonstrated a significant loss of dopamine D2 receptor 
binding in PD hypothalamus indicating that hypothalamic dysfunction along with 
involvement of other systems could be responsible for disturbances of sleep and other 
autonomic functions. 
 With the use of in vivo markers assessing the integrity of serotonergic terminals, it 
was performed a staging of serotonergic dysfunction in early, established and advanced 
PD patients, and an assessment of the possible role of such dysfunction in the 
development of depressive symptoms and weight changes in PD patients (Chapter 4). It 
was demonstrated a general widespread decrease of presynaptic serotonergic terminal 
function in PD that did not correlate with the duration of the disease or locomotor 
disability. It was also observed that chronic exposure to dopaminergic therapy did not 
influence SERT binding. The loss of presynaptic serotonergic terminal function starts 
from the caudate nucleus, thalamus, hypothalamus and ACC then spreading to the 
putamen, insular cortex, PCC and PFC in established disease and to ventral striatum, 
raphe nuclei and amygdala in advanced PD cases.  
The data showed that levels of depressive symptoms in anti-depressant naive PD 
patients correlate with higher SERT binding in median raphe nuclei and limbic structures 
(amygdala, PCC and hypothalamus). Patients with higher BDI-II and HRSD scores had 
relatively increased SERT binding in these areas compared to PD patients with low scores, 
though not compared to healthy controls. SERT binding in all other regions under 
investigation was similarly reduced in PD patients whether they had low or raised 
depressive symptom scores. These results justify the use of SSRIs or non-selective TCAs 
in PD patients with increased levels of depressive symptoms.  
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PD patients with a high BMI change over a 12-month period demonstrated a 
relative increase of SERT binding in median raphe nuclei, caudate, ventral striatum and 
the hypothalamus compared to PD patients with a low BMI change but not compared to 
the healthy controls. Also, SERT binding in these regions correlated with BMI changes in 
the PD patients. The findings from this study are suggestive of a serotonergic involvement 
in BMI changes in PD and while the hypothalamus and raphe nuclei have been directly 
associated with appetite regulation and 5-HT previously, the caudate nucleus and ventral 
striatum have been shown to possess functional roles related with cognition and emotion, 
which may be ultimately involved in the regulation of weight.  
 In Chapter 5, it was demonstrated that there are no differences in caudate and 
putamen D2 receptor binding between dyskinetics and non-dyskinetics PD patients. 
Clinical data showed that PD dyskinetics had more advanced disease, were more disabled 
while received more L-DOPA but not DA medication compared to a group of PD non-
dyskinetics. These findings suggest that dyskinesias are unlikely to arise from a primary 
abnormality of caudate or putamen postsynaptic dopamine D2 receptor binding.  
The findings from this chapter also demonstrate the active role of striatal 
serotonergic terminals in the development of peak-dose LIDs in PD patients. 
Administration of a high bolus dose of the 5-HT1A agonist, buspirone, resulted in a 
significant reduction of the high synaptic dopamine levels generated after administration 
of L-DOPA and in significant attenuation of dyskinesia severity, in a group of PD patients 
with LIDs. The results of this study also suggest that striatal serotonergic terminals 
particularly play a role in the development of mild to moderate LIDs. After the loss of 
dopaminergic terminals and the dysregulated release of dopamine in the synapse, 
serotonergic terminals through the relatively preserved SERT modulate the synaptic 
dopamine release that results in uncontrolled swings and consequently in the development 
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of dyskinesias. PD patients with mild to moderate LIDs respond well to administration of 
high bolus dose of the 5-HT1A agonist buspirone, which normalises the levels of dopamine 
and therefore significantly diminishes peak and average severity of dyskinesias. The effect 
of buspirone in LIDs in more severe dyskinetic PD patients, though beneficial, is less than 
the milder cases. This type of patients may benefit from the development and use of more 
selective 5-HT1A or 5-HT1B agonists. The involvement of other, non-serotonergic 
complementary mechanisms may also explain the lesser effect of buspirone in more 
severe cases. Overall, the results of this study prove the active role of striatal serotonergic 
terminals in the development of LIDs in PD and justify the use of 5-HT1A agonists for 
their management.    
 In Chapter 6, striatal serotonergic hyperinnervation in two patients with PD and 
GIDs who had received fetal cell transplantation was observed. This excess of 5-HT 
neurons is most likely derived from the graft as PD patients lose about 30% of their 
endogenous striatal serotonergic innervation and the excess of 5-HT neurons was confined 
to those areas implanted with VM tissue. The results also suggest that a high, graft-
derived, serotonergic/dopaminergic innervation ratio is associated with the development 
of dyskinesias. Both patients showed a remarkable attenuation of their GIDs after 
administration of low-repeated doses of the 5-HT1A agonist buspirone indicating that the 
dysregulated dopamine release coming out from the 5-HT terminals was indeed the cause 
of their GIDs. These findings have direct implications for the development of a clinically 
competitive cell replacement therapy in PD by indicating how the occurrence of GIDs 
might be prevented or minimized. First, the dissection of the VM could be performed in 
such a way as to minimize the serotonergic component in the graft tissue. Second, it needs 
to be determined that storage of tissue prior to implantation does not change the 
proportion of serotonergic and dopaminergic components. Tissue should not be stored and 
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cultured for long periods prior to implantation and patients should receive fresh tissue. 
Third, serotonergic neurons contaminating dopaminergic neuron populations generated 
from stem cells should be kept to a minimum, or removed by cell sorting. If, however, 
GIDs develop in future neural transplantation trials despite these preventive measures, it is 
shown here that they can be effectively treated with systemic administration of 5HT1A 
agonists. 
 In Chapter 7, it was demonstrated that duodopa provides stable striatal dopamine 
levels up to 10 hours after pump initiation with a significant clinical effect improving 
advanced PD patients’ motor, non-motor symptoms and overall quality of life. Duodopa 
seems to be an effective therapeutic strategy in the management of advanced PD but 
clinicians should be careful with patients who have history or tendency to impulsive 
behaviours.   
In conclusion, my observations justify the use of SSRIs or non-selective TCAs in 
PD patients with increased depression symptoms or abnormal weight changes. New trials 
testing the safety and efficacy of transplantation with fetal cells in PD should be 
conducted after considering the results from this thesis. Duodopa seems an effective 
treatment in advanced PD. Moreover, there is a need to further explore the 
pathophysiology underlining motor and non-motor complications that patients experience 
after years of disease progression and chronic exposure to dopaminergic therapy. With the 
development of modern PET radiotracers, investigation of the cannabinoid, glutamatergic 
and adenosine systems could be performed and newly developed hypotheses could clarify 
some of the remaining questions.  
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